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Abstract 
 
With a growing desire to explore three-dimensional chemical space, methods for the 
synthesis of spirocyclic compounds, more specifically aza-spirocycles, are becoming of great 
interest to medicinal chemists. The synthesis of 3- and 4-spiropiperidines are well 
documented, however, there is little precedent for the synthesis of 2-spiropiperidines. The 
research detailed in this thesis describes the efforts towards the synthesis of 2-
spiropiperidines via both a stepwise (Scheme i) and a one-pot procedure (Scheme ii), for use 
in a fragment drug discovery programme. The scopes of the procedures are demonstrated by 
the synthesis of a diverse range of 2-spiropiperidines. The 2-spiropiperidines were utilised as 
scaffolds to construct a small library of lead-like compounds that were analysed by LLAMA 
and principal moments of inertia analysis. The 2-spiropiperidines were consequently found to 
be three-dimensional. Methods for the construction of other structurally interesting 
piperidines are also presented, including bridged piperidines, fused piperidines, and 6-
spiropiperidines, though the efforts were unsuccessful.  
Scheme i. Stepwise synthesis of 2-spiropiperidines. 
 
 
Scheme ii. One-pot synthesis of 2-spiropiperidines. 
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1. Introduction 
 
The identification and generation of high quality lead compounds (compounds that possess 
pharmaceutical or biological activity that could be therapeutically useful) is imperative in the 
initial stages of drug discovery. The pharmaceutical industry remains heavily reliant on 
synthetic methodology to access small, drug-like molecules for drug discovery programmes.1 
Upon the synthesis of libraries of compounds varying in size and complexity, the compounds 
are then screened to identify new hits. However, the selection and optimisation of the hits 
are where major difficulties associated with the discovery process lie.2     
Two of the most commonly used modern methods for the identification and development of 
drug candidates are high-throughput screening (HTS) and fragment-based drug discovery 
(FBDD), of which are outlined below. 
 
1.1 High-Throughput Screening 
 
High-throughput screening is one of the more traditional methods adopted in drug discovery. 
This involves the construction of a large library of compounds, often in the region of 106 
compounds.3 These compounds possess ‘lead-like’ properties, which in the context of HTS, 
means they have a molecular weight <500 Da with a total number of heavy atoms <30, and a 
low lipophilicity (AlogP≤4).4 The large library is then screened across a multitude of targets to 
find a hit. Optimisation occurs through the elaboration of the initial hit, with further 
screenings of smaller libraries of analogues undertaken to identify the drug candidate. The 
HTS process is not fast, and it is currently estimated that it takes 13.5 years to reach approval 
of the drug from the initial target identification.5 Hit rates from HTS are often very low, and 
consequently HTS programmes can be very costly.6  
Maraviroc 2, developed by Pfizer, was approved in 2007 as a CCR5 agonist for the treatment 
of HIV.7 It was the product of a HTS programme that began in 1997 with the screening of 
~500,000 compounds from a Pfizer library.4 The initial hit was the piperidine ‘UK-107,543’ 1, 
and required the synthesis of over 1,000 analogues to identify the final candidate maraviroc 
2 (Figure 1).  
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Figure 1. Development of maraviroc 2 from UK-107,543 1. 
 
The total number of compounds possessing ‘lead-like’ properties with the number of heavy 
atoms (non-hydrogen atoms) less than 30 has been estimated to be in excess of 1063, which 
is a number far beyond comprehension.3,8 The vast number of compounds is referred to as 
the ‘virtual collection’ because they simply cannot feasibly be synthesised.8 The suggested 
number of globally-accessible compounds is estimated to be in the region of 108, so even a 
screen of these compounds would barely touch the surface of diversity space.9 In a typical 
HTS screen, approximately 106 compounds are screened.3 As with the globally-accessible 
compounds, this is a minute number in comparison to the total theoretical number of 
compounds, and so only a small insignificant area of drug-like chemical space can be sampled. 
In comparison, it has been estimated that approximately 107 different molecules exist with a 
molecular weight of less than 160 daltons.10 This number is now far more comprehensible, 
and a screen of 103 or 104 compounds means a much greater proportion of drug-like space 
can be sampled, hence is the reason for the introduction of FBDD programmes.  
 
1.2 Fragment-Based Drug Discovery 
 
The concept of FBDD arose from the synthesis of small fragment molecules, with restrictions 
imposed such as molecular weight and lipophilicity. Similar to Lipinski’s ‘rule of five’, which 
assesses the drug-likeness of molecules (molecular weight≤500, AlogP≤5, number of H-bond 
donors/acceptors≤5),11 a new set of stipulations have been derived to allow the synthesis of 
fragment libraries, often following a ‘rule of three’.12 For fragment libraries obeying the ‘rule 
of three’, all compounds have molecular weights≤300, AlogP≤3, number of hydrogen bond 
donors≤3, number of hydrogen bond acceptors≤3.12 Adding to this criteria, the fragments 
12 
 
should have a number of heavy atoms<20.13 Obeying the ‘rule of three’ is advisable as the 
optimisation studies tend to increase lipophilicity, molecular weight and complexity.14  
In the construction of fragment libraries, molecules are often synthesised that have handles 
to allow facile elaboration upon detection of hits.3 Owing to the small size of the molecules 
in a fragment library, hits from biological screens often exhibit milli-molar or weak μ-molar 
affinities to the targets.15 However, the small molecules then have a greater potential to be 
optimised to achieve nano-molar affinities.  
Adopting a FBDD approach allows the realistic construction of libraries that can exhaust the 
chemical space that a small molecule can occupy against a target. It was concluded by Hann 
that simple, small molecules have a greater chance of forming favourable interactions with 
respective binding sites, compared to larger, more complex molecules typically used in a HTS 
programme.16 
The first approved drug to arise from a FBDD programme was vemurafenib 3 (Figure 2) in 
2011 by Plexxicon, for the treatment of BRAF-mutated metastatic melanoma.17,18 A library of 
approximately 20,000 compounds possessing fragment-like properties (low molecular 
weights, good solubilities, low numbers of hydrogen bond acceptors/donors) were screened 
against five kinases.19 From the screen, 238 compounds showed a desirable weak binding to 
three of the kinases. From these hits, 7-azaindole 4 was selected as it co-crystallised with the 
target kinase well, and had a weak binding affinity (IC50>200 μM).19 7-Azaindole 4 was 
subsequently grown to aniline 5, which displayed greater potency (IC50~100 μM). Further 
optimisation identified p-methoxy benzyl 6 (IC50 1.9 μM), sulfonamide 7 (IC50 0.013 μM) and 
finally the end product vemurafenib 3 (IC50 0.031 μM).19 Despite the greater potency of 
sulfonamide 7 over vemurafenib 3, vemurafenib 3 was the selected candidate because the 
associated pharmacokinetic properties scaled better in clinical trials.17 
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Figure 2. Key steps in the discovery of vemurafenib 3. 
 
1.3 Methods for Detection 
 
An issue encountered with low binding affinities of the fragment hits means classical 
biological screening methods may not be sufficient for detection. Ellman demonstrated that 
screening higher concentrations is possible,20 however, screening at high concentrations can 
lead to issues such as false positives/negatives, target denaturation, and toxicity to cells.21 
Because of these disadvantages, biophysical methods such as NMR spectroscopy and X-ray 
crystallography have been employed.22 Methods such as mass spectrometry,23,24 isothermal 
titration calorimetry,25  and surface plasmon resonance21 have also been used for detection. 
For analysis by NMR spectroscopy, the most robust method employed involves the use of 15N-
labelled protein targets. Upon binding of the compounds to the target proteins, shifts in the 
1H-15N HSQC spectrum are detected, and consequently the location of the binding can be 
identified.22 Analysis via this method does have its disadvantages, such as the need for 
significant quantities of pure 15N-labelled protein, and the requirement for a high-field NMR 
spectrometer.22 To combat these drawbacks, a method for identification through 13C-labelled 
proteins was reported by Fesik and coworkers.26 Isotopically labelling the methyl groups of 
valine, leucine and isoleucine increased the sensitivity of the technique by nearly 3-fold 
compared to that of 1H-15N HSQC screening.  
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The use of X-ray crystallography to identify fragment hits is a very useful technique, as the 
exact interactions between the fragment and the protein target can be viewed. The technique 
was employed by Nienaber and coworkers by soaking a crystal of protein with a mixture of 
fragments for a period of time (1-24 h).27 The original crystal structure of the protein was then 
subtracted from the new crystal structure, and differences in the electron density maps 
allowed the identification of hits. Upon identification of a fragment hit, the fragment-protein 
interaction can be visualised and used as guidance for the addition of further functionality.21 
 
1.4 Methods for Fragment Elaboration 
 
With the identification of weakly binding fragment hits, the next important procedure is the 
elaboration of the hits. The goal of the elaboration process is to improve the binding affinity 
by several orders of magnitude, giving rise to a molecule suitable for progressing into clinical 
trials.15 The benefits of using NMR spectroscopy and X-ray crystallography for initial detection 
are that areas for elaboration can be immediately identified, as the binding interactions can 
be visualised. There are two major strategies for the conversion of fragment hits into lead 
compounds; fragment growing and fragment linking.22 
Fragment growing is the most closely related to traditional drug optimisation, in which various 
substitutions or expansions are made to the initial hit in order to improve binding affinities 
(Figure 3).28 The first fragment hit is identified by its weak binding to the desired target (Figure 
3, A), and using structural information of how the fragment binds to the target, an improved 
hit can be rapidly obtained (Figure 3, B). At this stage of the process, the compound may show 
activity in biological assays.28 From here, further iterations can be made to the molecule to 
give higher efficiency interactions with the active site of the target, giving rise to a final drug 
candidate (Figure 3, C). 
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Figure 3. Fragment growing. 
 
Fragment linking works by first identifying multiple fragment hits related to a specific target 
(Figure 4). Providing they bind to different but nearby sites, the fragments are then chemically 
linked to give the hybrid lead compound.29  
 
 
Figure 4. Fragment linking. 
 
A case study by Abell and coworkers towards the discovery of inhibitors of mycobacterium 
tuberculosis pantothenate synthetase, has compared and contrasted the two approaches for 
fragment elaboration.30 Interestingly, both approaches for fragment optimisation resulted in 
the identification of similar compounds with similar potencies. However, the limited number 
of suitable linkers rendered the fragment linking process as limiting. In contrast, the fragment 
growing process was shown to allow more freedom for development and optimisation at each 
stage.30  
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1.5 Shape Analysis 
 
It has been suggested that the presence of too many aromatic rings can have an adverse effect 
on the potential of a candidate to progress.31 Despite the possibility for π-π stacking 
interactions32 and cation-π interactions,33 the introduction of multiple aromatic rings 
increases the lipophilicity of the associated compounds,31 which has been shown to be a 
defining property of clinical candidates.34,35 The majority of FBDD programmes have been 
centred around the synthesis of sp2-rich compounds, often with multiple aromatic rings, 
which ultimately affects the overall three-dimensionality of the molecule. Nature recognises 
molecules three-dimensionally,36 and consequently molecules with a high degree of sp and 
sp2 character exhibit fewer interactions with the intended targets. There has therefore been 
a desire to begin probing three-dimensional chemical and biological space. 
The synthesis of sp3-rich, three-dimensional molecules introduces new vectors for 
elaboration,15 as well as improving the solubility by disrupting the solid state crystal lattice 
packing.37 An increase in sp3 character should deviate from the planarity associated with sp- 
and sp2-rich molecules, as well as increasing molecular complexity.38,39 To assess the 
complexity of potential drug candidates, a new descriptor called the fraction of sp3 (Fsp3) was 
coined by Lovering.38 This is defined by the number of sp3 hybridised carbons divided by the 
total carbon count. The rationale arises from saturation allowing the preparation of more 
complex molecules, without significantly increasing molecular weight.38 A good example for 
comparison is dimethylpyridine versus dimethylpiperidine. Dimethylpyridine has a Fsp3 of 
0.29, and has 5 accessible isomers. Comparatively, dimethylpiperidine has a Fsp3 of 1 and has 
34 accessible isomers, which are significantly more complex and exhibit greater three-
dimensionality than dimethylpyridine.   
The analysis and visualisation of molecular shape is an important tool in the design and 
characterisation of lead of compounds.40 The recognition of the large proportion of sp- and 
sp2-rich compounds in drug candidates, coupled with the desire to begin to explore three-
dimensional chemical space, has led to the increased synthesis of sp3-rich compounds. Having 
a high Fsp3 does not necessarily correlate to a molecule being three-dimensional, and 
consequently computational methods have been developed to analyse molecular shape. 
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1.5.1 Principal Moments of Inertia Analysis 
Principal moments of inertia (PMI) analysis is a means of portraying the three-dimensional 
shape of a molecule on a two-dimensional plot. The plot is ternary, and depicts the three 
extremes of molecular shape.41 The top left vertex of the plot represents an acetylene 
equivalent, a species that is sp hybridised and possesses a ‘rod-like’ shape. The bottom vertex 
of the plot represents a benzene equivalent, a species that is sp2 hybridised and possesses a 
planar shape. The top right vertex of the plot represents an adamantane equivalent, a species 
that is sp3 hybridised and possesses a cage or sphere-like structure. Therefore, a compound 
will lie somewhere between the three vertices depending on the degree of which it represents 
the three classes of morphology.42  
Different three-dimensional conformers are computationally generated, and the lowest 
energy conformer is determined. From this, moments of inertia are calculated along the x,y 
and z axes, to give Ix, Iy, and Iz respectively. Normalised PMI values are calculated by Ix/Iz and 
Iy/Iz which can then be represented on a two-dimensional plot.14,43,44 Owing to the 
normalisation of the values, the results of PMI analysis are irrespective of the size of the 
molecule.45 
PMI analysis can be used to profile the three-dimensionality of a large library of compounds 
with relative ease. The ZINC database is a free to use, online database of commercially 
available compounds for virtual screening. It currently contains almost one billion 
commercially available building-blocks, which in turn can be used for library synthesis.46 
Libraries from the ZINC database can be downloaded and analysed by users.  
A ‘lead-like’1 library was downloaded from the ZINC database, with restrictions on the 
properties of the compounds to have molecular weights <350 and AlogP values <3.5. The 
library consisted of 35,270 randomly selected molecules from the respective ZINC subset 
deemed to be ‘lead-like’. The 35,270 compounds were analysed using the LLAMA software, 
an open-access, online tool for the analysis of molecular scaffolds.14,47 Normalised PMI values 
were obtained and plotted onto a PMI plot (Figure 5). 
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Figure 5. PMI plot of the ZINC ‘lead-like’ database. 
 
The PMI plot shows that there is not a uniform distribution, and the area of space 
representing three-dimensional structures is very sparsely populated. In contrast, the area of 
space representing linear and planar molecules is very densely populated. The extra line on 
the plot represents a region where, to the left of the line, 75% of the molecules from the ZINC 
subset reside. This shows that 26,452 ‘lead-like’ compounds are in fact relatively two-
dimensional. The PMI plot above is a good representation of why there is a desire to 
synthesise more sp3 rich, three-dimensional compounds.  
 
1.5.2 Plane of Best Fit Analysis 
Plane of best fit (PBF) has been developed to quantify the three-dimensional character of 
molecules. The principal of PBF is to give a mean value for the atomic distance of all heavy 
atoms across the molecule from the plane through all heavy atoms, and a distance in 
angstroms is obtained. The bigger the distance, the more three-dimensional the molecule is.  
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In the context of the original precedent by Brown and Blagg, conformations of molecules were 
generated using CORINA software, with the absence of hydrogen atoms.40 From these 
conformations, coordinates were generated and subsequently used to calculate the plane of 
best fit via a least-squares method. The output of the equation was given as an average of the 
distances of the heavy atoms from the PBF in angstroms.  
Comparing the adamantane derivative 8 with amide 9 (Figure 6), the former exhibits a PBF 
score of 0.642 Å, whilst the latter has a PBF score of 0.805 Å.40 By means of PMI analysis, it 
would be assumed that the nitrile 8 bearing a spherical adamantane ring would be more 
three-dimensional than the amide 9 bearing an aromatic ring and a planar amide. However, 
placing a plane of best fit through the molecules, it can be seen that on average, the heavy 
atoms of amide 9 lie further from the plane than adamantane derivative 8. By PBF, amide 9 is 
more three-dimensional. 
 
 
Figure 6.Adamantyl derivative 8 and amide 9. 
 
To demonstrate the utility of PBF, two compounds NAD+ 10 and tricycle 11 (Figure 7) were 
analysed. The molecules have a similar Fsp3 of 0.476 and 0.474 respectively, however, NAD+ 
10 has a PBF of 1.53 Å and tricycle 11 has a PBF of 0.00475 Å. This highlights the potential 
flaws in the judgement of three-dimensionality based upon Fsp3. Comparison of the PBF score 
with the Fsp3 of 2465 fragment-like molecules (molecular weight<320, AlogP<3) showed that 
there was no correlation between the two methods of analysis.40  
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Figure 7. NAD+ 10 and tricycle 11. 
 
Whilst it should be noted that the Fsp3 was originally introduced as a measure of molecular 
complexity, it was recognised that there was a positive correlation between a high Fsp3 and 
clinical success.38 The introduction of PBF analysis has demonstrated that the use of Fsp3 can 
be misleading as a sole measure of three-dimensionality. Measurements of Fsp3 should be 
accompanied with either PBF or PMI analysis to assess three-dimensionality. Plane of best fit 
can itself be misleading when comparing molecules of vastly different sizes,40 however, in the 
context of small molecule analysis it is a useful method for quantifying three-dimensionality. 
Analysis by PMI gives normalised co-ordinates so results are irrespective of size, and it 
provides a visual representation of three-dimensionality on a plot for ease of comparison. 
Consequently, PMI analysis has been used for analysis of three-dimensionality in this thesis.  
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1.6 Synthesis of 2-Spiropiperidines 
 
Piperidines are among the most commonly found motifs in drugs, drugs candidates and 
natural products.48,49 As a fragment scaffold, they possess a hydrogen bond donor/acceptor 
for interactions with targets, as well as an amine handle for further functionalisations to be 
performed. Coupled with the desire to explore three-dimensional space, aza-spirocycles are 
consequently growing in popularity and frequency in medicinal chemistry as scaffolds and 
pharmacophores.48 Aza-spirocycles are conformationally well defined, which allows the 
elaboration of the spirocycle to occur along a series of well defined vectors. Troin reviewed 
the synthesis of spirocyclic piperidines as important building blocks in medicinal chemistry in 
2009.48 The review, however, only demonstrates the synthesis of 3- and 4-spiropiperidines, a 
result of the small amount of literature surrounding the synthesis of 2-spiropiperidines. 
It was therefore determined that an underrepresented yet highly desirable subset of 
spirocycles to synthesise were 2-spiropiperidines. Examples from the current literature for 
the synthesis of 2-spiropiperidines from both methodology and natural product synthesis 
perspectives are presented below. There are few examples that present general methods for 
the synthesis of 2-spiropiperidines, and the procedures are often solely for the synthesis of 
specific systems. The development of a general procedure for the synthesis of 2-
spiropiperidines was consequently highly appealing. 
An intramolecular Mannich reaction was developed by Troin for the synthesis of 2-
spiropiperidines.50 Condensation of amine 12 with cyclohexanone gave an iminium ion, which 
underwent an intramolecular Mannich reaction to give 2-spiropiperidine 13 in a good 74% 
yield (Scheme 1). The scope of the spirocyclisation was probed and was shown to proceed 
with four- to seven-membered aliphatic cyclic ketones, as well as with adamantanone.  
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Scheme 1. 2-Spiropiperidine synthesis via an intramolecular Mannich reaction. 
 
Rychnovsky presented a sequential alkylation of α-amino nitriles followed by a reductive 
lithiation and cyclisation to give 2-spiropiperidines.51 Alkylation of α-amino nitrile 14 with 
alkyl bromide 15 gave the cyclisation precursor 16 in an excellent 98% yield (Scheme 2). 
Reductive lithiation of α-amino nitrile 16 with lithium 4,4’-di-tert-butylbiphenylide (LiDBB) 
gave the lithiated intermediate 17. Subsequent cyclisation onto the terminal alkene gave 2-
spiropiperidine 18 in a good 67% yield with an excellent 20:1 diastereoselectivity. The 
reaction was demonstrated to introduce differently substituted five and six-membered 
spirocycles in moderate to good yields.  
 
 
Scheme 2. Reductive lithiaton/alkylation to furnish 2-spiropiperidines. 
 
The reductive lithiation-cyclisation reported by Rychnovsky forms the 2-spiropiperidine from 
a preformed piperidine ring.51 This approach was later reversed by Rychnovsky, and in 2013 
the synthesis of a 2-spiropiperidine from a preformed carbocyclic ring was developed, with 
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the formation of the piperidine as the key bond forming reaction.52 Just one example of a 2-
spiropiperidine was presented. α-Amino nitrile 19 was envisaged as a trianion synthon for a 
double alkylation/cyclisation sequence (Scheme 3). N-Boc-α-amino nitrile 19 underwent 
double alkylation with dibromide 20 which installed the tertiary α-amino centre of 21. The 
alcohol 22 was then revealed by the treatment of TBS-protected 21 with TBAF. Conversion of 
the alcohol to a leaving group gave phosphonate 23, and a subsequent reductive lithiation 
induced spirocyclisation to 2-spiropiperidine 24.  
 
 
Scheme 3. A trianion synthon approach to 2-spiropiperidines. 
 
Substituted benzopyrans had been determined as 5HT1A receptor ligands as well as potential 
anxiolytic agents by Guillaumet and coworkers.53 Cyclisation precursor 25 was synthesised by 
aldol addition of the nitro benzopyran with the respective aldehyde (Scheme 4). 
Hydrogenation of the nitro group gave the amine which induced lactamisation to 2-spiro-δ-
lactam 26 in a high 80% yield. The lactam was later reduced with BH3 to furnish the 2-
spiropiperidine, and the amine was derivatised to synthesis analogues.  
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Scheme 4. Reductive amidation to form a 2-spirolactam. 
 
Tin amine protocol (SnAP) reagents have been developed by Bode as precursors to 
functionalised heterocycles. Heterocyclic systems synthesised using SnAP reagents include 
piperazines and morpholines,54,55 thiomorpholines,56 piperidines and pyrrolidines,57 and 
diazepanes.58,59 The SnAP reagents are commercially available, and treatment of the SnAP 
reagents with aldehydes or ketones and Cu(OTf)2 gives rise to substituted and spirocyclic 
heterocycles. Condensation of SnAP reagent 27 with tetrahydro-4H-pyranone 28 gave imine 
29 (Scheme 5).57 Upon addition of Cu(OTf)2, homolytic cleavage of the C-Sn bond occurred 
followed by a radical addition to the imine, giving 2-spiropiperidine 30 in a moderate 41% 
yield. Utilisation of a different SnAP reagent 31 with azetidinone 32 under the same 
conditions gave 2-spiropiperidine 34 in a moderate 37% yield (Scheme 5).57 The robust 
reaction does not require protection of the piperidine nitrogen, and has been applied to the 
synthesis of a range of different 2-spiropiperidines. The reaction, however, does require the 
use of toxic organotin reagents. 
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Scheme 5. 2-Spiropiperidine synthesis with SnAP reagents. 
 
The synthesis of tricyclic, bridged 2-spiropiperidines was developed by Guo and coworkers by 
means of a silver-catalysed [6+3] cycloaddition. Under mild conditions, the cycloaddition 
proceeded to give 2-spiropiperidines in moderate to excellent yields with excellent 
diastereoselectivities.60 Treatment of precursor 35, which was derived from homoserine 
lactone, with AgOAc generated an azomethine ylide which underwent a [6+3] cycloaddition 
with tropone 36 to give the bridged 2-spiropiperidine 37 (Scheme 6). The scope of the 
cycloaddition was demonstrated with different aromatic substituents on the piperidine. 
 
 
Scheme 6. [6+3] Cycloaddition of tropone 36 to azomethine ylides. 
 
Silvani reported a ring closing metathesis reaction for the synthesis of a spiropiperidine-3,3’-
oxindole scaffold as a type II β-turn peptide isostere.61 The scaffold possessed a 2-
spiropiperidine, which was synthesised in five steps from isatine 38 (Scheme 7). Amine 38 was 
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formed via Grignard addition of allyl bromide into a chiral sulfinimine, followed by amine 
deprotection with HCl.62 Acetylation of amine 38 with Ac2O gave acetamide 39 in a high 85% 
yield, which was then alkylated with allyl bromide to give diene 40 in a good 70% yield. Ring 
closing metathesis gave tetrahydropyridine 41 which was subsequently reduced by 
hydrogenation to give 2-spiropiperidine 42 in an excellent 97% yield.61 
 
 
Scheme 7. Synthesis of a 2-spiropiperidine as a type II β-turn peptide isostere. 
 
Carreira also reported the synthesis of a 2-spiropiperidine via a ring closing metathesis.63 
Amine 44 underwent Michael addition into α,β-unsaturated aldehyde 43, followed by a Wittig 
methylenation to furnish diene 45 in a moderate 53% yield over 2 steps (Scheme 8). The 2-
spiropiperidine 46 was formed by a ring closing metathesis using Grubbs II catalyst, followed 
by a hydrogenation of the tetrahydropyridine. The simple procedure, however, only presents 
the synthesis of a spirocyclic oxetane. 
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Scheme 8. Ring closing metathesis to access spirocyclic oxetanes. 
 
An intramolecular 1,3-dipolar cycloaddition of nitrones was developed by Coldham for the 
synthesis of spirocyclic pyrrolidines and piperidines.64 Displacement of the chloride of ketone 
47 with hydroxylamine followed by an intramolecular condensation gave the intermediate 
nitrone 48 (Scheme 9). At elevated temperatures, nitrone 48 underwent an intramolecular 
1,3-dipolar cycloaddition with the terminal olefin to give tricycle 49 in an excellent 89% yield. 
The N-O bond was then reductively cleaved with Zn in AcOH to give 2-spiropiperidine 50. The 
1,3-dipolar cycloaddition was applied to the synthesis of five, six and seven-membered 
spirocycles in moderate to high yields.  
 
 
Scheme 9. 1,3-Dipolar cycloaddition followed by reductive cleavage for 2-spiropiperidine synthesis. 
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A ring expansion of enantiopure 2-spiropyrrolidines was presented by Robinson for the 
synthesis of 2-spiropiperidines.65 Enantiopure cyclisation precursor 51 was synthesised via a 
cross metathesis between N-Bz protected allylglycine and methylenecyclohexane (Scheme 
10). An acid mediated intramolecular cyclisation of amine 51 with TfOH gave 2-
spiropyrrolidine 52 in a good 79% yield. Reaction with LiAlH4 reduced the ester to the primary 
alcohol 53 as well as reducing the protecting group from a Bz to a Bn. Under Appel reaction 
conditions, the 2-spiropyrrolidine 53 underwent ring expansion to the 2-spiropiperidine 55. 
Seemingly the alcohol was converted to the bromide, which was then displaced by the 
pyrrolidine nitrogen to form the aziridinium intermediate 54. Re-addition of the bromide 
afforded ring opening of the aziridinium intermediate 54 to give 2-spiropiperidine 55. Due to 
the instability of the 2-spiropiperidine 55 to silica gel during column chromatography, 
conversion of the bromide to the thiocyanate analogue gave 2-spiropiperidine 56 in a good 
72% yield, though with a slight erosion of %ee (from 100% ee of enantiopure 51). 
 
 
Scheme 10. Ring expansion of a 2-spiropyrrolidine. 
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The 2-spiropiperidine motif has been identified in natural products. Histrionicotoxin 57 
(Figure 8) was isolated from the skin extracts of frogs,66 and has been used as an important 
neurophysiological research tool.67 Pinnaic acid 58 (Figure 8),68 and the closely related 
tauropinnaic acid68 and halichlorine,69 were all isolated from marine sponges and have been 
demonstrated to possess anti-inflammatory properties.70 Nankakurine A 59 (Figure 8) is a 
lycopodium alkaloid isolated from a club moss.71 It has been found to induce secretion of 
neurotrophic factors from human astrocytoma cells.72 Methods for the construction of the 2-
spiropiperidine core of these natural products will be presented below.  
 
 
Figure 8. Natural products containing 2-spiropiperidines; histrionicotoxin 57, pinnaic acid 58 and 
nankakurine A 59. 
 
Marquez developed a divergent approach to the polymaxenolide (2-spiropyran containing) 
and pinnaic acid (2-spiropiperidine containing) cores.73 Achmatowicz and aza-Achmatowicz 
rearrangements of α-hydroxy furans and α-amino furans gave 2-spiropyran-3-ones and 2-
spiropiperidin-3-ones respectively. Upon oxidation with mCPBA, α-amino furan 60 underwent 
an aza-Achmatowicz rearrangement to give 2-spirotetrahydropyridine 61 (Scheme 11). 
Subsequent allylation of the hemiaminal under Lewis acidic conditions gave 62 in a good 64% 
yield over the two steps. A selective 1,4-reduction of 2-spirotetrahydropyridine 62 with 
Stryker’s reagent furnished 63, which was deoxygenated with tosylhydrazine and DIBAL-H to 
give 2-spiropiperidine 64 in a moderate 55% yield.  
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Scheme 11. Aza-Achmatowicz rearrangement of an α-amino furan to a 2-spiropiperidine. 
 
There have been multiple syntheses of histrionicotoxin and related analogues beginning with 
syntheses by Kishi in 1985 (38 steps)74 and by Stork in 1990 (18 steps).75 Since these syntheses, 
more concise methods have been reported, including the use of cross metathesis,76 
displacement chemistry,77 ring expansions,78 and radical cyclisations.79  
Stockman reported the desymmetrisation of an open chain ketone 65 en route to the 
synthesis of histrionicotoxin 57 (Scheme 12).80 Oxime formation by condensation of 
hydroxylamine with ketone 65 followed by conjugate addition and a 1,4-prototopic shift gave 
nitrone 66. At 50 oC, nitrone 66 underwent an intramolecular [3+2] cycloaddition to form 
tricycle 67.  It was found that heating tricycle 67 to 180 oC in a sealed vial induced a retro [3+2] 
cycloaddition/[3+2] cycloaddition sequence to give the thermodynamic product 68 in an 
excellent 95% yield. The N-O bond was later cleaved with superstoichiometric CrCl2 and nPrSH 
to reveal the 2-spiropiperidine core. Ryan demonstrated that the N-O bond could be cleaved 
by hydrogenation in a similar synthesis to access the core 2-spiropiperidine of histrionicotoxin 
57.81 
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Scheme 12. 1,3-Dipolar cycloaddition for the synthesis of the core of histrionicotoxin. 
 
A conjugate addition/dipolar cycloaddition cascade was developed by Padwa for the synthesis 
of (±)-2,7,8-epi-perhydrohistrionicotoxin.82 The chemistry derives from research developed 
by Padwa in 1991 for the synthesis of 2-substituted- and 2-spiropiperidines.83 Oxime 69 
underwent conjugate addition with diene 70 to give a nitrone, and subsequent 1,3-dipolar 
cycloaddition generated 2-spiropiperidines 71 and 72 in a high 82% yield as a 1:1 mixture of 
diastereomers (Scheme 13). The lack of selectivity was not an issue, as the oxo-bridge was 
subsequently destroyed via a reductive cleavage with Na/Hg amalgam to give ketone 73 in a 
good 69% yield. The sulfone was then reduced to the alkane using radical reduction conditions 
of AIBN/SnBu3 to give 2-spiropiperidine 74. 
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Scheme 13. Conjugate addition/dipolar cycloaddition cascade to give a 2-spiropiperidine. 
 
Several syntheses of pinnaic acid have been reported, the first by Danishefsky in 2001, 
forming the 2-spiropiperidine by an aza-1,6-conjugate addition.84 Other reported syntheses 
include accessing the 2-spiropiperidine via a reductive cyclisation,85,86 aza-1,4 conjugate 
addition,87 and radical cylisations.88 Ring closing metathesis to form the piperidine was 
reported by Wright89 via a similar procedure presented by Silvani for the synthesis of an 
isatine analogue 42.61 
A racemic synthesis of pinnaic acid was performed by Heathcock.70 Allylation of hemiaminal 
75 with allyltrimethylsilane and TiCl4 gave terminal alkene 76 (Scheme 14). A cross metathesis 
of terminal alkene 76 with ethyl 3-oxo-4-pentenoate gave cyclisation precursor 77 in a high 
80% yield. Removal of the Cbz group of 77 by hydrogenation revealed the free amine, and 
subsequent 1,2-addition followed by dehydration and reduction gave 2-spiropiperidine 78 in 
an excellent 87% yield as a single isomer. Arimoto also reported a hydrogenative cyclisation 
but from an enantiopure starting material for the enantioselective synthesis of pinnaic 
acid.90,91   
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Scheme 14. Hydrogenation/hydrogenolysis sequence to access a 2-spiropiperidine. 
 
Overman presented an enantioselective synthesis of nankakurine A proceeding through an 
intramolecular azomethine imine cycloaddition with hydrazide 79 to give tetracyclic 
pyrazolidine 80 in a high 85% yield (Scheme 15).92,93 The N-N bond was cleaved with SmI2, and 
a selective in situ reductive amination gave diamine 81 in a high 80% yield over two steps. 
Hydrogenolytic cleavage revealed the free alcohol 82, and subsequent treatment with AlH3 
reduced the amide to give diamino alcohol 83. A selective O-mesylation allowed substitution 
to occur, furnishing the 2-spiropiperidine 84 in an excellent 96% yield. 
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Scheme 15. Intramolecular azo-methine imine dipolar cycloaddition to construct the precursor to 
the 2-spiropiperidine of nankakurine A. 
 
A ring closing metathesis approach was adopted by Waters for the synthesis of nankakurine 
A,94 and is reminiscent of the methodology presented by Silvani for the synthesis of the isatine 
analogue 42.61 Sequential alkylation of ketone 85 with allylamine and allyl magnesium 
bromide gave diene 86 (Scheme 16). Ring closing metathesis with Grubbs II catalyst formed 
the 2-spirotetrahydropyridine 87, which was then reduced by hydrogenation to give the 
natural product nankakurine A 59 in an excellent 98% yield.  
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Scheme 16. Ring closing metathesis to form the 2-spiropiperidine of nankakurine A. 
  
Whilst the presented examples are not extensive, the methodologies for the syntheses of the 
2-spiropiperidines highlight the absence of general procedures.  Moreover, the 
methodologies that do present general syntheses give rise to either non-functionalised 2-
spiropiperidines, or require the synthesis or use of complex reagents and intermediates. The 
combination of the limitations means that there is a possibility that the use of 2-
spiropiperidines in drug discovery programs has been underutilised.  
It was therefore recognised that the development of a general procedure for the synthesis of 
functionalised 2-spiropiperidines would be productive. This would allow the rapid generation 
of structurally interesting molecules that could be used for a drug discovery program.  
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2. Synthesis of 2-Spiropiperidines 
 
2.1 Aza-Maitland Japp 
 
The aza-Maitland Japp reaction was reported by Clarke for the synthesis of highly 
functionalised piperidines.95 Adapting previous methodology from within the group for the 
one-pot synthesis of highly functionalised tetrahydropyrans 90 (Scheme 17),96 the initial 
aldehyde equivalent 88 was substituted for a tosyl aldimine 91, giving rise to a one-pot 
synthesis of functionalised piperidines 93 (Scheme 18).95 
 
 
Scheme 17. The Maitland Japp reaction for highly functionalised tetrahydropyrans. 
 
 
Scheme 18. The aza-Maitland Japp reaction highly functionalised piperidines. 
 
Under the reaction conditions, ring opening of diketene with TiCl4 gave titanium enolate 94, 
which underwent Mannich addition to a tosyl aldimine 91 (Scheme 19). Methanolysis and 
protonation gave the intermediate N-tosyl-δ-amino-β-ketoester 92.  
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Scheme 19. Formation of the intermediate N-tosyl-δ-amino-β-ketoester 92 in the Aza-Maitland Japp 
reaction. 
 
The reaction was then postulated to proceed via one of two mechanistic pathways (Scheme 
20). By either first forming the Knoevenagel adduct 96 with the aldehyde, followed by an aza-
Michael addition to give functionalised piperidine 93, or in an alternate hypothesis, iminium 
ion 97 was formed with the aldehyde, and a second Mannich addition of the tautomerised β-
ketoester gave piperidine 93. 
 
 
Scheme 20. Plausible mechanistic pathways for the formation of piperidine 93. 
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The one-pot procedure was demonstrated to proceed with a range of aliphatic and aromatic 
C-2 and C-6 substituents in moderate to excellent yields and diastereoselectivities. Separation 
of the diastereomers was challenging. However, it was determined that the trans 
diastereomer could be epimerised to the cis diastereomer under basic conditions (Scheme 
21). Treatment of a mixture of cis 98a and trans 98b diastereomers with K2CO3 resulted in the 
exclusive isolation of the cis diastereomer 98a in an excellent 99% yield. 
 
 
Scheme 21. Epimerisation of diastereomers from the Aza-Maitland Japp reaction. 
 
The aza-Maitland Japp reaction had been shown to proceed with aldehydes and aldimines, 
however, the use of ketones or ketimines to give rise to spirocyclic piperidines had not been 
reported. It was therefore desirable to expand the scope of the Aza-Maitland Japp reaction 
to allow the synthesis of 2-spiropiperidines.  
 
2.2 Cyclisation Studies with a Tosyl Protecting Group 
Studies towards the synthesis of 2-spiropiperidines began with replication of the conditions 
reported for the synthesis of 2,6-substituted piperidines,95 except the aldehyde equivalent 
was exchanged for a ketone. N-Tosyl aldimine 101 was synthesised via a literature 
procedure.97 Benzaldehyde was treated with tosylamide and sodium toluenesulfinate to give 
the intermediate sulfone 100 (Scheme 22). Sulfone 100 was not isolated, and instead 
subjected to a basic wash with sat. aq. NaHCO3, which eliminated toluenesulfinic acid to give 
imine 101 in a good 78% yield. Imine 101 was used for the cyclisation without further 
purification. 
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Scheme 22. Synthesis of aldimine 101 from benzaldehyde. 
 
Aldimine 101 was treated with TiCl4, diketene and cyclohexanone under the reported 
conditions (Scheme 23).95 Unfortunately, no cyclised product was observed, however, N-
Tosyl-δ-amino-β-ketoester 102 was isolated from the reaction mixture in a moderate 37% 
yield. This showed that Mannich addition was occurring, but subsequent Knoevenagel/aza-
Michael or iminium/Mannich reactions were not taking place to form the desired 2-
spiropiperidine.  
 
 
Scheme 23. One-pot conditions for cyclisation with cyclohexanone. 
 
To see if cyclisation could be induced, N-tosyl-δ-amino-β-ketoester 102 was treated with 
different Lewis acids at room temperature in the presence of cyclohexanone. Lewis acids 
included TiCl4, YbCl3, AlCl3 and BF3.OEt2, but in all cases only unreacted starting material was 
isolated from the reaction mixtures.  
It was believed that synthesising the piperidine in a stepwise-manner could help elucidate the 
reaction pathway and understand the reasons for the unsuccessful one-pot procedure. Initial 
investigations used acetone, as it was the smallest, symmetrical ketone that could be used. 
This would ultimately not give rise to a 2-spiropiperidine, however, it would provide insight 
into cyclisations with a ketone. N-Tosyl aldimine 101 was treated with the Weiler dianion,98 
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the dianion of methyl acetoacetate, in a procedure highlighted by Bunch for the synthesis of 
N-Boc-δ-amino-β-ketoesters, to give rise to N-tosyl-δ-amino-β-ketoester 102 in a good 67% 
yield (Scheme 24).99  
 
 
Scheme 24. Synthesis of the Knoevenagel adduct 103. 
 
The synthesis of Knoevenagel adduct 103 was found to be challenging. Various methods were 
trialled for performing the Knoevenagel condensation, including the use of 
ethylenediamine,100 ZnCl2,101 acetic acid,102 and TiCl4.103 Only the use of TiCl4 yielded any of 
the desired Knoevenagel adduct 103, with the other methods giving no reaction, with starting 
material being re-isolated in all cases. The Knoevenagel condensation was found to be 
capricious, and a low 26% yield of isolation of 103 was the best result of multiple attempts. 
With the Knoevenagel adduct 103 in hand, the cyclisation was attempted to form the 2,2-
dimethyl piperidine. Treatment of Knoevenagel adduct 103 with TiCl4 did not induce 
cyclisation, instead the elimination of tosylamide was observed to give conjugated enone 104, 
along with unreacted starting material (Scheme 25).  
 
 
Scheme 25. Elimination of tosylamide to give conjugated enone 104. 
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To clarify the identity of enone 104, an alternate synthesis was devised (Scheme 26). δ-
Hydroxy-β-ketoester 105 was synthesised via a literature procedure by way of an aldol 
addition of diketene to benzaldehyde (Scheme 26).104 Acetate formation/elimination of the 
alcohol of δ-hydroxy-β-ketoester 105 with Ac2O yielded diene 106 in a moderate 44% yield.105 
Presumably the alcohol underwent acylation, but subsequent elimination of acetic acid in the 
presence of a base gave the conjugated system. This was a fortuitous result, as a Knoevenagel 
condensation would directly give the desired product enone 104. Treatment of diene 106 
with TiCl4 and acetone103 gave rise to the desired conjugated enone 104 in a low 13% yield. 
The data obtained for enone 104 was identical to the data obtained from the previous 
method.  
 
 
Scheme 26. Clarification of the structure of enone 104. 
 
In the proposed reactive intermediate for the cyclisation of the N-tosyl-δ-amino-β-ketoester 
onto the Knoevenagel adduct (Figure 9), an unfavourable 1,3-diaxial interaction between the 
phenyl group and the axial methyl group is observed (Figure 9, 107). Upon ring flipping, the 
destabilising interaction is eliviated, giving a more favoured conformation (Figure 9, 108).  
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Figure 9. Proposed reactive intermediates for the Knoevenagel pathway. 
 
Equally in the proposed reactive intermediates for the Mannich reaction of the enolate onto 
the iminium ion (Figure 10), a 1,3-diaxial interaction between the phenyl group and the axial 
methyl substituent is observed (Figure 10, 109). However, in the ring flipped conformation, 
an A1,2-like strain between the N-tosyl group and the phenyl group is observed (Figure 10, 
110). To properly elucidate which pathway is undertaken, a method such as ReactIR could be 
used to monitor Knoevenagel adduct/iminium formation. 
  
 
Figure 10. Proposed reactive intermediates for the iminium pathway. 
 
For cyclisation to occur, it was believed that at least one of these destabilising interactions 
had to be removed. Eradication of the 1,3-diaxial interaction was not possible, otherwise 2-
spiropiperidines could not be synthesised via this method. Consequently, it was believed that 
deprotection of the amine would remove the destabilising A1,2-like strain and induce 
cyclisation. Knoevenagel adduct 103 was treated with magnesium turnings and refluxed in 
methanol,106,107 but only decomposition of starting material was observed (Scheme 27). 
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Scheme 27. Attempted deprotection of δ-amino-β-ketoester 103. 
 
Owing to the low yielding reactions and the low quantities of material of the intermediates, 
an alternative approach was required. The N-protecting group was changed from an N-tosyl 
group to an N-Boc group. The Boc group is more labile than a tosyl group, so cyclisation could 
be attempted on the unprotected amine, yet also makes the imine carbon electrophilic 
enough for Mannich addition to occur. 
 
2.3 Cyclisation Studies with a Boc Protecting Group 
Studies began with the synthesis of N-Boc imine 113 in a procedure disclosed by Lam (Scheme 
28).108 Treatment of benzaldehyde with Boc-amide and sodium benzenesulfinate gave rise to 
sulfone 112, which was isolated in an excellent 94% yield. Elimination of benzenesulfinic acid 
was achieved by refluxing 112 in Cs2CO3, to give N-Boc imine 113 in a high 89% yield.  
 
 
Scheme 28. Synthesis of N-Boc imine 113. 
 
It was believed that subjecting N-Boc imine 113 to the original cyclisation conditions reported 
by Clarke with an aldehyde95 would result in deprotection and cyclisation (Scheme 29). 
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However, neither piperidine 115 nor the intermediate δ-amino-β-ketoester 114 was 
observed, instead a complex mixture of products was obtained.  
 
 
Scheme 29. One-pot conditions with an N-Boc imine. 
 
It was therefore decided to investigate, in the first instance, a stepwise approach towards the 
synthesis of 2-spiropiperidines. It was postulated that 2-spiropiperidine 116 could be formed 
from a cyclisation of salt 117 with a ketone (Scheme 30). The salt 117 would arise from 
deprotection of N-Boc-δ-amino-β-ketoester 118, which in turn could be synthesised via a 
Mannich reaction between an N-Boc imine 119 and the Weiler dianion 120. 
 
 
Scheme 30. Retrosynthetic plan for the synthesis of 2-spiropiperidines. 
 
Imine precursors 122a-k were synthesised using the procedure of Lam (Scheme 31),108 giving 
a wide range of aliphatic (122a-c), aromatic (122d-f, j) and heteroaromatic (122g-i) sulfones 
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in moderate to excellent yields.109 The synthesis was trialled with protected and non-
protected indoles, but issues with substrate solubility resulted in no reaction occurring.  
     
 
Scheme 31. Synthesis of N-Boc imine precursors 122a-j. 
 
Upon analysis of N-Boc-sulfones 122a-k, the desired mass peak was rarely observed in the 
compounds’ HRMS. Instead, the mass of the methanol adduct 124 was observed. The HRMS 
samples were run using methanol as a solvent, and the mass observed was the addition of 
methanol to the imine that was supposedly forming during the HRMS procedure through 
elimination of benzene sulfinate (Scheme 32).   
 
 
Scheme 32. Elimination of benzene sulfinate in HRMS. 
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Mannich product 126d was first synthesised using the procedure of Bunch99 with imine 113 
(Scheme 33). Double deprotonation of methyl acetoacetate 125 with 2 equivalents of LDA 
generated the Weiler dianion 120,98 which, when treated with imine 113, yielded δ-amino-β-
ketoester 126d in a moderate 44% yield. However, with multiple runs of the reaction, the 
experimental yield was always significantly lower than previously reported in the literature 
(44% yield experimental, 80% yield in literature99). There were also issues encountered with 
the isolation of aliphatic N-Boc imines, presumably because of their low molecular weights 
and assumed high volatility and instability. Consequently, it was believed that the formation 
of N-Boc imines should be performed in situ.  
 
 
Scheme 33. Mannich addition of the Weiler dianion to imine 113. 
 
Zwierzak reported the in situ formation of aliphatic N-Boc imines from similar N-Boc sulfones 
as electrophiles for the synthesis of aminoalkylphosphonates.110 Using a similar approach, N-
Boc sulfones 122a-j were treated with NaH, and after consumption of starting material by 
TLC, were added to the Weiler dianion 120 (Scheme 34).109 Through this method, N-Boc-δ-
amino-β-ketoester 126d was isolated in a higher 73% yield than that reported above in 
Scheme 33, and allowed the synthesis of N-Boc-δ-amino-β-ketoesters 126a-j in moderate to 
high yields. The robustness of the reaction was demonstrated by the synthesis of N-Boc-δ-
amino-β-ketoesters bearing aliphatic (126a-c), aromatic (126d-f, j) and heteroaromatic (126g-
i) substituents. The reaction was also found to be scalable with N-Boc-δ-amino-β-ketoesters 
126e, g, h synthesised on a 5 g scale, all with retention of yield.  
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Scheme 34. Synthesis of δ-amino-β-ketoesters 126a-j from N-Boc sulfones 122a-j. 
 
Treatment of N-Boc-δ-amino-β-ketoester 126d with TiCl4 and cyclohexanone unsurprisingly 
did not induce any desired cyclisation. It was therefore believed that deprotection of the 
amine had to occur for cyclisation to proceed. Davis reported the formation of 2,6-substituted 
piperidines by cyclisation of the TFA salt of δ-amino-β-ketoesters with an aldehyde.111 In a 
slightly modified approach, deprotection of N-Boc-δ-amino-β-ketoester 126d with neat TFA 
gave TFA salt 128d in a quantitative yield (Scheme 35). Subjecting TFA salt 128d to a biphase 
of sat. aq. NaHCO3 and CH2Cl2 in the presence of butyraldehyde induced cyclisation give 2,6-
substituted piperidine 129 in a 40% crude yield.  
Piperidine 129 was not purified due to issues with column chromatography, but its formation 
was confirmed by 1H NMR agreement with the data reported by Clarke.95 The overall yield of 
the reaction was difficult to obtain, as not only was column chromatography a challenge, the 
mass after deprotection was >100%. Consequently, there was not a true representation for 
the amount of starting TFA salt 128d. Lyophilisation was used to remove excess TFA from the 
salt 128d, but instead of retrieving an anticipated solid, the outcome was a highly viscous oil 
that was difficult to handle and still had a yield >100%.   
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Scheme 35. Cyclisation from the TFA salt. 
 
In concurrence with Davis, in the absence of an aldehyde, the free base of salt 128 underwent 
intramolecular lactamisation to give β-keto-δ-lactam 130 (Scheme 36).111 Lactam 130 was not 
observed in the formation of piperidine 129, suggesting that upon cracking of the salt, 
reaction with the aldehyde and subsequent cyclisation is faster than intramolecular 
lactamisation.  
 
Scheme 36. Cyclisation in the absence of an aldehyde to form a lactam. 
 
Owing to the difficulties associated with TFA salt isolation, the AcOH salt was synthesised 
instead using neat glacial AcOH. Cyclisations were performed using salt 131 and benzaldehyde 
to give known piperidine 13295 (Scheme 37, Table 1).  
Repetition of the conditions reported by Davis111 (Table 1, Entry 1) gave a low crude yield, and 
no product was isolated from the silica plug filtration. Reacting in a sat. aq. NaHCO3 biphase 
with different solvents (Table 1, Entry 2-5) gave low crude yields and low isolated yields with 
moderate dr. Introducing NaHCO3 as a solid instead of an aqueous solution with varied 
solvents (Table 1, Entry 6-8) gave much higher crude yields, however, the isolated yields were 
still low.  
Coupled with the accompanying low isolated yields of cyclisation, lyophilisation was deemed 
too time consuming, so the acetic acid salt was changed to the HCl salt; formed with 4M HCl 
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in dioxane solution through deprotection of the N-Boc-δ-amino-β-ketoester. Unlike the TFA 
and AcOH salts, the HCl salt was isolated as a stable solid. Treatment of the HCl salt with a 
basic biphase (Table 1, Entry 9) gave a low isolated yield, as did the use of solid NaHCO3 with 
THF and Et2O (Table 1, Entry 10-11). There was however one anomalous result with solid 
NaHCO3 and CH2Cl2 (Table 1, Entry 12), giving a high, reproducible 82% isolated yield and good 
6:1 dr. These conditions (5 eq NaHCO3 (s), 5 eq aldehyde, CH2Cl2 (0.3 M)) were selected as 
standard conditions to proceed with our studies towards the synthesis of 2-spiropiperidines. 
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Scheme 37. Cyclisation of different acid salts 131 to give piperidine 132. 
 
Entry Salt Conditions Solvent Crude Yield Isolated Yielda drb 
1 AcOH Sat. aq. NaHCO3 
quench 
CH2Cl2 72% n/a 5:1 
2 AcOH Sat. aq. NaHCO3 
(2.5 eq) biphase 
Et2O 57% 28% n/ab 
3 AcOH Sat. aq. NaHCO3 
(2.5 eq) biphase 
THF 120% 35% 4:1 
4 AcOH Sat. aq. NaHCO3 
(5 eq) biphase 
THF 87% 22% 5:1 
5 AcOH Sat. aq. NaHCO3 
(5 eq) biphase 
THF 68% 40% 6:1 
6 AcOH NaHCO3(s) Et2O 199% 36% 5:1 
7 AcOH NaHCO3(s) THF 148% 43% 5:1 
8 AcOH NaHCO3(s) THF 165% 20%  3:1 
9 HCl Sat. aq. NaHCO3 
(5 eq) biphase 
THF 188% 18% 5:1 
10 HCl NaHCO3(s) THF 106% 46% 5:1 
11 HCl NaHCO3(s) Et2O 98% 20% >20:1 
12 HCl NaHCO3(s) CH2Cl2 199% 82% 6:1 
 
Table 1. Conditions for the cyclisation of different acid salts 131 to give piperidine 132. aIsolated 
yields after a silica plug filtration. bThe dr of the cyclisation was derived from the 1H NMR spectrum 
of the crude reaction mixture.  
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2.4 Synthesis of 2-Spiropiperidines 
For the studies towards 2-spiropiperidines, the use of symmetrical ketones was desirable as 
the number of possible diastereomers would be just two. Acetone was the chosen ketone for 
the first cyclisation. Assuming clean and complete conversion, excess acetone would be 
removed in vacuo, so subsequent purification by column chromatography would not be 
required. Subjection of HCl salt 133 to 5 eq of acetone and 5 eq of NaHCO3 (s) in CH2Cl2 gave 
rise to 2,2,6-substituted piperidine 134a in high isolated yield and low 2.5:1 dr (Scheme 38), 
with no further purification required. The reaction was repeated for the use of aromatic 
(134b) and heteroaromatic (134c) C-6 substituents (Figure 11), with clean conversion to the 
respective piperidines observed and high isolated yields. 
 
 
Scheme 38. Initial cyclisation with a ketone. 
 
 
Figure 11. Examples of cyclisation with acetone. 
 
A geminal dimethyl group had been successfully installed at C-2 with acetone, so the next 
choice of ketone was different sized symmetrical carbocyclic ketones. Following the general 
procedure for piperidine synthesis (Scheme 39), 2-spiropiperidines were synthesised in good 
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to high yields (Figure 12). The procedure has been demonstrated with the introduction of 
cyclohexyl (135a-c), cyclopentyl (136) and cyclobutyl (137a-b) 2-spiropiperidines.  
 
 
Scheme 39. General procedure for the synthesis of 2-spiropiperidines. 
 
 
Figure 12. Examples of 2-spiropiperidines bearing carbocyclic spirocycles. 
 
The scope of the general procedure for the synthesis of 2-spiropiperidines was expanded for 
the introduction of heterocyclic spirocycles (Figure 13). Pyrans (138a-f), thiopyrans (139a-b), 
piperidines (140) and oxetanes (141) have been introduced via this method in moderate to 
high yield. The reaction has also been demonstrated with aliphatic, aromatic and 
heteroaromatic C-6 substituents. The synthesis of 2-spiropiperidine 138d was performed on 
a 1.5 g scale with retention of yield, demonstrating the robustness of the procedure.  
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Figure 13. Examples of 2-spiropiperidines bearing a heterocyclic spirocycle. 
 
It had been found that some of the 2-spiropiperidines were water soluble, and during 
aqueous work-up some product 2-spiropiperidine was lost in the water layer. Consequently, 
upon completion of the spirocyclisation for all 2-spiropiperidines, the reaction mixture was 
filtered, concentrated in vacuo and loaded directly onto silica gel for column chromatography. 
2-Spiropiperidines 135a and 135b were exceptions and were purified by aqueous work-up, 
because of co-elution of cyclohexanone with the 2-spiropiperidine. The use of polar C-6 
substituents ultimately made separation of the 2-spiropiperidine from the excess ketone 
easier. Many of the 2-spiropiperidines were found to be unstable to acidified silica gel during 
column chromatography, so triethylamine deadened silica gel was required. A plausible 
mechanism for decomposition would be to go via a retro-Mannich reaction, which would give 
rise to reactive intermediates susceptible to hydrolysis and other modes of reaction. 
Unfortunately, diastereomers could not be separated by column chromatography in all cases. 
Only the major diastereomer is reported in this thesis. Diastereomers were separable by 
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LCMS, but upon submission to purification by mass directed auto-purification (MDAP), no 
product was retrieved. This unfortunate result was consistent as multiple 2-spiropiperidines 
were subjected to MDAP for diastereomer separation, but all were unsuccessful and product 
was lost. Presumably, the 2-spiropiperidines were decomposing on the silica gel column 
during the chromatography. 
Interestingly, the dr of the crude reaction mixture for 2-spiropiperidine 139b was 0.95:1 in 
favour of the opposite diastereomer to that formed in the other spirocyclisations. However, 
after column chromatography on silica gel, the isolated 2-spiropiperidine 139b had a dr of 
3:1. To see if epimerisation was occurring on the column, spirocycle 139b was stirred in silica 
gel in the chromatography eluent for 30 mins at room temperature, then filtered (Scheme 
40). 2-Spiropiperidines 135a and 138e were treated under the same conditions, but in all 
three cases no change in dr was observed. It was therefore believed that preferential loss of 
one diastereomer on the column was occurring. Consequently, the isolated yields were lower 
than that was expected from the 1H NMR spectrum of the crude reaction mixture.  
 
 
Scheme 40. Epimerisation study of 2-spiropiperidine 139b on silica gel. 
 
In the case of 2-spiropiperidine 140 rotamers were observed, presumably around the N-Cbz 
bond, which made 1H NMR spectroscopic analysis slightly more challenging than other 2-
spiropiperidines. The execution of variable temperature NMR experiments would have aided 
analysis, but these were not carried out. Instead, the Cbz group was removed via 
hydrogenation in an excellent 90% yield (Scheme 41). The reaction proceeded cleanly and 
complete conversion was observed, with the product 2-spiropiperidine 142 not requiring 
column chromatography. This was fortunate, as the 2-spiropiperidine 142 was very polar and 
would have required the use of reverse-phase column chromatography. 
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Scheme 41. Cbz removal by hydrogenation. 
 
All 2-spiropiperidines had been synthesised with substituents at the C-6 position. For the 2-
spiropiperidine to be unsubstituted at C-6, the respective unsubstituted N-Boc sulfone would 
need to be synthesised. The N-Boc sulfone formed with formaldehyde had been reported,112 
but was not used for our studies. Instead, a small amount of N-Boc-δ-amino-δ-ketoester 144 
was provided by Dr William Unsworth, synthesised from the β-amino acid 143 (Scheme 42). 
 
 
Scheme 42. Synthesis of the unsubstituted δ-amino-δ-ketoester 144. 
 
Subjecting δ-amino-δ-ketoester 144 to the standard spirocyclisation conditions (Scheme 39) 
of 4 M HCl followed by treatment with a ketone and NaHCO3 gave rise to C-6 unsubstituted 
2,2-dimethyl piperidine 145 and 2-spiropiperidine 146 (Figure 14). 
 
 
Figure 14. Examples of C-6 unsubstituted piperidines. 
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2.5 Determination of the Stereochemistry 
 
It had initially been assumed that the stereochemistry of the major diastereomer was 
replicant of the results reported by Clarke for 2,6-di-substituted piperidines, positioning the 
C-3 ester and the C-6 substituent in an anti relationship.95 Upon analysis of the 1H NMR, the 
correct relative stereochemistry of the major diastereomer was confirmed to place the C-3 
ester and the C-6 substituent in a syn relationship. The 1H NMR spectrum of spirocycle 138a 
is shown in Figure 15, with expansions of two key regions of the spectrum shown in Figure 16.  
 
 
Figure 15. 1H NMR spectrum of spirocycle 138a. 
 
In the expansion of 3.40-2.90 ppm, two protons H-3 and H-6 (Figure 16, A and B) are observed, 
and in the expansion of 2.65-2.15 ppm, two protons H-5ax and H-5eq (Figure 16, C and D) are 
observed.  
The doublet at δ 3.26 ppm for H-3 has a 4J coupling of 1.0 Hz indicating a ‘W-coupling’ (Figure 
16, A). The ddd at δ 2.30 ppm also exhibits a 4J coupling of 1.0 Hz, indicating an equatorial 
57 
 
proton at C-5 and thus identifying H-5eq (Figure 16, D). Also in the ddd at δ 2.30 ppm, a 2J 
geminal coupling to H-5ax of 13.5 Hz is observed, as well as a 3J coupling of 3.7 Hz indicating 
an axial-equatorial coupling with H-6. The H-5ax was confirmed by the 2J geminal coupling of 
13.5 Hz with H-5eq, and the axial-axial 3J coupling of 10.5 Hz with H-6 (Figure 16, C). The dqd 
at δ 3.06 ppm has a 3J coupling of 3.7 Hz confirming the axial-equatorial coupling with H-5eq, 
and a 3J coupling of 10.5 Hz confirming the axial-axial coupling with H-5ax (Figure 16, B). With 
these couplings, it was deduced that the major diastereomer had a syn relationship between 
C-3 and C-6.  
 
 
 
Figure 16. Expansions of the 1H NMR spectrum of spirocycle 138a. 
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The relative stereochemistry of the major diastereomer from spirocyclisation was later 
confirmed with a crystal structure of spirocycle 138b (Figure 17). Interestingly, the C-3/C-6 
syn relationship places the ester in a seemingly unfavourable axial configuration. Presumably 
this is to avoid a destabilising steric interaction with the hydrogens on the adjacent spirocyclic 
ring.  The wide range of diastereomeric ratios obtained from the cyclisation procedure was 
also believed to be a consequence of the 2-spiropiperidines undergoing a retro-Mannich 
reaction. It was then believed that during the room temperature reaction, the system was 
slowly equilibrating, consequently giving a mixture of diastereomers. The electronics of the 
C-6 substituent also appeared to be a key factor, with the methyl substitutent giving much 
greater diastereomeric ratios than the aromatic C-6 subsitutents.  
 
 
Figure 17. Crystal structure of the major diastereomer of spirocycle 138b. 
 
2.6 PMI Analysis 
A library of novel compounds consisting of 18 2-spiropiperidines and four 2,2-dimethyl 
piperidines had been constructed via a novel stepwise procedure. It was important to be able 
to observe the relative three-dimensionality of the 2-spiropiperidines, as an original aim of 
the project was to synthesise three-dimensional compounds. The 22 compounds were 
plotted onto a PMI plot using the LLAMA software,14 with the 75% line from the ZINC database 
plot still shown for reference (Figure 18). It can be seen that 20 out of 22 2-spiropiperidines 
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lay on or to the right of the ZINC 75% line, with many examples pushing towards the area of 
relatively unpopulated three-dimensional chemical space.  
Unsurprisingly the 2-spiropiperidines bearing the aliphatic methyl group at C-6 were amongst 
the most three-dimensional. 2,2-Dimethyl piperidine 134a (Figure 18, A) was the best 
performing compound, reaching the spherical region of the PMI plot. The other stand out 
compound was 2-spiropiperidine 137a with a cyclobutane ring as the spirocycle (Figure 18, 
B). Of note is 2-spiropiperidine 135b with a phenyl ring at C-6 (Figure 18, C), which was more 
three-dimensional than similar sp2 C-6 substituents. 2-Spiropiperidine 140 was 
understandably the worst performer (Figure 18, D), containing an aromatic C-6 substitutent 
and a Cbz protecting group. The negative impact of the Cbz protecting group was recognised 
by the performance of the Cbz deprotected 2-spiropiperidine 142 (Figure 18, E).    
 
 
Figure 18. PMI plot for the 2-spiropiperidines. 
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The outcome of the PMI plot was promising, with the majority of the 2-spiropiperidines 
occupying the underrepresented region of chemical space. The next aim of the project was to 
utilise the 2-spiropiperidines as scaffolds for a fragment based drug discovery program. 
Iterations would be made to the 2-spiropiperidines, so it was interesting to see if the relative 
three-dimensionality of the functionalised 2-spiropiperidines was retained.  
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3. Functionalisations 
 
With a robust procedure in place for the synthesis of 2-spiropiperidines, and with the 
knowledge that they occupy the desired region of chemical space, attention turned to 
exploring their versatility for elaboration. The 2-spiropiperidines were identified as useful 
scaffolds for a fragment drug discovery programme. Whilst the C-6 substituents and the 
spirocycles could be readily varied, the 2-spiropiperidines also possessed three handles that 
could be used for further functionalisations; an ester, a ketone and an amine (Figure 19).  
 
 
Figure 19. Highlighted handles for 2-spiropiperidine elaboration. 
 
The functionalisations were deemed relevant to improve the lead-likeness of the 2-
spiropiperidines. Planned functionalisations included the manipulation of the C-3 ester, which 
is an undesirable functional group to be present for screening,113 to give either 
decarboxylated 2-spiropiperidines or amidated 2-spiropiperidines. Methods for the 
introduction of fluorine at C-3 and C-4 were trialled to improve hydrophilicity and 
bioavailability.114 Derivatisation of the ketone via reductive methods would give a better Fsp3, 
which was therefore assumed that the respective three-dimensionality would also improve. 
Manipulation of the amine or the reduced ketone would introduce new vectors to allow 
further exploration of the underrepresented region of chemical space. 
Consequently, a small library of structurally interesting, medicinally relevant 2-
spiropiperidines was constructed with the implication for use in a fragment based drug 
discovery programme. 
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3.1 Decarboxylation 
 
Aliphatic esters have been flagged as an undesirable functional group to be present in clinical 
candidates.14,113 The electrophilic ester has the potential to be unintentionally reactive 
towards proteins and is susceptible to decomposition by solvolysis or hydrolysis. This can 
consequently lead to false-positives that can plague screening efforts.115 It was therefore 
deemed necessary to be able to manipulate the methyl ester of the 2-spiropiperidine.  
Investigations began with the decarboxylation of 2-spiropiperidine 138a through microwave 
irradiation, using known conditions developed in the group’s tetrahydropyran work (Scheme 
43).116 Unfortunately, this led to decomposition of starting material and no decarboxylation 
was observed from the 1H NMR spectrum of the crude reaction mixture.  
 
 
Scheme 43. Decarboxylation using microwaves. 
 
Attention was then turned to conditions for Krapcho decarboxylation of 2-spiropiperidine 
138b using LiI in DMSO at elevated temperatures (Scheme 44).117,118 As the product was 
suspected to have a high water solubility, the DMSO was subsequently removed via kugelrohr 
distillation. Purification by chromatography gave the decarboxylated product 147b in a 
pleasing 63% yield.  
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Scheme 44. Decarboxylation with Krapcho conditions. 
 
However, it was quickly determined that the reaction was capricious and the yield for the 
decarboxylation of 2-spiropiperidine 138b was found to be irreproducible. Consequently, a 
new approach for the decarboxylation had to be made. A base-mediated decarboxylation 
with LiOH in a THF/H2O biphase was initially trialled with 2-spiropiperidine 138a,119 however, 
the reaction gave a disappointing 8% yield (Scheme 45). It was believed that the product was 
lost on work-up at the end of the reaction because of the high water solubility of the resultant 
2-spiropiperidine.  
 
 
Scheme 45. Base-mediated decarboxylation of 2-spiropiperidine 138a. 
 
The partition coefficient (AlogP) of a molecule is a measure of its solubility in a water/n-
octanol system.120 A low AlogP value corresponds to a hydrophilic molecule, and conversely 
a high AlogP value corresponds to a lipophilic molecule. The calculated AlogP value for the 
decarboxylated 2-spiropiperidine 147a was determined to be 0.1.14,47 Compared to the 
calculated AlogP value of 0.35 for THF which is relatively water miscible, it is understandable 
why the product may have been lost during the aqueous work-up. Consequently, the C-6 
substituent was changed to a 4-fluorophenyl group 138b, which increased the lipophilicity of 
the resultant product 147b with an AlogP value of 1.1.14,47 Pleasingly the decarboxylated 2-
spiropiperidine 147b was isolated in a 70% yield (Scheme 46). 
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Scheme 46. Base-mediated decarboxylation of 2-spiropiperidine 138b. 
 
The new conditions were found to be reproducible as well as higher yielding, and three more 
examples were synthesized (Figure 20), demonstrating the robustness of the decarboxylation 
procedure. In all cases, complete decarboxylation occurred with no carboxylic acid formation 
observed.  
 
 
Figure 20. Substrate scope for the base-mediated decarboxylation. 
 
3.2 Ketone Reduction 
 
The ketone was viewed as a reactive handle to functionalise. Reactions such as reductions 
and additions would introduce a new sp3 centre. This in turn would introduce new vectors to 
explore three-dimensional chemical space and consequently give rise to molecules with 
greater three-dimensionality.   
Reduction of ketone 138a to the alcohol 148a with NaBH4 delivered a disappointing 20% yield 
of alcohol 148a after work-up and column chromatography (Scheme 47). It was believed that 
the low yield was a consequence of an aqueous work-up. It had already been determined that 
the 2-spiropiperidines were relatively water soluble, and the work-up procedure also involved 
an acidic wash giving potential for salt formation. It was therefore unsurprising to observe 
low crude and isolated yields.  
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Scheme 47. Ketone reduction with NaBH4 and aqueous work-up. 
 
Despite the low yield of reduction, crystallographic data was obtained. The crystal structure 
confirmed the relative stereochemistry of alcohol 148a, placing the alcohol anti to the C-3 
ester. Despite showing the enantiomer, the crystal confirms the relative stereochemistry 
originally deduced.  It is interesting to note the crystal structure is a salt with a Cl-:HCO3- ratio 
of 88:12. The HCl salt must arise either as a consequence of the acidic work-up, or the 
presence of HCl in a potentially dated bottle of CDCl3, however the carbonate salt would have 
to be a consequence of the original spirocyclisation. This could explain the difficulties 
associated with the purification of the 2-spiropiperidines and their high water solubility, 
though further investigation was required. 
 
 
Figure 21. Crystal structure of alcohol 148a. 
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It was therefore deemed necessary to avoid an aqueous work-up after the reduction of the 
ketone. Upon quenching the excess NaBH4 with acetone, the reaction mixture was 
concentrated in vacuo and purified by column chromatography to give 148a in a high 81% 
yield (Scheme 48).  
 
 
Scheme 48. Ketone reduction without aqueous work-up. 
 
This method proved successful, and the much-improved yield demonstrated the importance 
of avoiding aqueous work-ups for this chemistry. Through this method, aliphatic, aromatic 
and heteroaromatic C-6 substituents furnished alcohols 148a-d in good to high yields with 
good selectivities (Figure 22). The diastereomeric ratio of products of 148c could not be 
determined from both the crude 1H NMR spectrum and the purified 1H NMR spectrum. 
 
 
Figure 22. Substrate scope for ketone reduction. 
 
The reduction of decarboxylated 2-spiropiperidine 147b was also achieved (Scheme 49). Both 
NaBH4 and L-Selectride were used for the reduction, and both delivered the same major 
diastereomer. Analysis of the crystal structure of alcohol 149 (Figure 23) showed that axial 
delivery of the hydride would involve an unfavourable steric interaction with the spirocycle. 
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With NaBH4, a small reducing agent, a 2:1 ratio of diastereomers was observed, showing that 
axial delivery of the hydride was still occurring. Unsurprisingly, with the bulky L-Selectride, 
greater selectivity of >20:1 was observed for equatorial hydride delivery.   
 
 
Scheme 49. Reduction of ketone 147b with different reducing agents. 
 
 
Figure 23. Crystal structure of alcohol 149. 
 
3.3 Amidation 
 
The C-3 ester provided an extra vector to explore three-dimensional chemical space, so the 
subsequent removal by decarboxylation was not ideal. Manipulation of the ester group to an 
amide was therefore deemed an appropriate transformation. Amide bonds play a crucial role 
in life as they are the backbone of proteins, and are also found in a large number of 
pharmacologically active compounds.121 According to a survey of drug candidates, 67% 
68 
 
possess at least one amide bond.122 Typical procedures for amide couplings via the carboxylic 
acid were not viable as hydrolysis of the ester resulted in decarboxylation. It was therefore 
concluded that a procedure for direct amidation of the ester was required.  
Investigations began with methods for activation of the ester, first by a lanthanum triflate 
catalysed amidation in solvent-free conditions.123 The procedure demonstrates the direct 
amidation of ethyl esters with primary and secondary amines, including the amidation of an 
unprotected piperidinyl ethyl ester. However, when the conditions were applied to the 2-
spiropiperidines, no reactivity was observed and unreacted starting material was re-isolated.  
Aluminium trichloride was utilised to directly amidate quinolone ethyl esters in a procedure 
by Schwaebe.124 Quinolone esters exhibit a β-ketoester system like the 2-spiropiperidine 
scaffolds, and it was believed that similar amidation results would be observed. 
Unfortunately, no reactivity was observed when the 2-spiropiperidine scaffolds were treated 
under the same conditions. The industrially favoured guanidine derived 1,5,7-
triazabicyclodecene (TBD), which has also been shown to efficiently directly amidate esters,125 
also yielded no reaction. 
With no success in the activation of the ester, a method for increasing the nucleophilicity of 
the amine by deprotonation was trialled. The DABCO-trimethylaluminium complex 
(DABAL.Me3) developed by Woodward has been reported to directly amidate esters including 
β-ketoester systems.126 However, as with previous at attempts at the direct amidation, upon 
treatment of the 2-spiroperidines to the conditions of Woodward, no amidation was 
observed.  
It was believed that the lack of reactivity arose from the steric hindrance of the ester and the 
presence of the β-ketoester system. Upon reduction of the ketone, 2-spiropiperidine 148c 
was treated with TBD and butylamine, however still no reactivity was observed. This was an 
unsurprising result as the reaction required the formation of a hindered intermediate on an 
already hindered system. The complex DABAL.Me3 was revisited, and in the presence of 
butylamine with 2-spiropiperidine 148c, amide formation was achieved to give amide 150a in 
a moderate 44% yield (Scheme 50).  
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Scheme 50. Procedure for amidations with DABAL.Me3. 
 
Using this method, two further amidations were performed on 2-spiropiperidine 148d (Figure 
24). The use of propargylamine to give amide 150c introduces a new handle to the scaffold. 
This could be utilised for a palladium-mediated coupling such as a Sonogashira coupling127 or 
it could be used for Click (azide-alkyne) chemistry.128 
 
 
Figure 24. Examples of amidation on 2-spiropiperidine 148d. 
 
3.4 Hydrazone Formation 
 
Retaining focus on the ester handle, formation of a hydrazide was an appealing 
transformation. Whilst installing an amide bond which is known to be desirable, it also 
introduces an amine, which is an extra hydrogen bond donor/acceptor and can be used for 
further manipulation. Following literature precedent,129 2-spiropiperidine 138e was refluxed 
with hydrazine in THF, however, no hydrazide formation was observed (Scheme 51). Instead, 
the hydrazine reacted with the ketone, giving the resultant hydrazone 151.  
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Scheme 51. Hydrazone formation. 
 
The formation of the hydrazone 151 over the hydrazide was not regarded as a disappointing 
outcome, as the hydrazone could be used for further functionalisation. Hydrazone 151 was 
heated in KOH under Wolff-Kishner reduction conditions to reduce to the alkane 152, but 
unfortunately this resulted in complete decomposition of starting material (Scheme 52).130 
 
 
Scheme 52. Attempted Wolff-Kishner reduction of hydrazone 151. 
 
The utility of the hydrazone 151 could be further probed by converting to the vinyl halide130 
or by performing addition reactions such as allylation,131 however neither transformation was 
attempted in the substrate scope. 
 
3.5 N-Functionalisation 
 
Having had early success manipulating the ketone and ester handles, the reactivity of the 
amine was next probed. Without substitution, the amine can act as a hydrogen bond donor 
for interactions with other molecules. However, manipulation of the amine can introduce 
new vectors to further explore the underrepresented region of chemical space.  
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2-Spiropiperidine 138a was first subjected to conditions for carbamate formation. Treatment 
of the 2-spiropiperidine with Boc2O and DMAP for N-Boc formation,132 and methyl 
chloroformate and K2CO3 for methyl carbamate synthesis133 resulted in no carbamate 
formation in both cases. Acetylation by treatment of the 2-spiropiperidine with acetyl 
chloride and triethylamine134 was also unsuccessful. Formation of a sulfonamide by tosylation 
with triethylamine and tosyl chloride,135 and by mesylation with triethylamine and mesyl 
chloride136 also yielded no desired product.  
It was disappointing that none of the reactions showed any conversion to the respective 
products. The piperidine nitrogen is sterically encumbered by the adjacent C-2 spirocycle and 
C-6 substituent, making it difficult to react to form a planar bond in the cases of the reactions 
trialled. The lack of reactivity may also be associated with the results obtained from the 
reduction of the ketone, showing that the 2-spiropiperidine may be existing as a salt. Further 
investigations were required to determine whether the 2-spiropiperidines exist a salt, and for 
time constraints, further functionalization attempts of the piperidine nitrogen were 
consequently stopped. 
 
3.6 Fluorination 
 
The desire for the incorporation of fluorine into organic molecules is growing in medicinal 
chemistry.137 Metabolic stability of the molecule is increased by the replacement of an 
oxidisable C-H bond with a C-F bond, and the binding affinity of the respective molecule has 
been shown to increase.114 The incorporation of fluorine also increases hydrophilicity and 
improves bioavailability.114 Therefore attempts were made to incorporate fluorine into the 2-
spiropiperidine scaffolds. This proved to be a challenging transformation.  
Introduction of a geminal difluoride group through treatment of 2-spiropiperidine 138e with 
diethylaminosulfur trifluoride (DAST) was unsuccessful, and did not yield fluorinated 
piperidine 153 (Scheme 53).138 It was believed the DAST reagent was too harsh, as only 
decomposition of 2-spiropiperidine 138e was observed. Upon decarboxylation and treatment 
with DAST, fluorinated 2-spiropiperidine was still not formed. 
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Scheme 53. DAST fluorination to access a geminal difluoro-alkane. 
 
It was postulated that the acidic C-3 position could be manipulated through deprotonation 
with NaH and treatment with N-fluorobenzenesulfonimide (NFSI);139 a mild electrophilic 
fluorinating agent. Upon submission of 2-spiropiperidine 138e to NaH and NFSI, C-3 
fluorination was observed by LCMS and crude NMR spectroscopy to give fluoride 154 (Scheme 
54). The crude residue was purified by mass directed autopurification (MDAP), however, the 
yield of recovery was too low to obtain characterisation. The reaction was found to be 
capricious and repetition of the reaction was unsuccessful, which was believed to be a 
consequence of the steric hindrance at C-3. In similar tetrahydropyran systems, it was found 
that only addition to small electrophiles like MeI and allyl bromide resulted in C-3 
functionalisation.116  
 
 
Scheme 54. Electrophilic fluorination with NFSI at C-3. 
 
Manipulation of the 2-spiropiperidine with the β-ketoester was proving challenging, so the 
fluorination strategy was altered to proceed through the alcohol. Displacement of the alcohol 
with a fluoride would give rise to a 4-fluoro-2-spiropiperidine. Alcohol 148b was subjected to 
three different fluorinating agents. With DAST140 and XtalFluor-E (the BF4- salt of DAST),141 as 
the sources of fluorine, no reactivity was observed and starting alcohol 148b was re-isolated. 
With PyFluor 155,142 no fluorination occurred as with the other two reagents, however, α,β-
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unsaturated ester 156 was isolated from the reaction (Scheme 55). Presumably, reactive 
intermediate 157 undergoes elimination to form the more stable α,β-unsaturated ester 156 
(Scheme 56). 
 
 
Scheme 55. Alcohol elimination with PyFluor. 
 
 
Scheme 56. Plausible mechanism for alcohol elimination. 
 
Believing the piperidine nitrogen could also be hindering the fluorination by reacting with 
fluorinating agent, alcohol 148b was treated with HCl to form the salt. Treatment of the salt 
of alcohol 148b to DAST, once again, resulted in decomposition of starting material, and no 
fluorinated product 158 (Scheme 57). The disappointing results ceased any further attempts 
at fluorination of the 2-spiropiperidine scaffolds. 
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Scheme 57. Formation of the HCl salt prior to DAST addition. 
 
3.7 O-Alkylation 
 
With the desire to explore three-dimensional space along a new vector, etherification of the 
alcohol was the next functionalisation to be trialled. Alkylation of alcohol 148b was envisaged 
to proceed via a Williamson ether synthesis,143 by deprotonation of the alcohol with NaH and 
displacement with cyclohexyl bromide (Scheme 58). However, no alkylated product was 
observed, instead α,β-unsaturated ester 156 was isolated in low yield. Presumably, 
etherification was occurring, and the subsequent alkoxide eliminated to form the favourable 
α,β-unsaturated ester 156 and cyclohexanol. To achieve O-alkylation it was believed that a 
decarboxylation was required, but this was not attempted.  
 
 
Scheme 58. Alcohol elimination by etherification. 
 
Alcohol 148b was treated with silver oxide and iodomethane at 85 oC in a sealed vial in the 
dark (Scheme 59).144 Interestingly, this led to N-methylation and not O-methylation, 
furnishing 159 in 50% yield. This was first time reactivity at the piperidine nitrogen had been 
observed, showing the methyl group is a small enough electrophile to be attacked by the 
congested piperidine nitrogen.  
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Scheme 59. N-Methylation with silver oxide and iodomethane. 
 
3.8 Reductive Amination 
 
With similar intentions to the O-alkylation, performing a reductive amination of the 2-
spiropiperidines would allow for elaboration along a new vector to explore three-dimensional 
space. The transformation converts an sp2 centre to an sp3 centre which increases the three-
dimensionality of the 2-spiropiperidine. It also introduces an amine to the 2-spiropiperidine, 
which is a hydrogen bond donor/acceptor and can increase solubility. Treatment of 2-
spiropiperidine 138d with butylamine and sodium triacetoxyborohydride did not provide the 
desired amine product, instead formation of enamine 160 was observed (Scheme 60).145  
 
 
Scheme 60. Enamine formation under conditions for reductive amination. 
 
Formation of the iminium must be occurring, but subsequent tautomerisation to the 
conjugated enamine must be faster than reduction with sodium triacetoxyborohydride. 
Supporting evidence for the formation of enamine 160 was obtained from LCMS and NMR 
spectroscopy of the crude reaction mixture, but was not isolated. Column chromatography of 
the crude reaction mixture returned no desired product nor any starting 2-spiropiperidine 
138d that may have resulted from hydrolysis. After repeating the reductive amination 
reaction procedure, the crude reaction mixture was treated with NaBH4, but still no desired 
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amine product was observed. There are reported methods for the reduction of enamines in 
the literature such as hydrogentation with platinum146 or rhodium,147 and by microwave 
irradiation with alcohols148 but these were not trialled.  
To avoid tautomerisation, the β-ketoester system of 2-spiropiperidine 138b was removed 
through decarboxylation to give ketone 147b. Ketone 147b was then treated with 
propargylamine and sodium triacetoxyborohdyride, furnishing amine 161 as a single 
diastereomer in a moderate 42% yield (Scheme 61).  
 
 
Scheme 61. Reductive amination on 2-spiropiperidine 147b. 
 
3.9 Methylenation 
 
Olefination of the ketone was regarded a logical transformation, owing to the large literature 
precedent for the Wittig reaction.149,150,151 Introduction of an olefin would, depending on the 
substrate chosen, give rise to at least one new functional group, and also increase the 
lipophilicity of the resultant 2-spiropiperidine. A simple olefination was desired, and 
introduction of a methylene group would give rise to just one product and not generate E/Z 
stereoisomers. The ylide was generated in situ through the deprotonation of methyl 
triphenylphosphonium bromide with n-BuLi, and subsequent treatment with 2-
spiropiperidine 147b gave the olefinated 2-spiropiperidine 162 in a moderate 36% yield 
(Scheme 62).152  
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Scheme 62. Wittig methylenation of 2-spiropiperidine 147b. 
 
3.10 Epoxidation 
 
Having achieved success with a methylenation and a reductive amination of the ketone, it 
was postulated performing a Corey-Chaykovsky epoxidation with a sulfoxonium ylide. 
Treatment of ketone 147b with the trimethylsulfoxonium ylide, formed by deprotonation of 
trimethylsulfoxonium iodide with NaH, furnished epoxide 163 as a single diastereomer in a 
moderate 41% yield (Scheme 63).153 The success of the reaction was pleasing as it generated 
a structurally interesting 2,4-bis-spiropiperidine. 
 
 
Scheme 63. Corey-Chaykovsky epoxidation of 2-spiropiperidine 147b. 
. 
 
3.11 Other Functionalisations 
 
Having successfully synthesised a small library of functionalised 2-spiropiperidines (17 
compounds), there was still material left from the scaffold synthesis to trial some speculative 
chemistry. Unsworth had recently published methods for successive ring expansions to form 
macrocycles utilising β-ketoesters.154 Addition of the enolate formed at C-3 of 2-
spiropiperidine 138b into the acid chloride of Fmoc-β-Ala-OH 164 to form macrocyclisation 
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precursor 165 was unsuccessful (Scheme 64). It is believed that this is yet again a consequence 
of the sterically encumbered C-3 position. 
 
 
Scheme 64. Step one for 2-spiropiperidine macrocyclization. 
 
Had the installation of Fmoc-β-Ala-OH been successful, deprotection of the amine with 
piperidine would have induced formation of aminal 167 and subsequent macrocyclisation to 
macrocyclic 2-spiropiperidine 168 (Scheme 65).   
 
 
Scheme 65. Mechanism for 2-spiropiperidine macrocyclisation. 
 
The cyclisation step for the two-step synthesis of 2-spiropiperidines required treatment of the 
HCl salt of a δ-amino-β-ketoester with a ketone. Decarboxylation of the 2-spiropiperidines 
gave rise to ketones, which we believed could be used in the cyclisation step for 2-
spiropiperidine synthesis. HCl salt 169 was subjected to the original spirocyclisation 
conditions with ketone 147e, in the hope of forming a structurally interesting 2,4-bis 
spiropiperidine 170 (Scheme 66). The molar equivalents of ketone 147e was reduced from 5 
to 1, a consequence of the limited amount of ketone 147e in hand. Unfortunately, the 1H NMR 
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spectrum of the crude reaction mixture showed just unreacted ketone 147e, despite HRMS 
finding the desired mass of 2-spiropiperidine 170. 2-Spiropiperidine 170 was not isolated. 
 
 
Scheme 66. Spirocyclisation using 2-spiropiperidine 147e as the ketone. 
 
3.12 LLAMA Analysis 
 
Having constructed a small library of 2-spiropiperidines utilising a diverse range of chemistry 
to introduce new functional groups, the lead-likeness and the relative three-dimensionality 
of the 2-spiropiperidines was of interest. The 18 functionalised 2-spiropiperidines were 
analysed through LLAMA to gauge their lead-likeness and three-dimensionality. 
 
3.12.1 Lead-Likeness 
It has been determined that the lipophilicity of a molecule is a defining characteristic for its 
potential success as a drug candidate.34 In order to facilitate delivery of a drug candidate to 
the desired pharmacological target as well as participate in subsequent interactions, aqueous 
solubility is a necessity.155 If the molecule is too hydrophobic, it has the ability to interact with 
other biological environments and consequently have potentially undesired toxic effects.1,156 
It has therefore been determined that a low lipophilicity is required for lead compounds prior 
to lead optimization. It has also been deduced that during the lead optimisation process, an 
increase in both molecular weight and lipophilicity is observed, as extra complexity and size 
are added to the molecules.157 Tentative limits are therefore installed to deduce whether a 
compound can be described as ‘lead-like’, based on its molecular weight and lipophilicity. 
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Whilst not all drugs are administered orally, these guidelines that describe molecules as ‘lead-
like’ represents the best starting points to allow maximum flexibility through optimisation.1  
Churcher described an area of chemical space in which lead compounds reside, in which there 
is a potential for the development into a drug candidate.1 This area of chemical space, coined 
as ‘lead-like space’, defines compounds as having AlogP values in the range of -1 to +3 and a 
molecular weight in the range of 200-350 (14-26 non-hydrogen atoms) (Figure 25). The 
orange oval described as optimal drug-like space gives a broad representation of the 
properties of oral drug candidates (Figure 25), and typically as molecular weight increases, 
the associated lipophilicity also increases. 
 
 
Figure 25. Molecular weight vs AlogP for identification of ‘lead-like’ space. 
 
Whilst a compound may exhibit the desirable properties to describe it as ‘lead-like’, it may 
also possess certain properties and functionalities that impose a negative impact on its overall 
‘lead-likeness’. Consequently, a ‘lead-likeness’ penalty was introduced by Marsden and 
Nelson.14 The penalty is an integer value calculated by analysing the key properties of the 
molecule; the AlogP value, the heavy atom count, the number of aromatic rings, and the 
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number of undesirable functional groups. The AlogP value should ideally be between -1 and 
+3,1 the heavy atom count should be between 17-24,1 the number of aromatic rings present 
should not exceed two,38 and there should be no reactive functional groups that can interfere 
with potential bindings.14,113 Penalty points are awarded based upon how far outside the ideal 
space the molecule lies, and the further away from the ideal space, the larger the penalty. 
The largest penalty that can be imposed is for the presence of a bad functional group. The 
closer the penalty to zero, the greater the ‘lead-likeness’ of a compound. Using the LLAMA 
online software, an example of the calculation of the penalty is described for 2-
spiropiperidine 138a (Figure 26).47 Both the heavy atom count and the AlogP value fit within 
the desired guidelines, however, the lack of an aromatic group and a presence of a methyl 
ester (undesirable functional group, as defined by LLAMA) gives 2-spiropiperidine 138a a 
‘lead-likeness’ score of six. 2-Spiropiperidine 138a is therefore not described as ‘lead-like’.  
 
 
Figure 26. Calculation of the ‘lead-likeness’ score of 2-spiropiperidine 138a. 
 
The ‘lead-likeness’ of the functionalised 2-spiropiperidines were analysed using the LLAMA 
online software.47 An example calculation of the lead-likeness of 2-spiropiperidine 163 is 
described below (Figure 27). As well as satisfying the guidelines for the heavy atom count and 
AlogP value, 2-spiropiperidine 163 also has an aromatic ring, and has been decarboxylated so 
the bad functional group has been removed. As a result, 2-spiropiperidine 163 has a ‘lead-
likeness’ score of zero, deeming the compound to be ‘lead-like’. 
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Figure 27. Calculation of the ‘lead-likeness’ score of 2-spiropiperidine 163. 
 
LLAMA analysis of the functionalised 2-spiropiperidines has shown that over half of the 
compounds have an excellent ‘lead-likeness’ score of zero (Figure 28).47 The higher-scoring 
amides 150a and 150b have earnt their penalty from the number of heavy atoms, exceeding 
the desired number for a ‘lead-like’ compound. The remaining 2-spiropiperidines all have 
‘lead-likeness’ scores of five and six. This is because of the presence of the ester group, and 
in the case of 2-spiropiperidine 148a, the lack of an aromatic group. Removal or manipulation 
of the ester group of the 2-spiropiperidines would consequently improve the ‘lead-likeness’ 
of all compounds.    
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Figure 28. LLAMA analysis of the functionalised 2-spiropiperidines. 
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3.12.2 PMI Analysis 
Having assessed the ‘lead-likeness’ of the 2-spiropiperidines, the 18 functionalised 2-
spiropiperidines were next plotted onto a PMI plot using the LLAMA software, with the 75% 
line from the ZINC database plot still shown for reference (Figure 29).47,14  
 
 
Figure 29. PMI plot for the functionalized 2-spiropiperidines. 
 
It can be seen that a greater proportion of the functionalised 2-spiropiperidines lie to the left 
of the ZINC 75% line than the respective 2-spiropiperidine scaffolds. This is a consequence of 
numerous factors. All of the examples were performed on 2-spiropiperidines with aromatic 
C-6 substituents (except the reduction of 138a), which consequently adds planarity to the 
structure. Approximately one half of the structures underwent decarboxylation, which in turn 
removed the C-3 tether, which was a vector to point into and explore three-dimensional 
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space. Adding to this, the introduction of alkenes and alkynes reduces the fsp3 in the 
molecules and ultimately reduces three-dimensionality. 
Interestingly, the most three-dimensional structure was hydrazone 151 (Figure 29, A), 
presumably a consequence of the hydrazone functional group, with the amine providing an 
extra vector for elaboration and exploration. It also exhibits a plane of best fit of 1.468 Å, 
compared to approximately 1-1.2 Å for the other functionalised 2-spiropiperidines.47,14 The 
other three-dimensional 2-spiropiperidine was alcohol 148a (Figure 29, B). The reduction was 
performed on an aliphatic C-6 substituent (methyl group), the C-3 ester remained, and the 
sp2 ketone was reduced to an sp3 alcohol. Understandably, two of the most two-dimensional 
was 2-spiropiperidine 161 (Figure 29, C) and 147d (Figure 29, D). Amine 161 exhibits all three 
of the negative impacting factors described above; an aromatic C-6 substituent, C-3 
decarboxylation, and introduction of an alkyne. Ketone 147d possesses similar properties but 
contains a linear nitrile on the aromatic ring.  
The synthesis of a library of functionalised 2-spiropiperidines that exhibit greater three-
dimensionality can be achieved by careful design of substrate, reaction and reagent. Aliphatic 
and substituted aromatic C-6 substituents on the parent 2-spiropiperidine scaffold aid in 
giving three-dimensionality to the functionalised 2-spiropiperidine. Reactions that remove 
substituents such as the C-3 ester or the C-4 ketone increases two-dimensionality, so 
functional group interconvention is preferential. Choice of the coupling reagent is also 
essential, as the introduction of alkynes, alkenes and aromatics will reduce three-
dimensionality. Examples of functionalised 2-spiropiperidines that all lie to the right of the 
75% ZINC line on the PMI plot that have been designed with the above rules are demonstrated 
below (Figure 30, 164, 165 and 166).  
 
 
Figure 30. Designed functionalised three-dimensional 2-spiropiperidines. 
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4. One-Pot Synthesis of 2-Spiropiperidines 
 
4.1 Preliminary Studies 
 
A stepwise procedure for the synthesis of 2-spiropiperidines had been successfully developed, 
and it was next deemed desirable to synthesise 2-spiropiperidines in one-pot.  
In preliminary studies, diketene 168 was used to be consistent with the previous one-pot 
piperidine synthesis reported from within the group.95 Due to its commercial unavailability, 
diketene 168 had to be prepared through treatment of acetyl chloride 167 with triethylamine 
(Scheme 67).158,159 Under the reaction conditions, ketene was formed which spontaneously 
dimerised to diketene 168. Aqueous work-up of the reaction mixture would result in 
hydrolysis of diketene 168, so the solvent choice was crucial. Diketene 168 has a high 
volatility, so would be used as a solution in subsequent reactions. Toluene was chosen as the 
solvent due to the insolubility of the by-product triethylamine hydrochloride. The preferred 
solvent would have been Et2O, however, the subsequent reaction would require the use of 
TiCl4 which is incompatible with Et2O.160 Upon filtration of triethylamine hydrochloride, 
diketene 168 was retrieved as a 4.91 wt% solution in a moderate 50% yield (Scheme 67), and 
was prepared freshly for each reaction. The formation of diketene was confirmed by 1H NMR 
spectroscopy. 
 
 
Scheme 67. Diketene synthesis. 
 
To test the synthetic tractability of the diketene solution, a trial aldol addition with 
benzaldehyde was undertaken using literature conditions,104 with the exception that toluene 
was used instead of CH2Cl2 (Scheme 68). The desired δ-hydroxy-β-ketoester 105 was isolated 
in a low 25% yield. Whilst it was pleasing to observe reactivity, the low yield was 
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disappointing. Unfortunately, further results were inconsistent and irreproducible, so the use 
of diketene 168 for the one-pot investigations was halted. 
 
 
Scheme 68. Aldol addition of diketene onto benzaldehyde. 
 
Chan’s diene 170,161 the bis-silyl enol ether of methyl acetoacetate, has been described for 
use in asymmetric Mukaiyama-aldol reactions.162,163,164 Mukaiyama-Mannich reactions have 
also been described with Chan’s diene165 as well as related silyl ketene acetals.166,167 It was 
envisaged to perform the one-pot procedure via a Mukaiyama-Mannich reaction with Chan’s 
diene. Chan’s diene 170 was synthesised according to literature precedent from methyl 
acetoacetate 125 (Scheme 69).168 Deprotonation of methyl acetoacetate with triethylamine 
generated the enol ether, which was trapped with TMS-chloride to give silyl enol ether 169 in 
an excellent 93% yield. The second deprotonation required the use of LDA, and subsequent 
trapping with TMS-chloride gave the bis-silyl enol ether, Chan’s diene 170, in an excellent 97% 
yield. The reaction was performed on a 12 g scale, which yielded 22 g of Chan’s diene 170. 
 
 
Scheme 69. Synthesis of Chan’s diene 170. 
 
Unpublished results from within the group demonstrated the synthesis of N-phenyl and N-
PMP protected 2,6-piperidines 172 from the respective N-protected imines 171 and 
aldehydes with Chan’s diene 170 and ZnCl2 (Scheme 70).169 It was postulated that a similar 
approach could be made to access 2-spiropiperidines.  
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Scheme 70. Zinc chloride mediated synthesis of piperidines. 
 
Condensation of aniline 173 with benzaldehyde 99, using MgSO4 as a dehydrating agent gave 
N-phenyl imine 174 in a moderate 56% yield (Scheme 71).170 With Chan’s diene 170 and N-
phenyl imine 174 in hand, a stepwise approach towards the piperidine 172 was investigated. 
 
 
Scheme 71. Synthesis of N-phenyl imine 174. 
 
In the presence of ZnCl2, a Mukaiyama-Mannich reaction between N-phenyl imine 174 and 
Chan’s diene 170 gave the desired δ-amino-β-ketoester 175 in a moderate 56% yield (Scheme 
72). The reaction did not go to completion, explaining the relatively lower than expected yield. 
Extra Chan’s diene and ZnCl2 were added to the reaction, but still unreacted imine remained. 
Enough δ-amino-β-ketoester 175 had been formed, however, to trial the cyclisation, so 
Mannich reaction optimisation was not carried out at this stage.  
 
 
Scheme 72. Zinc chloride mediated Mukaiyama-Mannich reaction of N-Ph imine 174 with Chan’s 
diene. 
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Upon re-subjecting δ-amino-β-ketoester 175 to the Mukaiyama-Mannich reaction conditions 
in the presence of benzaldehyde, no reaction was observed and δ-amino-β-ketoester 175 was 
re-isolated from the crude reaction mixture (Scheme 73). It was reported that the 
introduction of two molar equivalents of TFA would induce cyclisation,169 but still none of the 
desired piperidine 176 was formed.  
  
 
Scheme 73. Cyclisation with δ-amino-β-ketoester 175. 
 
With unpromising results using N-phenyl imine 174, similar procedures were trialled with N-
PMP glyoxal imine 179, as the N-PMP glyoxal imine is more electrophilic than the N-phenyl 
imine. Condensation of ethyl glyoxylate 177 with p-anisidine 178 using Na2SO4 as a 
dehydrating agent gave N-PMP imine 179 in a moderate 48% yield (Scheme 74).171 Upon 
changing the dehydrating agent to MgSO4, the yields improved to give an excellent 89% yield. 
 
 
Scheme 74. Synthesis of N-PMP imine 179. 
 
To begin the investigations towards the zinc-mediated cyclisations, N-PMP imine 179 was 
treated with Chan’s diene 170 and ZnCl2 to form the δ-amino-β-ketoester 180 (Scheme 75). 
The reaction proceeded to give δ-amino-β-ketoester 180 in a moderate 46% yield, though 
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complete consumption of N-PMP imine 179 was observed by TLC and 1H NMR spectroscopy 
of the crude reaction mixture. 
 
 
Scheme 75. Zinc-mediated Mukaiyama-Mannich reaction of N-PMP imine 179 with Chan’s diene. 
 
The Mukaiyama-Mannich reaction was found to be capricious, as inconsistent yields of 
isolated product were obtained. However, it was found that β-keto-δ-lactam 181 was forming 
under the reaction conditions, with lactamisaton occurring by addition of the electron rich 
amine into the zinc-activated ester (Scheme 76). The formation of β-keto-δ-lactam 181 was 
not detected by the TLC of the reaction mixture, so lactamisation must be occurring during 
aqueous work-up and column chromatography. The ratios of formation of δ-amino-β-
ketoester 180 to β-keto-δ-lactam 181 were inconsistent and could not be controlled. It was 
therefore decided to take two separate approaches; the first was to not isolate the δ-amino-
β-ketoester 180 and to add an aldehyde/ketone to the reaction mixture to induce cyclisation 
to the piperidine in situ, and the second was to use the tert-butyl ester of Chan’s diene for 
the Mannich reaction to avoid lactamisation. 
 
 
Scheme 76. Formation of lactam 181 from δ-amino-β-ketoester 180. 
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The N-PMP imine 179 was treated with Chan’s diene 170 in the presence of ZnCl2 and, before 
detection of β-keto-δ-lactam 181 by TLC, benzaldehyde was added to induce cyclisation 
(Scheme 77).169 Pleasingly, piperidine 182 was isolated from the reaction mixture, though as 
an inseparable mixture of diastereomers in a moderate 47% yield, however, no formation of 
β-keto-δ-lactam 181 observed. With the use of cyclohexanone, no cyclisation to the 2-
spiropiperidine was observed. 
 
 
Scheme 77. One-pot cyclisation to form N-PMP piperidines. 
 
In parallel with the efforts towards the one pot synthesis with N-PMP imine 179 and Chan’s 
diene 170, investigations towards the stepwise cyclisation using the tert-butyl variant of 
Chan’s diene 170 were undertaken. tert-Butyl Chan’s diene 185 was synthesised from tert-
butyl acetoacetate 183 using the same procedure as reported for the synthesis of Chan’s 
diene 170 (Scheme 78).  
 
 
Scheme 78. Synthesis of tert-butyl Chan’s diene 185. 
 
Under the previously reported Mukaiyama-Mannich reaction conditions with tert-butyl 
Chan’s diene 185 and N-PMP imine 179 in the presence of ZnCl2, δ-amino-β-ketoester 186 
was synthesised in a low 24% yield (Scheme 79). As expected, no lactamisation to the 
respective β-keto-δ-lactam was observed. Submission of δ-amino-β-ketoester 186 to the 
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reaction conditions in the presence of cyclohexanone gave no desired 2-spiropiperidine 187. 
Unreacted δ-amino-β-ketoester 186 was reisolated from the crude reaction mixture. 
Repeating the reaction conditions with isobutyraldehyde yielded similar results, so it was 
believed the PMP group was hindering cyclisation. 
 
 
Scheme 79. Attempted 2-spiropiperidine synthesis with tert-butyl Chan’s diene. 
 
Ceric ammonium nitrate (CAN) has been reported to oxidatively cleave the N-PMP bond, and 
the procedure was applied to the deprotection of δ-amino-β-ketoester 186 (Scheme 80).172 
Unfortunately, only decomposition of the starting material was observed, with no 
deprotected δ-amino-β-ketoester 188 or the subsequent lactamised product found in the 1H 
NMR spectrum of the crude reaction mixture. 
 
 
Scheme 80. Deprotection of N-PMP-δ-amino-β-ketoester 186. 
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4.2 Synthesis of 2-Spiropiperidines 
 
With disappointing results for the use of N-phenyl and N-PMP imines towards the one-pot 
synthesis of 2-spiropiperidines, it was decided to return to N-Boc imines 189. Refluxing N-Boc 
sulfones 122e-k in a suspension of K2CO3 and Na2SO4 in THF, followed by filtration and careful 
concentration gave N-Boc imines 189e-k in excellent yields (Scheme 81).173  
 
 
Scheme 81. Synthesis of N-Boc imines. 
 
Treatment of N-Boc imine 189e with Chan’s diene in the presence of ZnCl2 gave δ-amino-β-
ketoester 126e in a good 62% yield (Scheme 82). However, upon treatment of δ-amino-β-
ketoester 126e with acetone and ZnCl2, no cyclisation to piperidine 190 was observed. Even 
under reflux, δ-amino-β-ketoester 126e was recovered unchanged. 
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Scheme 82. Zinc-mediated cyclisation with N-Boc δ-amino-β-ketoester 126e. 
 
The utility of ZnCl2 as the Lewis acid for the one-pot synthesis was proving unsuccessful, so 
different Lewis acids were investigated. Investigations began with Cu(OTf)2, which had been 
demonstrated to catalyse the addition of silyl enol ethers to N-acyl imines.174 Addition of N-
Boc imine 189e to a solution of Chan’s diene 170 and Cu(OTf)2 did not yield the desired δ-
amino-β-ketoester 126e. Interestingly, β-amino-β’-ketoester 191 was isolated from the 
reaction mixture in a 62% yield, arising from addition of the less reactive position of Chan’s 
diene 170 (Scheme 83).  
 
 
Scheme 83. Cu(OTf)2-mediated addition of Chan’s diene to N-Boc imine 189e. 
 
The next Lewis acid of choice was Ti(OiPr)4 as it had been shown to promote Mannich 
reactions with Chan’s diene.162 Addition of Chan’s diene 170 to N-Boc imine 189e at -78 oC 
with Ti(OiPr)4 gave the desired δ-amino-β-ketoester 126e in a low 20% yield (Scheme 84). Also 
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isolated from the reaction mixture was amine 192. Presumably amine 192 is formed by the 
addition of methanol to unreacted N-Boc imine 189e when the reaction is quenched with 
methanolic citric acid. The formation of amine 192 was surprising as the TLC of the reaction 
mixture showed complete consumption of the N-Boc imine 189e.  
 
 
Scheme 84. Ti(OiPr)4-mediated addition of Chan’s diene to N-Boc imine 189e. 
 
It was deemed that Ti(OiPr)4 was too slow reacting towards the addition of Chan’s diene 170 
to N-Boc imine 189e, so attention returned to the use of the more reactive TiCl4. Pleasingly, 
δ-amino-β-ketoester 126e was isolated in a good 61% yield (Scheme 85). Upon treatment of 
δ-amino-β-ketoester 126e with cyclohexanone with TiCl4 at -78 oC, no reaction was observed 
and starting material was re-isolated. 
 
 
Scheme 85. TiCl4-mediated addition of Chan’s diene to N-Boc imine 189e and subsequent cyclisation. 
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It was believed that the Boc group was still hindering cyclisation to the desired 2-
spiropiperidine, so one-pot conditions for the cyclisation would require in situ deprotection. 
It was postulated that at elevated temperatures the TiCl4 could affect deprotection. Stability 
studies of N-Boc-δ-amino-β-ketoester 126e were undertaken by stirring N-Boc-δ-amino-β-
ketoester 126e with TiCl4 in CH2Cl2. At -78 oC and -40 oC, no change to starting material was 
observed over a period of 1h. However, at -20 oC, starting material slowly began to be 
consumed by TLC, with the baseline spot on the TLC plate becoming more visible, which was 
consistent with expected deprotection. Assuming deprotectection had occurred, 
cyclohexanone was then introduced to the reaction. This yielded no 2-spiropiperidine and 
instead a complex mixture of products was observed by 1H NMR spectroscopy of the crude 
reaction mixture (Scheme 86). The same procedure was repeated except at 0 oC, and yet again 
a complex mixture of products was obtained (Scheme 86). 
 
 
Scheme 86. Attempted TiCl4-mediated cyclisation. 
 
It was concluded that an additive would be required to affect efficient deprotection. The 
introduction of MeOH would initiate methanolysis of TiCl4, generating Ti(OMe)4 and four 
molar equivalents of HCl. In the stepwise procedure 15 molar equivalents of HCl was required 
for efficient deprotection, so the amount of TiCl4 used in the reaction was increased to 4 molar 
equivalents, which would in turn generate 16 molar equivalents of HCl. Upon formation of δ-
amino-β-ketoester 126e by TLC, MeOH was added and the reaction was warmed to room 
temperature, which resulted in effective deprotection of N-Boc-δ-amino-β-ketoester 126e 
(Scheme 87). As with the stepwise procedure, cyclohexanone and NaHCO3 (s) were then 
added and the reaction was stirred overnight. Pleasingly, 2-spiropiperidine 135c was formed 
under the reaction conditions, although in a low 8% yield after column chromatography. 
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Scheme 87. Initial one-pot cyclisation results. 
 
Despite the low yield, this was the first successful example of a one-pot procedure for the 
synthesis of a 2-spiropiperidine. It was believed the low yield was a consequence of the work-
up procedure, which involved a quench with sat. aq. NaHCO3 and resulted in the formation of 
an emulsion that was difficult to handle. Upon completion of the reaction, the quench was 
changed to 1.59 M citric acid in MeOH as used in the one-pot synthesis of 2,6-piperidines,95 
followed by the addition of water. Vigorous stirring of the biphasic mixture gave clear 
separation, making the aqueous work-up much easier. After column chromatography, 2-
spiropiperidine 135c was isolated in a good 61% yield (Scheme 88). This was very pleasing, as 
the overall yield for the synthesis of 2-spiropiperidine 135c in the two-step procedure was 
58%.  
 
 
Scheme 88. One-pot procedure for the improved yield of 2-spiropiperidine 135c. 
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The reaction was found to be reproducible, so having developed conditions for 
spirocyclisation, the scope of the reaction was explored (Figure 31). Owing to the difficulty of 
isolating aliphatic N-Boc imines, the reaction was performed with aromatic and 
heteroaromatic N-Boc imines 189e-k. With the exception of 2-spiropiperidine 136b, the yield 
of spirocyclisation for the one-pot procedure was better than the two-step procedure. 2-
Spiropiperidine 138e was also synthesised on a 1.5 g scale in a 43% yield, showing that the 
reaction is also scalable. Purification of the 2-spiropiperidines from the one-pot procedure 
was found to be challenging. Unlike the relatively clean crude reaction mixtures obtained 
from the two-step procedure, the one-pot procedure required purification of a complex 
mixture of products. Despite these challenges, 2-spiropiperidines were isolated in moderate 
to good yields (Figure 31).  
 
 
Figure 31. 2-Spiropiperidines synthesised using the one-pot procedure. 
99 
 
Interestingly, in some cases the dr of the one-pot procedure was better than the two-step 
procedure, and in others it was the opposite. With the reactions run at the same temperature, 
and the possibility of retro-Mannich reactions to occur under the reaction conditions, it was 
clear that there was not much control over the outcome of the reactions. An increase in 
reaction temperatures to induce retro-Mannich reactions and generate the thermodynamic 
product may be a method to increase diastereoselectivity.  
The one-pot procedure had its limitations, and imines 189g and 189i performed badly under 
these conditions. The benefit of using the pyridine and pyrazole derivatives in the two-step 
reaction was that the 2-spiropiperidines were easy to separate from the respective crude 
reaction mixtures, because of their higher polarities. However, in the one-pot procedure, 2-
spiropiperidine 138f was isolated in a low 7% yield, and 2-spiropiperidine 138d was not 
formed at all (Scheme 89). 
 
 
Scheme 89. Limitations of the one-pot procedure. 
   
Presumably, the TiCl4 was co-ordinating to the nitrogen of the aromatic group of the imine, 
and consequently hindering reactivity towards Mukaiyama-Mannich addition of Chan’s diene 
170. To test this hypothesis, the Mukaiyama-Mannich was performed with Chan’s diene 170 
and N-Boc imine 189e (Scheme 90). δ-Amino-β-ketoester 126g was isolated in a low 12% 
yield, and confirmed that a pyridine is a poor substrate for the one-pot procedure.  
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Scheme 90. Mukaiyama-Mannich addition of Chan’s diene to N-Boc imine 189g. 
 
Interestingly, when N-Boc imine 189h was treated under the one-pot reaction conditions, 
there was a reversed selectivity to give 2-spiropiperidine 199 with a 1:1.5 dr (Scheme 91). This 
was the first example of an isolation of a 2-spiropiperidine where the C-3 and C-6 substituents 
exhibited an anti-relationship as the major product. As discussed previously, the electronics 
of the C-6 substituent may be key for the possibility of a retro-Mannich reaction occurring 
under the reaction conditions. The thiazole C-6 substituent gave no selectivity in the two-step 
procedure, yet gave a 1:1.5 dr in the one-pot procedure. Consequently, the anti product may 
be the thermodynamic product, which was slowly forming under the reaction conditions. An 
increase in the reaction temperature may increase the dr of the reaction. 
 
 
Scheme 91. First example of a 2-spiropiperidine with C-3 and C-6 substituents exhibiting an anti-
relationship. 
 
As with the previous identification of the major diastereomer of cyclisation, the 2-
spiropiperidine anti diastereomer 199 was confirmed through analysis of the 1H NMR 
spectrum. The expansion of the 1H NMR spectrum between 4 ppm and 2.3 ppm is shown 
below (Figure 32). The H-3 proton was observed as a singlet, meaning no ‘W-coupling’ was 
occurring with H-5eq. The H-5eq proton was now observed as a dd indicating only a coupling to 
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H-6 and a geminal coupling with H-5ax. There was also a shift in the ppm of the H-5eq proton 
from δ 2.97 ppm for the 199 minor product to δ 2.40 ppm for the 199 major product. There 
was also an enhancement of the H-5ax proton at 2.59 ppm.  
 
 
Figure 32. Expansion of the 1H NMR for 2-spiropiperidine 199. 
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5. Towards Other Functionalised Piperidines 
 
5.1 Bridged Piperidines 
 
Initial aims of the project involved the synthesis and elaboration of 2-spiropiperidines, 
however, bridged piperidines were also deemed compounds of interest. Piperidines bridged 
between the C-2 and C-6 positions include molecules such as tropanes ([3.2.1] bicycles, 200) 
and 9-azabicyclo[3.3.1]nonanes ([3.3.1] bicycles 201) (Figure 33). Natural products containing 
tropanes include the well-known recreational drug cocaine,175 and hyoscyamine used for 
treatment of Parkinson’s disease.176 9-Azabicyclo[3.3.1]nonanes have also found use in 
medicinal chemistry as sigma-2 receptors177 and serotonin receptors.178 
 
 
Figure 33. Bridged piperidines. 
 
The synthesis of tropanes and 9-azabicyclo[3.3.1]nonanes have been reported to proceed 
from preformed piperidine rings, as well as forming the piperidine ring as the key bridge 
forming transformation. Huang demonstrated the synthesis of tropanes from γ-lactams 
202.179 Treatment of γ-lactam 202 with TBSOTf gave silyl enol ether 203 in an excellent 90% 
yield (Scheme 92). Formation of the iminium triflate with Tf2O/2,6-di-tert-butyl-4-
methylpyridine (DTBMP) followed by an intramolecular cyclisation generated the tropane 
ring, and the subsequent iminium ion was quenched with a halogen source to give tropane 
204 in a high 86% yield. The scope of the reaction was demonstrated by the synthesis of 9-
azabicyclo[3.3.1]nonanes as well, by the use of a δ-lactam.  
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Scheme 92. Tropane synthesis by synthesis of the piperidine ring. 
 
Harada and coworkers reported the synthesis of tropanes and 9-azabicyclo[3.3.1]nonanes via 
a carbenoid insertion to an amide bond with a low copper catalyst loading.180 Upon treatment 
of isoindolinone 205 with Cu(tfacac)2, the carbene generated inserted into the amide bond, 
forming the bridged amine 206 in a good 67% yield (Scheme 93). An example has also been 
presented by Harada for the synthesis of a non-aromatic tropane.  
 
 
Scheme 93. 9-Azabicyclo[3.3.1]nonane synthesis by amide insertion. 
 
With expertise in the synthesis of piperidines, it was believed that the methods published 
from within the group could give rise to bridged piperidines.181,182,95,109 If successful, these 
methods would provide a novel approach towards the synthesis of tropanes, 9-
azabicyclo[3.3.1]nonanes and other bridged piperidines.  Investigations began with a  
retrosynthetic analysis utilising the one-pot procedure reported by Clarke,95 using aldimines 
and aldehydes with alkene-terminated chains (Scheme 94). The desired bridged piperidine 
207 would arise from a ring closing metathesis of 2,6-substituted piperidine 207. To keep the 
new ring size respectably small, only aldimines 209a-b and aldehydes 210a-b derived from 
acrolein and but-3-enal were used for the investigations. Depending on the combination used, 
bicyclic systems of [3.2.1], [3.3.1] and [4.3.1] could be accessed. 
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Scheme 94. Retrosynthetic plan for bridged piperidines. 
 
In preliminary studies the use of diketene was used as the primary nucleophilic species, so 
diketene had to be re-synthesised.158,159 Unlike the previous synthesis that gave diketene as 
a solution in toluene, Et2O was used as the reaction solvent, and the ethereal solution of 
diketene was carefully concentrated via nitrogen blow-down. Despite the extra care taken, 
large amounts of the highly volatile diketene was still lost giving diketene in 33% yield. As with 
the previous synthesis of diketene, the diketene was freshly prepared before use in each 
reaction. 
To attempt the one-pot synthesis of 208, access to the respective aldehydes 210 and 
aldimines 209 was required. Acrolein was commercially available, however, but-3-enal had to 
be synthesised. Using literature procedures, the Barbier addition of allyl bromide to glyoxal 
211 gave diol 212 in a good 71% yield,183 which subsequently underwent oxidative cleavage 
with NaIO4 to give but-3-enal 210b in a high 82% yield as a solution in CH2Cl2 (Scheme 95).184  
 
 
Scheme 95. Synthesis of but-3-enal from glyoxal. 
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On first attempts, the N-tosyl aldimines of acrolein and but-3-enal could not be synthesised. 
Unsure of the stability and reactivity of the synthesised diketene 168, a trial reaction using N-
tosyl aldimine 101 in the one-pot procedure was run (Scheme 96).95 Disappointingly, with 
both acrolein 210a and but-3-enal 210b, the reaction yielded a complex mixture of products, 
with no desired piperidine 213a or 213b observed in the LCMS or 1H NMR spectrum of the 
crude reaction mixtures. The product of initial Mannich addition was not observed either, 
indicating the diketene may have decomposed. The reaction may also have failed as the 
source of TiCl4 was an old bottle of a 1 M solution of TiCl4. Competing reactions such as 
conjugate addition and polymerisation may also be occurring under TiCl4. Equally, the one-
pot procedure proceeding by addition into acrolein or but-3-enal may not be favourable.  
 
 
Scheme 96. One-pot procedure for piperidine synthesis with synthesised diketene. 
 
With difficulties in achieving success with the one-pot procedure, attention was turned to 
synthesising the bridged piperidines by applying the recently developed stepwise procedure 
for 2-spiropiperidines (Scheme 97). N-Boc sulfone 214 was synthesised using the standard 
procedure for sulfone synthesis,108 however, the synthesis of δ-amino-β-ketoester 215 was 
unsuccessful after multiple attempts.   
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Scheme 97. Stepwise procedure for the synthesis of bridged piperidines. 
 
Uncertain as to why the Mannich reaction was unsuccessful, efforts were made to liberate 
and isolate the respective imine. N-Boc sulfone 214 was treated with Cs2CO3, and upon 
consumption of starting material, the mixture was filtered and concentrated in vacuo 
(Scheme 98). The isolated species was identified as enamine 219 (Scheme 98), and its 
presence was observed in the 1H NMR spectrum of the crude reaction mixture of the 
unsuccessful Mannich reactions. The formation of the enamine 219 was understandable, as 
upon formation of the imine, tautomerisation to the enamine 219 brings the system into 
conjugation with the alkene making it more stable. Existing as the enamine, it is no longer a 
reactive electrophile and so explains the lack of reactivity for the Mannich reaction. The 
enamine 219 was stable to column chromatography, and was isolated as an inseparable 
mixture of E/Z stereoisomers. 
 
 
107 
 
 
Scheme 98. Confirmation of conjugated enamine 219. 
 
The formation of enamine 219, coupled with an inability to form the N-Boc sulfone from 
acrolein, effectively ended the efforts towards a stepwise procedure. In a final attempt to 
form a bridged piperidine 220, intramolecular delivery of the aldehyde was envisaged, 
requiring the synthesis of imine 221, which would arise from the imine precursor N-tosyl 
sulfone 222 (Scheme 99).  
 
 
Scheme 99. Retrosynthetic plan for intramolecular delivery of the aldehyde equivalent. 
 
Glutyraldehyde 223 was subjected to standard conditions for N-tosyl sulfone formation, and 
a white solid was isolated as expected from the reaction (Scheme 100).97 However, the 1H 
NMR spectrum did not show formation of the desired N-tosyl sulfone 222, nor the expected 
double addition product. Analysis of 1H NMR spectrum suggested the formation of enamine 
224, which was confirmed by 2D NMR spectroscopy and HRMS.  
 
 
Scheme 100. Synthesis of enamine 224 from glutyraldehyde. 
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A plausible mechanism for the formation of enamine 224 proceeded via the desired N-tosyl 
sulfone 222 (Scheme 101). Aminal formation followed by dehydration gave imine 227 which 
subsequently tautomerised to enamine 224. 
 
 
Scheme 101. Plausible mechanism for the formation of enamine 224. 
 
Owing to time constraints, the synthesis of bridged piperidines was no longer pursued. A 
potential method to access bridged piperidines could be to use an alkene that cannot 
tautomerise into conjugation, such as pent-4-enal. This however, would ultimately lead to a 
bridged system with a larger ring size than may be desired. If but-3-enal was used, the 2-
position would need to be ‘blocked’ by having a quaternary carbon, in order to avoid imine-
enamine tautomerisation. Though lengthy, this stepwise procedure would then give rise to 
spirocyclic bridged piperidines (Scheme 102). 
 
 
Scheme 102. Stepwise synthesis of spirocyclic bridged piperidines. 
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5.2 Fused Piperidines 
 
Another class of desirable compounds were 2-spiropiperidines with fused rings. Examples of 
natural product containing piperidines with fused rings include indolizidine 209B 230185 and  
pumiliotoxins A and B 231186 (Figure 34), isolated from poison frogs. 
 
 
Figure 34. Natural products containing fused piperidine rings. 
 
The pumiliotoxins have been synthesised by a variety of methods,187 however the reported 
syntheses of indolizidine 209B has been found to proceed via the same procedure.188,189,190 
Treatment of alcohol 232 under Appel conditions converted to the bromide 233, which was 
subsequently displaced by the piperidine nitrogen upon addition of Et3N to give the fused 
piperidine 234 (Scheme 103).188 
 
 
Scheme 103. Indolizidine synthesis by bromide displacement. 
 
It was postulated that extension of the two-step procedure for the synthesis of 2-
spiropiperidines systems similar to that of alcohol 232 would give access to fused ring 
systems. Aldehyde 237 was synthesised in excellent yield over two steps from 1,4-butanediol 
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235; first by TIPS protection to alcohol 236191 followed by Swern oxidation to aldehyde 237192 
(Scheme 104). The imine precursor N-Boc sulfone 238 was synthesised via the procedure of 
Lam108 in a good 66% yield, and subsequent Mannich reaction109 with the Weiler dianion98 
gave the N-Boc-δ-amino-β-ketoester 239 in a moderate 57% yield. Deprotection of the amine 
also resulted in fortuitous TIPS deprotection to give 240 in an excellent 93% yield. Using the 
reported conditions for spirocyclisation, HCl salt 240 was treated with cyclobutanone to give 
2-spiropiperidine 241 in a disappointingly low 8% yield after column chromatography. It was 
believed that product was lost during column chromatography, as the high yielding crude 
reaction showed a relatively clean 1H NMR spectrum. Finally, upon subjection of 2-
spiropiperidine 241 to the conditions presented by Davis for indolizidine synthesis,188 no 
reaction was observed by TLC or by 1H NMR spectrum of the crude reaction mixture. The mass 
peak of product indolizidine 242 was observed by HRMS, but was not isolated. Due to time 
constraints, the synthesis of indolizidine 242 could not be reattempted.  
 
 
Scheme 104. Indolizidine synthesis via the two-step procedure for 2-spiropiperidines. 
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6. Conclusions  
 
The first general synthesis of highly functionalised 2-spiropiperidines has been presented via 
a simple, robust, stepwise procedure. Preliminary results using N-Tosyl aldimines were 
unsuccessful, however the use of N-Boc imines ultimately furnished the desired 2-
spiropiperidines. The scope of the stepwise procedure was demonstrated by the synthesis of 
a range of aromatic- and aliphatic-substituted 2-spiropiperidines bearing carbocyclic and 
heterocyclic spirocycles. The cyclisation reaction proceeded in moderate to excellent yields, 
with moderate to good diastereoselectivities.  
A small library of functionalised 2-spiropiperidines was constructed, by performing a range of 
reactions on the ester, ketone and amine handles. The manipulations were driven by the 
desire to introduce medicinally relevant properties, and in the case of the methyl ester, to 
remove undesirable functionality. Successful reactions included decarboxylation, reduction, 
amidation, alkylations, and epoxidation. Unfortunately, fluorination of the 2-spiropiperidines 
was unsuccessful and requires further work.  
The three-dimensionality of the 2-spiropiperidines was analysed by PMI analysis. It was 
determined that the 2-spiropiperidine scaffolds occupy the underrepresented region of 
chemical space. Whilst the functionalised 2-spiropiperidines were less three-dimensional 
than the respective scaffolds, they still occupied the desired region of chemical space. LLAMA 
analysis of the functionalised 2-spiropiperidines also rendered them as ‘lead-like’, concluding 
that the 2-spiropiperidines have potential to be medicinally relevant. 
The procedure for the synthesis of 2-spiropiperidines was developed to a one-pot procedure 
using N-Boc imines and Chan’s diene with TiCl4. An in situ deprotection of the δ-amino-β-
ketoester allowed cyclisation to proceed, furnishing the 2-spiropiperidines in moderate to 
good yields and moderate to good diastereoselectivities.  
The synthesis of other structurally interesting piperidines was trialled. The synthesis of 
bridged piperidines using but-3-enal resulted in unwanted tautomerisation, and a procedure 
to allow intramolecular delivery of the second aldehyde was also unsuccessful. Initial results 
for the stepwise synthesis of fused piperidines was also unsuccessful, however, the procedure 
112 
 
to access the cyclisation precursor was straightforward, and so the subsequent cyclisation to 
the fused piperidine can be trialled with a range of bases.  
 
7. Future Work 
 
7.1 Towards an Asymmetric Synthesis 
 
With a one-pot procedure in place, it would now be possible to devise an asymmetric 
synthesis of 2-spiropiperidines. It is desirable to perform the reaction in one-pot, so the use 
of titanium-based catalysts is preferred, despite the precedent for Mukaiyama addition of 
Chan’s diene to electrophiles.162,193 Asymmetric Mukaiyama-aldol reactions have been 
reported for the addition of silyl enol ethers,194 and Chan’s diene164 with Ti(BINOL) and BINOL 
derived195 complexes. Asymmetric Mukaiyama-Mannich reactions have been reported with 
silyl ketene acetals196,197 with Ti(BINOL) complexes, and it is believed the scope can be 
extended for the use with Chan’s diene 170.  
For the synthesis to proceed, HCl may need to be introduced via a different method after 
Mannich addition of Chan’s diene 170. Clarke reported the use of Ti(OiPr)4/BINOL/LiCl 
mixtures for the Mannich addition,164 which clearly would not generate HCl upon addition of 
MeOH. Methanolic HCl may be an option to investigate. A hypothetical one-pot procedure 
has been presented with Chan’s diene 170 and an N-Boc imine 189 (Scheme 105), though the 
initial Mannich reaction to generate the δ-amino-β-ketoester would need to be investigated 
first.  
 
 
Scheme 105. Plausible asymmetric synthesis of 2-spiropiperidines. 
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7.2 Non-Symmetrical 2-Spiropiperidines 
 
The method for the synthesis of 2-spiropiperidines had only been applied to symmetrical 
ketones for ease with analysis. The use of a non-symmetrical ketone would generate 
additional diastereomers making analysis more challenging. Treatment of HCl salt 169 with 
tetrahydrofuran-3-one gave 2-spiropiperidine 244 in a moderate 54% yield (Scheme 106).  
 
 
Scheme 106. Synthesis of a non-symmetrical 2-spiropiperidine. 
 
The reported 54% yield for the cyclisation with tetrahydrofuran-3-one was the yield for all 
diastereomers, with no separation achieved by column chromatography. Interpretation of 
the 1H and 13C NMR spectra was consequently challenging, with multiple overlapping peaks 
observed in the 1H NMR spectrum, as shown in the expansion between δ 4.60 ppm and δ 2.30 
ppm (Figure 35). Identification of the major diastereomer was not possible. A key feature of 
the 1H NMR spectrum that could be clearly identified was the H-5ax proton double-doublet 
for the C-3/C-6 syn 2-spiropiperidines at δ 2.97 ppm and δ 2.89 ppm (Figure 35). The other 
clear feature for the C-3/C-6 syn 2-spiropiperidines was the H-3 doublets at δ 3.47 ppm and δ 
3.40 ppm. These confirmed the formation of 2-spiropiperidine 244, and the desired mass peak 
was found in HRMS. Believing the diastereomers could be separated, MDAP was attempted 
on 2-spiropiperidine 244, but no product was retrieved from the purification process. 
Preparative HPLC may be required to achieve separation of the diastereomers. 
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Figure 35. Expansion of the 1H NMR of 2-spiropiperidine 244. 
 
Conditions for a more selective cyclisation will need to be devised. Use of 2,2-
dimethylcyclohexanone 245 could bias the selectivity and eradicate the formation of two 
diastereomers by avoiding the large steric clash between the geminal-dimethyl group and the 
C-3 ester (Scheme 107). 
 
 
Scheme 107. Synthesis of a non-symmetrical 2-spiropiperidine with 2,2-dimethylcyclohexanone. 
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The original spirocyclisation allowed the introduction of piperidine rings as the spirocycle, for 
example 2-spiropiperidine 142. It would also be desirable to install piperidine rings as the 
spirocycle at the 2- (247) and 3- (248) positions (Figure 36). Spirocycle 248 could be 
synthesised from the respective non-symmetrical piperidin-3-one, however similar problems 
encountered with 2-spiropiperidine 244 may occur, so a large bulky protecting could bias 
selectivity and make purification easier.  
 
 
Figure 36. Example 2-spiropiperidines with piperidine spirocycles. 
 
The synthesis of 2-spiropiperidine 247 would require a slightly different approach, as the 
respective ketone is actually a lactam. Consequently, no reactivity would be observed under 
the cyclisation conditions. It is believed that a species such as iminium 250 would need to be 
synthesised. O-Methylation of N-methyl-δ-valerolactam 249 with Meerwein’s salt gives imine 
250,198 which could be treated under the two-step spirocyclisation reaction conditions to give 
rise to 2-spiropiperidine 247 (Scheme 108). 
 
 
Scheme 108. Plausible synthesis of 2-spiropiperidine 247. 
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7.3 6-Spiropiperidines 
 
Having devised a stepwise procedure for the synthesis of 2-spiropiperidines, the synthesis of 
6-spiropiperidines was also desirable. To use the reported 2-step procedure, this would 
require the synthesis of an N-Boc ketimine. The synthesis of N-Boc ketimines has been 
reported, but only on specific systems such as benzylic ketones. Maruoka reported the 
synthesis of non-symmetrical N-Boc α-ketimino esters (Scheme 109).199 Treatment of N-TMS 
Boc amide 249 with n-BuLi, followed by addition into ethyl benzoyl formate 250 gave 
tetrahedral intermediate 251, which subsequently collapsed upon addition of TMS-chloride 
to give N-Boc α-ketimino ester 252. The reaction has been demonstrated with different 
benzylic systems and varied aliphatic esters.  
 
 
Scheme 109. Synthesis of N-Boc α-ketimino esters. 
 
The most common handle for N-Boc ketimine synthesis is an isatin, with varied degrees of 
substitution. Using the same conditions as Maruoka,199 Nakamura and coworkers 
demonstrated the application of the chemistry to substituted isatins 253 (Scheme 110).200 
Utility of N-Boc ketimine 255 would provide access to a non-symmetrical 6-spiropiperidine.  
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Scheme 110. Maruoka’s synthesis of N-Boc ketimines applied to isatins. 
 
An Aza-Wittig reaction201 was performed on isatin 257 with N-Boc-imino-
triphenylphosphorane 256 as demonstrated by Pedro202 and Wang203 (Scheme 111). N-Boc 
ketimines have been described to be substituted around the aromatic ring, as well as on the 
isatin nitrogen. Wang also described the addition of a 1,3-dicarbonyl to the N-Boc ketimine,203 
showing hindered systems can be formed.  
    
 
Scheme 111. Aza-Wittig reaction for the synthesis of N-Boc ketimines. 
 
Unsurprisingly, when conditions were repeated on cyclohexanone, no reaction occurred. The 
formation of reported N-Boc ketimines have all been performed on highly electron withdrawn 
systems. This would explain the lack of literature precedent for the formation of simple, cyclic, 
symmetrical N-Boc ketimines.  
In the two-step synthesis of 2-spiropiperidines, a procedure was presented for the synthesis 
of 2-spiropiperidines without a C-6 substituent (Scheme 42). It was believed that this 
procedure could be adapted to allow the synthesis of 6-spiropiperidines. The synthesis of the 
β-amino acid precursor has been described by Rai,204 and subsequent Boc-protection would 
give rise to carboxylic acid 259 (Scheme 112). Treatment of carboxylic acid 259 with CDI 
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followed by ethyl potassium malonate205 would give δ-amino-δ-ketoester 260, which would 
undergo the two-step cyclisation procedure reported to give rise to 6-spiropiperidines 261 or 
2,6-bis-spiropiperidines 262. Initial attempts at the formation of carboxylic acid 259 were 
unsuccessful, and due to time constraints, the method was not pursued. 
 
 
Scheme 112. Plausible synthesis for 6-spiropiperidines or 2,6-bis-spiropiperidines. 
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8. Experimental 
 
8.1 General Experimental 
 
Unless otherwise noted all compounds were bought from commercial suppliers and used 
without further purification. Unless otherwise noted the dry solvent used was purified by 
PureSolv alumina columns from Innovative Technologies. Melting points were determined 
using a Stuart SMP3 apparatus. Infra-red spectra were acquired on a ThermoNicolet Avatar 
370 FT-IR spectrometer. Nuclear magnetic resonance spectra were recorded on a Jeol ECS-
400, a Jeol 500 Avance III HD 500 or a Jeol AV500 at ambient temperature. Coupling constants 
(J) are quoted in Hertz. Mass spectrometry was performed by the University of York mass 
spectrometry service using electron spray ionisation (ESI) technique. Thin layer 
chromatography was performed on aluminium-backed plates coated with Merck Silica gel 60 
F254. The plates were developed using ultraviolet light, acidic aqueous ceric ammonium 
molybdate or basic aqueous potassium permanganate. Liquid chromatography was 
performed using forced flow (flash column) with the solvent systems indicated. The stationary 
phase was silica gel 60 (220–240 mesh) supplied by Sigma-Aldrich. 
 
8.2 Methods and Characterisation of Compounds 
 
General Procedure A - Synthesis of benzenesulfonyl carbamic esters pg. 124 
General Procedure B - Synthesis of N-Boc-δ-amino-β-ketoesters pg. 130 
General Procedure C - Synthesis of 2-spiropiperidines from N-Boc-δ-amino-β-ketoesters pg. 
140 
General Procedure D – Decarboxylation of the 2-spiropiperidines pg. 154 
General Procedure E – Ketone reduction of the 2-spiropiperidines pg. 157 
General Procedure F – Direct amidation of the 2-spiropiperidines pg. 161 
General Procedure G - Synthesis of N-Boc-imines pg. 176 
General Procedure H - One-Pot cyclisation pg. 181 
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N-Benzylidene-4-methyl-benzenesulfonamide (101) 
To a solution of benzaldehyde (400 mg, 3.77 mmol) in water/formic acid (1:1, 22 mL), was 
added tosylamide (645 mg, 3.77 mg), and p-toluene sulfinic acid sodium salt (672 mg, 3.77 
mmol) at rt. The mixture was stirred overnight at rt. The precipitate was filtered, washed with 
water (2 x 5 mL), and hexane (10 mL). The solid was dissolved in CH2Cl2 (30 mL), and was 
stirred in sat.aq. NaHCO3 (20 mL) for 1 hour at rt. The layers were separated and the aqueous 
was extracted with CH2Cl2 (20 mL). Organics were combined, dried (MgSO4), filtered and 
concentrated in vacuo to give the title compound (484 mg, 2.15 mmol, 78% yield) as a white 
solid. Mp 115-117 oC; 1H NMR (500 MHz, CDCl3): δ 9.02 (1H, s, CH), 7.93-7.76 (4H, m, ArH), 
7.63-7.58 (1H, m, ArH), 7.48 (2H, t, J = 7.6 Hz, ArH), 7.34 (2H, d, J = 8.0 Hz, ArH), 2.43 (3H, s, 
CH3) ppm; 13C NMR (101 MHz, CDCl3): δ 170.4 (CH), 144.8 (C), 139.2 (C), 135.2 (C), 131.5 (CH), 
129.8 (CH), 129.2 (CH), 128.2 (CH), 126.6 (CH), 21.7 (CH3) ppm; HRMS (ESI) 260.0748 (M + H+. 
C14H14NO2S requires 260.0740); IR (ATR): νmax 3071, 1595, 1572, 1449, 1315, 1304, 1154, 1085 
cm-1. 
 
 
Methyl 3-oxo-5-phenyl-5-(toluene-4-sulfonylamino)-pentanoate (102) 
To a solution of diisopropylamine (824 µL, 5.89 mmol) in THF (10 mL) at -78 oC was added n-
BuLi (2.41 mL, 5.79 mmol) dropwise. The mixture was warmed to 0 oC for 15 mins, then re-
cooled to -78 oC. A solution of methyl acetoacetate (312 µL, 2.90 mmol) in THF (2 mL) was 
added via syringe pump over 20 mins. The mixture was warmed to -50 oC, and a solution of 
101 (250 mg, 0.965 mmol) in THF (2 mL) was added fast. The reaction was stirred for 40 mins, 
then quenched with sat. aq. NH4Cl (4 mL). The mixture was warmed to rt, and layers were 
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separated. The aqueous was extracted with EtOAc (2 x 20 mL). Organics were combined, 
washed with water (10 mL), and brine (10 mL), dried (MgSO4), filtered, and concentrated in 
vacuo. The residue was purified by column chromatography (10-30% EtOAc/hexane) to give 
the title compound (242 mg, 0.647 mmol, 67% yield) as a colourless oil. 1H NMR (400 MHz, 
CDCl3): δ 7.59-7.54 (2H, m, ArH), 7.20-7.11 (5H, m, ArH), 7.09-7.04 (2H, m, ArH), 5.69 (1H, d, J 
= 7.2 Hz, NH), 4.73 (1H, dt, J = 7.2, 6.3 Hz, H-5), 3.65 (3H, s, OCH3), 3.36 (1H, d, J = 15.5 Hz, H-
2), 3.31 (1H, d, J = 15.5 Hz, H-2), 3.17 (1H, dd, J = 17.4, 6.3 Hz, H-4), 3.01 (1H, dd, J = 17.4, 6.3 
Hz, H-4), 2.36 (3H, s, CH3) ppm; 13C-NMR (101 MHz, CDCl3): δ 200.6 (C=O), 167.3 (C=O), 143.5 
(C), 139.5 (C), 137.1 (C), 129.6 (CH), 128.7 (CH), 127.9 (CH), 127.3 (CH), 126.7 (CH), 54.0 (CH), 
52.5 (CH3), 49.5 (CH2), 49.3 (CH2), 21.6 (CH3) ppm; HRMS (ESI) 398.1024 (M + 
Na+.C19H21NNaO5S requires 398.1033); IR (ATR): νmax  3277, 2953, 1740 (C=O), 1713 (C=O), 
1321, 1154 cm-1. 
 
 
Methyl 2-isopropylidene-3-oxo-5-phenyl-5-(toluene-4-sulfonylamino)-pentanoate (103) 
To a 0.5 M solution of TiCl4 in THF (2 mL, 1.07 mmol) at 0 oC was added a solution of 102 (400 
mg, 1.07 mmol), acetone (156 µL, 2.13 mmol), and pyridine (345 µL, 4.26 mmol) in THF (2 mL). 
The reaction was stirred overnight at rt. The reaction mixture was partitioned between water 
(10 mL) and EtOAc (30 mL). The aqueous was extracted with EtOAc (2 x 15 mL). Organics were 
combined, washed with NaHCO3 (30 mL), water (30 mL), and brine (30 mL), dried (MgSO4), 
filtered, and concentrated in vacuo. The residue was purified by column chromatography 
(15% EtOAc/hexane) to give the title compound (115 mg, 0.277 mmol, 26% yield) as a yellow 
oil. 1H NMR (400 MHz, CDCl3): δ 7.59-7.54 (2H, m, ArH), 7.19-7.12 (5H, m, ArH), 7.11-7.05 (2H, 
m, ArH), 5.71 (1H, d, J = 7.0 Hz, NH), 4.74 (1H, dt, J = 7.0, 6.2 Hz, H-2), 3.60 (3H, s, OCH3), 3.12 
(1H, dd, J = 17.5, 5.9 Hz, H-1), 2.96 (1H, dd, J = 17.5, 6.2 Hz), 2.36 (3H, s, ArCH3), 2.05 (3H, s, 
CCH3), 1.65 (3H, s, CCH3) ppm; 13C-NMR (101 MHz, CDCl3): δ 201.1 (C=O), 165.5 (C=O), 156.1 
(C), 143.3 (C), 139.8 (C), 137.4 (C), 130.9 (C), 129.5 (CH), 128.5 (CH), 127.7 (CH), 127.3 (CH), 
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126.8 (CH), 54.3 (CH), 51.9 (CH3), 49.4 (CH2), 23.5 (CH3), 23.1 (CH3), 21.6 (CH3) ppm; HRMS 
(ESI) 438.1338 (M + Na+. C22H25NNaO5S requires 438.1346); IR (ATR): νmax 3278, 2952, 1726 
(C=O), 1694 (C=O), 1156 cm-1. 
 
 
2-Isopropylidene-3-oxo-5-phenyl-pent-4-enoic acid methyl ester (104) 
Method A: To a solution of 103 (85 mg, 0.205 mmol) in CH2Cl2 (2 mL) at rt was added TiCl4 
(112 μL, 1.03 mmol). The mixture was stirred overnight at rt. Water (5 mL) was carefully 
added, followed by dilution with CH2Cl2 (10 mL). The layers were separated and the aqueous 
was extracted with CH2Cl2 (10 mL). The organics were combined, dried (MgSO4), filtered and 
concentrated in vacuo. The residue was purified by column chromatography (20% 
EtOAc/hexane) to give the title compound (5.4 mg, 0.0223 mmol, 11% yield) as a yellow oil. 
 
Method B: To a 0.5 M solution of TiCl4 in THF (1.5 mL, 0.735 mmol) at 0 oC was added a solution 
of 106 (150 mg, 0.735 mmol), acetone (108 µL, 1.47 mmol), and pyridine (240 µL, 2.94 mmol) 
in THF (1 mL). The reaction was stirred overnight at rt. The reaction mixture was partitioned 
between water (5 mL) and EtOAc (30 mL). The aqueous was extracted with EtOAc (2 x 15 mL). 
Organics were combined, washed with NaHCO3 (30 mL), water (30 mL), and brine (30 mL), 
dried (Na2SO4), filtered, and concentrated in vacuo. The residue was purified by column 
chromatography (5% EtOAc/hexane) to give the title compound (23 mg, 0.0942 mmol, 13% 
yield) as a yellow oil. 1H NMR (500 MHz, CDCl3): δ 7.58 – 7.49 (2H, m, ArH), 7.42 – 7.35 (3H, 
m, ArH), 7.42 (1H, d, J = 16.2 Hz, H-1), 6.80 (1H, d, J = 16.2 Hz, H-2), 3.69 (3H, s, OCH3), 2.26 
(3H, s, CH3), 1.87 (3H, s, CH3) ppm; 13C-NMR (101 MHz, CDCl3): δ 195.5 (C=O), 165.5 (C=O), 
154.8 (C), 145.6 (CH), 134.5 (C), 130.9 (C), 129.5 (CH), 129.1 (CH), 128.6 (CH), 127.6 (CH), 51.9 
(CH3), 24.2 (CH3), 22.5 (CH3) ppm; HRMS (ESI) 267.0992 (M + Na+. C16H16NaO3 requires 
267.0992); IR (ATR): νmax 3063, 2912, 1708 (C=O), 1641 (C=O), 1620, 1596, 1435, 1301, 1238, 
1217, 1201, 1097, 1033 cm-1. 
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Methyl 5-hydroxy-3-oxo-5-phenyl-pentanoate (105) 
A 3 M solution of TiCl4 in CH2Cl2 (3.60 mL, 10.8 mmol) was added dropwise to a solution of 
diketene (2.79 mL, 18.1 mmol) and benzaldehyde (0.96 mL, 9.43 mmol) in CH2Cl2 (45 mL) at -
78 oC. The mixture was stirred for 5 mins, followed by the addition MeOH (12 mL). The 
reaction was stirred at -16 oC for 50 mins. The mixture was poured onto ice cooled 0.44 M 
K2CO3 solution (65 mL). EtOAc (120 mL) was added and the layers were separated. The 
aqueous was extracted with EtOAc (3 x 50 mL). Organics were combined, washed with 
NaHCO3 (150 mL), and brine (150 mL), dried (MgSO4), filtered, and concentrated in vacuo. The 
residue was purified by column chromatography (15-20% EtOAc/hexane) to give the title 
compound (1.60 g, 7.22 mmol, 76% yield) as a yellow oil. 1H NMR (500 MHz, CDCl3): δ 7.39 – 
7.32 (4H, m, ArH), 7.32 – 7.27 (1H, m, ArH), 5.19 (1H, dd, J = 9.3, 3.1 Hz, H-5), 3.74 (3H, s, CH3), 
3.50 (2H, s, H-2), 3.01 (1H, dd, J = 17.4, 9.3 Hz, H-4), 2.91 (1H, dd, J = 17.4, 3.1 Hz, H-4). 13C-
NMR (101 MHz, CDCl3): δ 202.8 (C=O), 167.4 (C=O), 142.6 (C), 128.7 (CH), 127.9 (CH), 125.7 
(CH), 69.9 (CH), 52.6 (CH3), 51.7 (CH2), 49.8 (CH2) ppm; HRMS (ESI) 245.0776 (M + Na+. 
C12H24NaO4 requires 245.0784). 1H NMR data was in agreement with literature.96  
 
 
3-Hydroxy-5-phenyl-penta-2,4-dienoic acid methyl ester (106) 
To a solution of 105 (500 mg, 2.25 mmol) in CH2Cl2 (3 mL) was added acetic anhydride (223 
µL, 2.36 mmol), Et3N (470 µL, 3.38 mmol) and DMAP (cat.). The reaction was stirred for 2h at 
rt. MeOH (400 µL) was added, and the mixture stirred for 15 mins. The mixture was diluted 
with CH2Cl2 (8 mL) and partitioned with 0.1 M HCl (10 mL). Organics were combined, washed 
with water (10 mL), CuSO4 (10 mL), and brine (10 mL), dried (MgSO4), filtered, and 
concentrated in vacuo. The residue was purified by column chromatography (5% 
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EtOAc/hexane) to give the title compound (201 mg, 0.905 mmol, 44% yield) as a white solid. 
Mp 93-96 °C; 1H NMR (400 MHz, CDCl3): δ 11.9 (1H, s, OH), 7.51-7.47 (2H, m, ArH), 7.44 (1H, 
d, J = 16.0 Hz, H-3), 7.39-7.31 (3H, m, ArH), 6.44 (1H, dd, J = 16.0, 1.5 Hz, H-2), 5.18 (1H, s, H-
1), 3.77 (3H, s OCH3) ppm; 13C-NMR (101 MHz, CDCl3): δ 173.4 (C=O), 169.4 (C), 137.1 (C), 
135.4 (C), 129.5 (CH), 128.9 (CH), 127.7 (CH), 121.9 (CH), 91.7 (CH), 51.5 (CH3) ppm; HRMS 
(ESI) 227.0695 (M + Na+. C14H16NNaO5 requires 227.0679); IR (ATR): νmax 3027, 2953, 1634 
(C=O), 1590, 1445, 1202 cm-1. 
 
General Procedure A - Synthesis of benzenesulfonyl carbamic esters 
To a solution of aldehyde (53.6 mmol) in water, methanol and formic acid (2:1:0.7, 142 mL) 
was added tert-butyl carbamate (35.7 mmol) and benzenesulfinic acid sodium salt (71.4 
mmol). The mixture was stirred at room temperature for 3 days. The precipitate was filtered 
and washed with water (150 mL) and hexane (300 mL), and used without further purification.  
 
 
(1-Benzenesulfonyl-ethyl)-carbamic acid tert-butyl ester (122a) 
Following general procedure A with acetaldehyde (3 mL, 53.6 mmol), tert-butyl carbamate 
(4.18 g, 35.7 mmol) and benzenesulfinic acid sodium salt (11.7 g, 71.4 mmol) gave the title 
compound (8.27 g, 29.0 mmol, 81% yield) as a white solid. Mp 129-131 oC; 1H NMR (400 MHz, 
CDCl3): δ 7.91 (2H, d, J = 7.5 Hz, H-1), 7.63 (1H, t, J = 7.5 Hz, H-3), 7.54 (2H, dd, J = 7.5, 7.5 Hz, 
H-2), 5.08 (1H, d, J = 10.5 Hz, N-H), 4.99 (1H, dq, J = 10.5, 7.0 Hz, CH), 1.62 (3H, d, J = 7.0 Hz, 
CH3), 1.20 (9H, s, (CH3)3) ppm; 13C NMR (101 MHz, CDCl3): δ 153.5 (C=O), 136.7 (C), 134.0 (CH), 
129.5 (CH), 129.2 (CH), 80.9 (C), 66.9 (CH), 28.1 (CH3), 13.0 (CH3) ppm; HRMS (ESI) 308.0918 
(M + Na+. C13H19NNaO4S requires 308.0927); IR (ATR): νmax 3337, 2973, 1691 (C=O), 1518, 
1313, 1145 cm-1. 
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(1-Benzenesulfonyl-2-methyl-propyl)-carbamic acid tert-butyl ester (122b) 
Following general procedure A with isobutyraldehyde (4.67 mL, 51.3 mmol), tert-butyl 
carbamate (4.00 g, 34.2 mmol) and benzenesulfinic acid sodium salt (11.2 g, 68.4 mmol) gave 
the title compound (4.93 g, 4.25 mmol, 47% yield) as a white solid. Mp 116-117.5 oC; 1H NMR 
(400 MHz, CDCl3): δ 7.91-7.86 (2H, m, H-1), 7.64-7.58 (1H, m, H-3), 7.55-7.49 (2H, m, H-3), 
5.14 (1H, d, J = 11.0 Hz, N-H), 4.84 (1H, dd, J = 11.0, 3.5 Hz, CH), 2.82-2.73 (1H, m, H-4), 1.22 
(9H, s, (CH3)3), 1.14 (3H, d, J = 7.0 Hz, CH3), 1.07 (3H, d, J = 7.0 Hz, CH3) ppm; 13C NMR (101 MHz, 
CDCl3): δ 154.2 (C=O), 138.2 (C), 133.8 (CH), 129.2 (CH), 129.1 (CH), 80.9 (C), 74.4 (CH), 28.1 
(CH2), 26.8 (CH), 20.8 (CH3), 17.0 (CH3) ppm; HRMS (ESI) 226.1404 (M + Na+. C10H21NNaO3 
requires 226.1414 for the methanol adduct); IR (ATR): νmax 3356, 3232, 3142, 2965, 1704 
(C=O), 1364, 1307, 1141, 1082 cm-1. 
 
 
(1-Benzenesulfonyl-butyl)-carbamic acid tert-butyl ester (122c) 
Following general procedure A with butyraldehyde (1.15 mL, 12.8 mmol), tert-butyl 
carbamate (1.00 g, 8.54 mmol) and benzenesulfinic acid sodium salt (2.80 g, 17.1 mmol) gave 
the title compound (1.33 g, 4.25 mmol, 50% yield) as a white solid. Mp 117-118 oC; 1H NMR 
(400 MHz, CDCl3): δ 7.91-7.86 (2H, m, H-1), 7.62-7.56 (1H, m, H-3), 7.54-7.47 (2H, m, H-2), 
7.48-7.39 (2H, m, H-4), 7.09 (2H, t, J = 8.5 Hz, H-5), 5.07 (1H, d, J = 11.0 Hz, N-H), 4.84 (1H, d, 
J = 11.0 Hz, CH), 2.24-2.13 (1H, m, H-4), 1.79-1.65 (1H, m, H-4), 1.62-1.48 (1H, m, H-5), 1.46-
1.35 (1H, m, H-5), 1.24 (9H, s, (CH3)3) ppm; 13C NMR (101 MHz, CDCl3): δ 153.9 (C=O), 137.1 
(C), 133.9 (CH), 129.4 (CH), 129.1 (CH), 80.8 (C), 70.7 (CH), 28.3 (CH2), 28.1 (CH3), 18.8 (CH2), 
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13.6 (CH3) ppm; HRMS (ESI) 336.1243 (M + Na+. C15H23NNaO4S requires 336.1240); IR (ATR): 
νmax 3286, 2960, 2874, 1690 (C=O), 1526, 1310, 1246, 1144, 1083 cm-1. 
 
 
(Benzenesulfonyl-phenyl-methyl)-carbamic acid tert-butyl ester (122d) 
Following general procedure A with benzaldehyde (1.52 mL, 15 mmol), tert-butyl carbamate 
(1.17 g, 10 mmol), and benzenesulfinic acid sodium salt (3.28 g, 20 mmol) gave the title 
compound (3.26 g, 9.42 mmol, 94% yield) as a white solid. Mp 158-161 oC; 1H NMR (400 MHz, 
CDCl3): δ 7.92 (2H, d, J = 7.5 Hz, H-1), 7.64 (1H, t, J = 7.5 Hz, H-3), 7.53 (2H, dd, J = 7.5, 7.5 Hz, 
H-2), 7.48-7.39 (5H, m, ArH), 7.09 (2H, t, J = 8.5 Hz, H-5), 5.94 (1H, d, J = 10.5 Hz, CH), 5.87 
(1H, d, J = 10.5 Hz, N-H), 1.25 (9H, s, (CH3)3) ppm; 13C NMR (101 MHz, CDCl3): δ 153.6 (C=O), 
137.0 (C), 134.1 (CH), 130.0 (CH), 129.6 (CH), 129.2 (CH), 129.1 (CH), 128.9 (CH), 125.1 (C), 
81.4 (C), 74.0 (CH), 28.1 (CH3) ppm; HRMS (ESI) 260.1257 (M + Na+. C13H19NNaO3 requires 
260.1257 for the methanol adduct); IR (ATR): νmax 3355, 3274, 2978, 1693 (C=O), 1508, 1306, 
1141 cm-1. 
 
 
[Benzenesulfonyl-(4-fluoro-phenyl)-methyl]-carbamic acid tert-butyl ester (122e) 
Following general procedure A with 4-fluorobenzaldehyde (9.61 mL, 90.0 mmol), tert-butyl 
carbamate (7.00 g, 59.8 mmol) and benzenesulfinic acid sodium salt (19.6 g, 120 mmol) gave 
the title compound (19.9 g, 54.4 mmol, 91% yield) as a white solid. Mp 167-170 oC; 1H NMR 
(400 MHz, CDCl3): δ 7.91 (2H, d, J = 7.5 Hz, H-1), 7.65 (1H, t, J = 7.5 Hz, H-3), 7.54 (2H, dd, J = 
7.5, 7.5 Hz, H-2), 7.48-7.39 (2H, m, H-4), 7.13-7.04 (2H, m, H-5), 5.94 (1H, d, J = 10.5 Hz, CH), 
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5.85 (1H, d, J = 10.5 Hz, N-H), 1.24 (9H, s, (CH3)3) ppm; 13C NMR (101 MHz, CDCl3): δ 163.7 (d, 
JF = 251 Hz,  CF), 153.6 (C=O), 136.8 (C), 134.2 (CH), 131.0 (d, JF = 8.5 Hz, CH), 129.6 (CH), 129.2 
(CH), 125.9 (d, JF = 3.5 Hz, C), 116.0 (d, JF = 21.5 Hz, CH), 81.5 (C), 73.3 (CH), 28.1 (CH3) ppm; 
HRMS (ESI) 278.1150 (M + Na+. C13H18FNNaO3 requires 278.1163 for the methanol adduct); IR 
(ATR): νmax 3367, 2972, 1703 (C=O), 1506, 1309, 1140 cm-1. 
 
 
[Benzenesulfonyl-(4-methoxy-phenyl)-methyl]-carbamic acid tert-butyl ester (122f) 
Following general procedure A with 4-anisaldehyde (3.85 mL, 31.7 mmol), tert-butyl 
carbamate (2.48 g, 21.1 mmol) and benzenesulfinic acid sodium salt (6.94 g, 42.3 mmol) gave 
the title compound (5.63 g, 14.9 mmol, 71% yield) as a white solid. Mp 156-158 oC; 1H NMR 
(400 MHz, CDCl3): δ 7.91 (2H, d, J = 7.5 Hz, H-1), 7.63 (1H, t, J = 7.5 Hz, H-3), 7.53 (2H, dd, J = 
7.5, 7.5 Hz, H-2), 7.37 (2H, d, J = 8.5 Hz, H-4), 6.93 (2H, d, J = 8.5 Hz, H-5), 5.88 (1H, d, J = 10.5 
Hz, CH), 5.76 (1H, d, J = 10.5 Hz, N-H), 3.82 (3H, s, OCH3), 1.24 (9H, s, (CH3)3) ppm; 13C NMR 
(101 MHz, CDCl3): δ 160.4 (C), 153.2 (C=O), 137.1 (C), 134.0 (CH), 130.3 (CH), 129.6 (CH), 129.2 
(CH), 121.8 (C), 114.4 (CH), 81.3 (C), 73.6 (CH), 55.5 (CH3), 28.1 (CH3) ppm; HRMS (ESI) 
290.1350 (M + Na+. C14H21NNaO4 requires 290.1363 for the methanol adduct); IR (ATR): νmax 
3361, 2967, 1695 (C=O), 1503, 1310, 1162, 1149 cm-1. 
 
 
(Benzenesulfonyl-pyridin-3-yl-methyl)-carbamic acid tert-butyl ester (122g) 
Following general procedure A with nicotinaldehyde (7.8 mL, 83.0 mmol), tert-butyl 
carbamate (6.50 g, 55.5 mmol) and benzenesulfinic acid sodium salt (18.2 g, 111 mmol) gave 
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the title compound (9.09 g, 26.1 mmol, 47% yield) as a white solid. Mp 168.5-171 oC; 1H NMR 
(400 MHz, CDCl3): δ 8.70-8.65 (2H, m, H-6 and H-7), 7.93 (2H, d, J = 7.5 Hz, H-1), 7.85 (1H, ddd, 
J = 8.0, 2.0, 2.0 Hz, H-4)  7.67 (1H, t, J = 7.5 Hz, H-3), 7.56 (2H, dd, J = 7.5, 7.5 Hz, H-2), 6.03 
(1H, d, J = 10.5 Hz, N-H), 5.98 (1H, d, J = 10.5 Hz, CH), 1.25 (9H, s, (CH3)3) ppm; 13C NMR 
(101 MHz, CDCl3): δ 153.6 (C=O), 151.0 (CH), 150.1 (CH), 136.5 (CH), 136.4 (C), 134.5 (CH), 
129.6 (CH), 129.4 (CH), 126.4 (C), 123.7 (CH), 81.8 (C), 72.0 (CH), 28.1 (CH3) ppm; HRMS (ESI) 
239.1392 (M + H+. C12H19N2O3 requires 239.1390 for the methanol adduct); IR (ATR): νmax 
3200, 3064, 2979, 1716 (C=O), 1531, 1303, 1140 cm-1. 
 
 
[Benzenesulfonyl-(4-methyl-thiazol-5-yl)-methyl]-carbamic acid tert-butyl ester (122h) 
Following general procedure A with 4-methylthiazole-5-carbaldehyde (6.68 g, 52.5 mmol), 
tert-butyl carbamate (4.10 g, 35.0 mmol) and benzenesulfinic acid sodium salt (11.5 g, 70.0 
mmol) gave the title compound (6.70 g, 18.2 mmol, 52% yield) as an off-white solid. Mp 167-
169 oC; 1H NMR (400 MHz, CDCl3): δ 8.80 (1H, s, H-4), 7.90 (2H, d, J = 7.5 Hz, H-1), 7.67 (1H, t, 
J = 7.5 Hz, H-3), 7.56 (2H, dd, J = 7.5, 7.5 Hz, H-2), 6.26 (1H, d, J = 10.5 Hz, CH), 5.59 (1H, d, J = 
10.5 Hz, NH), 3.42 (3H, s, CH3), 1.27 (9H, s, (CH3)3) ppm; 13C NMR (101 MHz, CDCl3): δ 153.5 
(C=O), 153.3 (CH), 136.2 (C), 134.5 (CH), 129.6 (CH), 129.4 (CH), 121.1 (C), 81.9 (C), 68.4 (CH), 
28.1 (CH3), 15.7 (CH3) ppm; HRMS (ESI) 259.1114 (M + H+. C11H19N2O3 requires 259.1111 for 
the methanol adduct); IR (ATR): νmax 3153, 3071, 2976, 1707 (C=O), 1535, 1302, 1140 cm-1. 
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[Benzenesulfonyl-(1-methyl-1H-pyrazol-4-yl)-methyl]-carbamic acid tert-butyl ester (122i) 
Following general procedure A with 1-methyl-1H-pyrazole-4-carbaldehyde (1.50 g, 13.6 
mmol), tert-butyl carbamate (1.05 g, 8.96 mmol) and benzenesulfinic acid sodium salt (2.94 
g, 17.9 mmol) gave the title compound (1.42 g, 4.04 mmol, 71% yield) as a white solid. Mp 
153.7-156.5 oC; 1H NMR (400 MHz, CDCl3): δ 7.92 (2H, d, J = 7.5 Hz, H-1), 7.66 (1H, s, H-4), 
7.66-7.59 (2H, m, H-3 and H-5), 7.54 (2H, dd, J = 7.5, 7.5 Hz, H-2), 5.95 (1H, d, J = 10.5 Hz, CH), 
5.73 (1H, d, J = 10.5 Hz, N-H), 3.92 (3H, s, CH3), 1.21 (9H, s, (CH3)3) ppm; 13C NMR (101 MHz, 
CDCl3): δ 153.5 (C=O), 138.9 (CH), 136.6 (C), 134.2 (CH), 130.7 (CH), 129.7 (CH), 129.2 (CH), 
125.0 (C), 81.3 (C), 67.4 (CH), 39.4 (CH3), 28.1 (CH3) ppm; HRMS (ESI) 264.1305 (M + Na+. 
C11H19N3NaO3 requires 264.1319 for the methanol adduct); IR (ATR): νmax 3359, 2971, 1709 
(C=O), 1521, 1303, 1148, 1136 cm-1. 
 
 
[Benzenesulfonyl-(4-cyano-phenyl)-methyl]-carbamic acid tert-butyl ester (122j) 
Following general procedure A with 4-cyanobenzaldehyde (8.40 g, 64.1 mmol), tert-butyl 
carbamate (5.00 g, 8.96 mmol) and benzenesulfinic acid sodium salt (14.0 g, 85.4 mmol) gave 
the title compound (14.9 g, 40.1 mmol, 94% yield) as a white solid. Mp 151-154 oC; 1H NMR 
(400 MHz, CDCl3): δ 7.92 (2H, dd, J = 7.5, 7.5 Hz, H-1), 7.73-7.64 (3H, m, H-3 and H-5), 7.62-
7.53 (4H, m, H-2 and H-4), 6.00 (1H, d, J = 10.5 Hz, CH), 5.93 (1H, d, J = 10.5 Hz, NH), 1.24 (9H, 
s, (CH3)3) ppm; 13C NMR (101 MHz, CDCl3): δ 153.5 (C=O), 136.4 (C), 135.1 (C), 134.6 (C), 133.0 
(CH), 132.5 (CH), 130.0 (CH), 129.8 (CH), 129.6 (CH), 129.4 (CH), 118.2 (C), 113.8 (C), 81.9 (C), 
77.4 (CH), 28.1 (CH3) ppm; HRMS (ESI) 285.1213 (M + Na+. C14H18N2NaO3 requires 285.1210 
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for the methanol adduct); IR (ATR): νmax 3369, 2962, 2235 (CN), 1701 (C=O), 1506, 1308, 1143 
cm-1. 
 
 
[Benzenesulfonyl-(4-trifluoromethyl-phenyl)-methyl]-carbamic acid tert-butyl ester (122k) 
Following general procedure A with 4-(trifluoromethyl)benzaldehyde (6.00 g, 34.5 mmol), 
tert-butyl carbamate (2.69 g, 23.0 mmol) and benzenesulfinic acid sodium salt (7.54 g, 46.0 
mmol). The white precipitate was triturated by stirring in diethyl ether (50 mL) for 1h at rt. 
Filtration gave the title compound (6.87 g, 16.6 mmol, 72% yield) as a white solid. Mp 174.5-
176 °C; 1H NMR (400 MHz, CDCl3): δ 7.94 (2H, d, J = 7.8 Hz, H-1), 7.70-7.65 (3H, m, H-3 and H-
4), 7.63-7.53 (4H, m, H-2 and H-5), 6.02 (1H, d, J = 10.5 Hz, CH), 5.93 (1H, d, J = 10.5 Hz, NH), 
1.23 (9H, s, (CH3)3) ppm; 13C NMR (101 MHz, CDCl3): δ 153.6 (C=O), 136.6 (C), 134.4 (CH), 133.9 
(C), 132.0 (q, JF = 33.0 Hz, C), 129.6 (CH), 129.6 (CH), 129.4 (CH), 125.8 (q, JF = 3.3 Hz, CH), 
123.9 (q, JF = 274 Hz, C), 81.7 (C), 73.4 (CH), 28.1 (CH3) ppm; 19F NMR (376 MHz, CDCl3): δ -
62.8 ppm; HRMS (ESI) 438.0961 (M + Na+. C19H20F3NNaO4S requires 438.0957); IR (ATR): νmax 
3354, 2984, 1696 (C=O), 1508, 1325, 1313, 1166, 1142, 1130, 1068 cm-1. 
 
General Procedure B - Synthesis of N-Boc-δ-amino-β-ketoesters 
To a solution of diisopropylamine (21.0 mmol) in THF (60 mL) at -78 °C was added n-BuLi (2.5 
M in hexanes, 21.0 mmol). The solution was stirred for 10 mins at -78 °C then a further 5 mins 
at room temperature. A solution of methyl acetoacetate (10.5 mmol) in THF (12 mL) was 
added over 10 mins at -78 °C, then stirred for a further 40 mins. The imine was prepared by 
the portionwise addition of sulfone (3.50 mmol) to a suspension of NaH (60% dispersion in 
mineral oil, 7.00 mmol) in THF (24 mL) at room temperature. The subsequent mixture was 
stirred for 20 mins, then immediately transferred to the dianion mixture at -50 °C.  The 
reaction was stirred for 30 mins, then quenched with 10 M acetic acid in THF (2.5 mL). The 
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mixture was warmed to room temperature and concentrated in vacuo. The residue was 
partitioned between EtOAc (30 mL) and water (25 mL). The aqueous layer was extracted with 
EtOAc (2 x 25 mL). Organics were combined, washed with water (50 mL) and brine (50 mL), 
dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by column 
chromatography to give the N-Boc δ-amino-β-ketoester. 
 
 
Methyl 5-tert-butoxycarbonylamino-3-oxo-hexanoate (126a) 
Following general procedure B with sulfone 122a (1 g, 3.50 mmol), NaH (60% dispersion in 
mineral oil, 280 mg, 7.00 mmol), methyl acetoacetate (1.16 mL, 10.5 mmol), diisopropylamine 
(2.94 mL, 21.0 mmol) and n-BuLi (1.91M in hexanes, 11.0 mL, 21.0 mmol). The crude residue 
was purified by column chromatography (20% EtOAc/hexane) to give the title compound (681 
mg, 2.66 mmol, 76% yield) as a colourless oil that solidified to a white solid on standing. Mp 
55-56 °C; 1H NMR (400 MHz, CDCl3): δ 4.80 (1H, br s, NH), 4.07-3.95 (1H, m, H-5), 3.72 (3H, s, 
OCH3), 3.48 (1H, d, J = 15.5 Hz, H-2), 3.43 (1H, d, J = 15.5 Hz, H-2), 2.79 (1H, dd, J = 16.5, 5.0 
Hz, H-4), 2.69 (1H, dd, J = 16.5, 6.0 Hz, H-4), 1.41 (3H, s, (CH3)3), 1.20 (3H, d, J = 7.0 Hz, CH3) 
ppm; 13C-NMR (101 MHz, CDCl3): δ 201.6 (C=O), 167.6 (C=O), 155.2 (C=O), 79.5 (C), 52.5 (CH3), 
49.4 (CH2), 49.1 (CH2), 43.3 (CH), 28.5 (CH3), 20.6 (CH3) ppm; HRMS (ESI) 282.1321 (M + Na+. 
C12H21NNaO5 requires 282.1312); IR (ATR): νmax 3366, 3312, 3000, 2976, 1737 (C=O), 1702 
(C=O), 1679 (C=O), 1535 cm-1. 
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Methyl 5-tert-butoxycarbonylamino-6-methyl-3-oxo-heptanoate (126b) 
Following general procedure B with sulfone 122b (2.00 g, 6.39 mmol), NaH (60% dispersion 
in mineral oil, 307 mg, 12.8 mmol), methyl acetoacetate (2.06 mL, 19.2 mmol), 
diisopropylamine (5.36 mL, 38.3 mmol) and n-BuLi (1.97M in hexanes, 19.5 mL, 38.3 mmol). 
The crude residue was purified by column chromatography (20% EtOAc/hexane) to give the 
title compound (917 mg, 3.20 mmol, 50% yield) as a colourless oil that solidified to a white 
solid on standing. Mp 60-62 °C; 1H NMR (400 MHz, CDCl3): δ 4.75 (1H, d, J = 9.2 Hz, NH), 3.81-
3.71 (1H, m, H-5), 3.73 (3H, s, OCH3), 3.56 (1H, d, J = 15.7 Hz, H-2), 3.47 (1H, d, J = 15.7 Hz, H-
2), 2.77 (1H, dd, J = 16.2, 4.7 Hz, H-4), 2.69 (1H, dd, J = 16.2, 7.4 Hz, H-4), 1.91-1.79 (1H, m, H-
6), 1.42 (9H, s, (CH3)3), 0.90 (6H, d, J = 9.2 Hz, H-7) ppm; 13C-NMR (101 MHz, CDCl3): δ 202.0 
(C=O), 167.7 (C=O), 155.7 (C=O), 79.4 (C), 52.7 (CH), 52.4 (CH3), 49.0 (CH2), 45.6 (CH2), 31.8 
(CH), 28.4 (CH3), 19.5 (CH3) ppm; HRMS (ESI) 310.1618 (M + Na+. C14H25NNaO5 requires 
320.1625); IR (ATR): νmax 3356, 2974, 2958, 1748 (C=O), 1713 (C=O), 1686 (C=O), 1525, 1307, 
1128 cm-1. 
 
 
Methyl 5-tert-butoxycarbonylamino-3-oxo-octanoate (126c) 
Following general procedure B with sulfone 122c (400 mg, 1.28 mmol), NaH (60% dispersion 
in mineral oil, 61 mg, 2.56 mmol), methyl acetoacetate (413 µL, 3.84 mmol), diisopropylamine 
(1.07 mL, 7.68 mmol) and n-BuLi (1.91M in hexanes, 4.02 mL, 7.68 mmol). The crude residue 
was purified by column chromatography (20% EtOAc/hexane) to give the title compound (238 
mg, 0.829 mmol, 65% yield) as a colourless oil that solidified to a white solid on standing. Mp 
53-55 °C; 1H NMR (400 MHz, CDCl3): δ 4.78 (1H, d, J = 7.7 Hz, NH), 3.95-3.79 (1H, m, H-5), 3.72 
(3H, s, OCH3), 3.50 (1H, d, J = 15.7 Hz, H-2), 3.43 (1H, d, J = 15.7 Hz, H-2), 2.73 (2H, d, J = 5.7 
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Hz, H-4), 1.52-1.22 (4H, m, H-6 and H-7), 1.40 (9H, s, (CH3)3), 0.89 (3H, t, J = 7.2 Hz, H-8) ppm; 
13C-NMR (101 MHz, CDCl3): δ 201.9 (C=O), 167.6 (C=O), 155.6 (C=O), 79.4 (C), 52.5 (CH3), 49.4 
(CH2), 47.7 (CH2), 47.3 (CH), 36.8 (CH2), 28.5 (CH3), 19.5 (CH2), 13.9 (CH3) ppm; HRMS (ESI) 
310.1636 (M + Na+. C14H25NNaO5 requires 310.1625); IR (ATR): νmax 3288, 2964, 2933, 1742 
(C=O), 1704 (C=O), 1679 (C=O), 1539, 1262, 1173 cm-1. 
 
 
Methyl 5-tert-butoxycarbonylamino-3-oxo-5-phenyl-pentanoate (126d) 
Following general procedure B with sulfone 122d (1.00 g, 2.89 mmol), NaH (60% dispersion 
in mineral oil, 134 mg, 5.78 mmol), methyl acetoacetate (934 µL, 17.3 mmol), 
diisopropylamine (2.43 mL, 17.3 mmol) and n-BuLi (9.08 mL, 17.3 mmol). The residue was 
purified by column chromatography (20% EtOAc/hexane) to give the title compound (672 mg, 
2.09 mmol, 73% yield) as a colourless oil that solidified on standing. Mp 83.7-85.5 °C; 1H NMR 
(500 MHz, CDCl3): δ 7.34-7.22 (5H, m, ArH), 5.34 (1H, br. s, NH), 5.10 (1H, br. s, H-5), 3.68 (3H, 
s, OCH3), 3.42 (1H, d, J = 15.5 Hz, H-2), 3.38 (1H, d, J = 15.5 Hz, H-2),  3.17 (1H, J = 16.5, 6.5 Hz, 
H-2), 3.04 (1H, dd, J = 16.5, 5.0 Hz, H-2) 1.41 (9H, s, (CH3)3) ppm; 13C-NMR (101 MHz, CDCl3): 
δ 200.9 (C=O), 172.8 (C), 167.4 (C=O), 155.2 (C=O), 128.8 (CH), 127.7 (CH), 126.3 (CH), 79.9 
(C), 52.5 (CH3), 50.9 (CH), 49.5 (CH2), 48.8 (CH2), 28.4 (CH3) ppm; HRMS (ESI) 344.1463 (M + 
Na+. C17H23NNaO5 requires 344.1468); IR (ATR): νmax 3393, 2978, 1752 (C=O), 1718 (C=O), 1681 
(C=O), 1170, 1152 cm-1. 
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Methyl 5-tert-butoxycarbonylamino-5-(4-fluoro-phenyl)-3-oxo-pentanoate (126e) 
Method A: Following general procedure B with sulfone 122e (5.00 g, 13.7 mmol), NaH (60% 
dispersion in mineral oil, 1.66 g, 41.1 mmol), methyl acetoacetate (4.42 mL, 41.1 mmol), 
diisopropylamine (11.6 mL, 82.2 mmol) and n-BuLi (2.5 M in hexanes, 32.9 mL, 82.2 mmol). 
The residue was purified by column chromatography (15-20% EtOAc/hexane) to give the title 
compound (3.59 g, 10.6 mmol, 77% yield) as a white solid. 
Method B: To a solution of 189e (120 mg, 0.538 mmol) in THF (5.4 mL) at -78 oC was added 
ZnCl2 (1.9M in Me-THF, 283 μL, 0.538 mmol). The mixture was stirred for 30 mins before the 
dropwise addition of Chan’s diene (350 mg, 1.35 mmol). The reaction was stirred for 1h then 
quenched with sat. aq. NaHCO3 (5 mL). The mixture was warmed to rt and THF was removed 
in vacuo. CH2Cl2 (10 mL) was added and the layers were separated. The aqueous was extracted 
with CH2Cl2 (3 x 5 mL). The organics were combined, washed with water (10 mL) and brine (10 
mL), dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by column 
chromatography (15-20% EtOAc/petroleum ether (40-60)) to give the title compound (111 
mg, 0.334 mmol, 62% yield) as a white solid. 
Method C: To a solution of 189e (113 mg, 0.507 mmol) in CH2Cl2 (5 mL) at -78 oC was added 
TiCl4 (56 μL, 0.507 mmol). Chan’s diene (263 mg, 1.01 mmol) was added and the mixture was 
stirred for 25 mins, then quenched with 1.59M citric acid in MeOH (1 mL). Water (5 mL) was 
added and the mixture was warmed to rt. The layers were separated and the aqueous was 
extracted with CH2Cl2 (5 x 5 mL). The organics were combined, washed with NaHCO3 (10 mL) 
and brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo. The residue was purified 
by column chromatography (15-20% EtOAc/petroleum ether (40-60)) to give the title 
compound (106 mg, 0.309 mmol, 61% yield) as a white solid. Mp 87-88.5 °C; 1H NMR (400 
MHz, CDCl3): δ 7.30-7.23 (2H, m, H-6), 7.04-6.97 (2H, m, H-7), 5.33 (1H, br. s, NH), 5.13-5.01 
(1H, m, H-5), 3.69 (3H, s, OCH3), 3.42 (1H, d, J = 15.5 Hz, H-2), 3.38 (1H, d, J = 15.5 Hz, H-2), 
3.16 (1H, dd, J = 17.0, 6.0 Hz, H-4), 3.02 (1H, dd, J = 17.0 Hz, 6.0 Hz, H-4), 1.41 (9H, s, (CH3)3) 
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ppm; 13C-NMR (101 MHz, CDCl3): δ 200.7 (C=O), 167.4 (C=O), 162.1 (d, JF = 247.0 Hz, CF), 155.2 
(C=O), 137.2 (C), 128.1 (d, JF = 8.0 Hz, CH), 115.6 (d, JF = 21.5 Hz, CH), 80.1 (C), 52.6 (CH3), 50.4 
(CH), 49.5 (CH2), 48.7 (CH2), 28.4 (CH3) ppm; 19F NMR (376 MHz, CDCl3): δ -116.7 ppm; HRMS 
(ESI) 340.1556 (M + H+. C17H23FNO5 requires 340.1555); IR (ATR): νmax 3306, 2982, 1741 (C=O), 
1713 (C=O), 1673 (C=O), 1535, 1511, 1365, 1328, 1286, 1221, 1161, 999 cm-1.  
 
 
Methyl 5-((tert-butoxycarbonyl)amino)-5-(4-methoxyphenyl)-3-oxopentanoate (126f) 
Following general procedure B with sulfone 122f (3.00 g, 7.95 mmol), NaH (60% dispersion in 
mineral oil, 0.954 g, 23.8 mmol), methyl acetoacetate (2.71 mL, 23.8 mmol), diisopropylamine 
(6.80 mL, 47.7 mmol) and n-BuLi (2.5 M in hexanes, 19.1 mL, 47.7 mmol). The residue was 
purified by column chromatography (15-20% EtOAc/hexane) to give the title compound (1.49 
g, 4.25 mmol, 53% yield) as a yellow oil. 1H NMR (400 MHz, CDCl3): δ 7.24-7.19 (2H, m,  H-6), 
6.89-6.84 (2H, m, H-7), 5.20 (1H, br. s, NH), 5.11-5.01 (1H, m, H-5), 3.80 (3H, s, H-8), 3.70 (3H, 
s, OCH3), ), 3.43 (1H, d, J = 16.0 Hz, H-2), 3.41 (1H, d, J = 16.0 Hz, H-2), 3.15 (1H, dd, J = 16.5, 
6.5 Hz, H-4), 3.05 (1H, dd, J = 16.5, 6.5 Hz, H-4), 1.42 (9H, s, (CH3)3) ppm; 13C-NMR (101 MHz, 
CDCl3): δ 200.7 (C=O), 167.3 (C=O), 159.0 (C), 155.0 (C=O), 133.3 (C), 127.4 (CH), 114.1 (CH), 
79.8 (C), 55.3 (CH3), 52.4 (CH3), 50.5 (CH), 49.4 (CH2), 48.8 (CH2), 28.3 (CH3); HRMS (ESI) 
352.1743 (M + H+. C18H26NO6 requires 352.1755); IR (ATR): νmax 3356, 2974, 2839, 1748 (C=O), 
1708 (C=O), 1679 (C=O), 1512, 1243, 1163, 1037 cm-1. 
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Methyl 5-tert-butoxycarbonylamino-3-oxo-5-pyridin-3-yl-pentanoate (126g)  
Following general procedure B with sulfone 122g (5.00 g, 14.4 mmol), NaH (60% dispersion 
in mineral oil, 1.73 g, 43.2 mmol), methyl acetoacetate (4.66 mL, 43.2 mmol), 
diisopropylamine (12.2 mL, 86.4 mmol) and n-BuLi (2.5 M in hexanes, 34.6 mL, 86.4 mmol). 
The residue was purified by column chromatography (50% EtOAc/hexane then 100% EtOAc) 
to give the title compound (2.58 g, 8.01 mmol, 56% yield) as an off-white solid. Mp 96.5-99.5 
°C; 1H NMR (400 MHz, CDCl3): δ 8.56 (1H, d, J = 2.5 Hz, H-9), 8.50 (1H, dd, J = 4.5, 1.5 Hz, H-8), 
7.64 (1H, dt, J = 8.0, 1.5 Hz, H-6), 7.26 (1H, dd, J = 8.0, 4.5 Hz, H-7), 5.51 (1H, br. s, NH), 5.13 
(1H, br. s, H-5), 3.69 (3H, s, CH3), 3.45 (1H, d, J = 15.5 Hz, H-2), 3.40 (1H, d, J = 15.5 Hz, H-2), 
3.24 (1H, dd, J = 17.0, 4.0 Hz, H-4), 3.08 (1H, dd, J = 17.0, 4.0 Hz, H-4), 1.41 (9H, s, (CH3)3) ppm; 
13C-NMR (101 MHz, CDCl3): δ 200.6 (C=O), 167.3 (C=O), 155.1 (C=O), 148.9 (CH), 148.2 (CH), 
136.9 (C), 134.2 (CH), 123.5 (CH), 80.3 (C), 52.6 (CH3), 49.3 (CH2), 48.8 (CH), 48.1 (CH2) ppm; 
HRMS (ESI) 323.1594 (M + H+. C16H23N2O5 requires 323.1601); IR (ATR): νmax 3208, 2982, 1756 
(C=O), 1709 (C=O), 1542, 1365, 1282, 1178, 1082, 1005 cm-1. 
 
 
5-tert-Butoxycarbonylamino-5-(4-methyl-thiazol-5-yl)-3-oxo-pentanoic acid methyl ester 
(126h) 
Following general procedure B with sulfone 122h (5.00 g, 13.6 mmol), NaH (60% dispersion 
in mineral oil, 1.63 g, 40.8 mmol), methyl acetoacetate (4.40 mL, 40.8 mmol), 
diisopropylamine (11.5 mL, 81.6 mmol) and n-BuLi (2.5 M in hexanes, 32.6 mL, 81.6 mmol). 
The residue was purified by column chromatography (50% EtOAc/hexane then 100% EtOAc) 
to give the title compound (2.69 g, 7.87 mmol, 58% yield) as a red oil that solidified on 
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standing. Mp 91.5-94 °C; 1H NMR (400 MHz, CDCl3): δ 8.60 (1H, s, H-6), 5.40 (1H, dd, J = 14.0, 
6.0 Hz, H-5), 5.27 (1H, br. s, NH), 3.71 (3H, s, OCH3), 3.46 (1H, d, J = 15.5 Hz, H-2), 3.42 (1H, d, 
J = 15.5 Hz, H-2), 3.21 (1H, dd, J = 17.5, 6.0 Hz, H-4), 3.06 (1H, dd, J = 17.5, 6.0 Hz), 2.49 (3H, 
s, CH3), 1.41 (3H, s, (CH3)3) ppm; 13C-NMR (101 MHz, CDCl3): δ 200.2 (C=O), 167.2 (C=O), 154.8 
(C=O), 150.5 (CH), 149.9 (C), 132.7 (C), 80.4 (C), 52.7 (CH3), 49.4 (CH2), 44.5 (CH2), 28.4 (CH3), 
15.5 (CH3) ppm; HRMS (ESI) 343.1314 (M + Na+. C15H23N2O5S requires 343.1322); IR (ATR): νmax 
3214, 2976, 1752 (C=O), 1719 (C=O), 1701 (C=O), 1532, 1277, 1172, 1127, 1003 cm-1. 
 
 
Methyl 5-((tert-butoxycarbonyl)amino)-5-(1-methyl-1H-pyrazol-4-yl)-3-oxopentanoate 
(126i) 
Following general procedure B with sulfone 122i (1.3 g, 3.51 mmol), NaH (60% dispersion in 
mineral oil, 0.422 g, 10.5 mmol), methyl acetoacetate (1.14 mL, 10.5 mmol), diisopropylamine 
(3.01 mL, 21.1 mmol) and n-BuLi (1.60M in hexanes, 13.2 mL, 21.1 mmol). The residue was 
purified by column chromatography (50% EtOAc/hexane then 100% EtOAc) to give the title 
compound (652 mg, 2.00 mmol, 57% yield) as a colourless oil. 1H NMR (400 MHz, CDCl3): δ 
7.37 (1H, s, H-6), 7.30 (1H, s, H-7), 5.22 (1H, br. s, NH), 5.12-5.03 (1H, m, H-5), 3.85 (3H, s, H-
8), 3.73 (3H, s, OCH3), 3.48 (1H, d, J = 15.5 Hz, H-2), 3.44 (1H, d, J = 15.5 Hz, H-2), 3.12 (1H, dd, 
J = 17.0, 5.5 Hz, H-4), 3.05 (1H, dd, J = 17.0, 6.5 Hz, H-4), 1.44 (9H, s, (CH3)3) ppm; 13C-NMR 
(101 MHz, CDCl3): δ 200.8 (C=O), 172.7 (C=O), 167.3 (C=O), 137.1 (CH), 128.3 (CH), 122.4 (C), 
79.8 (C), 52.4 (CH3), 49.3 (CH2), 48.4 (CH2), 43.0 (CH), 38.9 (CH3), 28.4 (CH3) ppm; HRMS (ESI) 
326.1697 (M + H+. C15H24N3O5 requires 326.1711); IR (ATR): νmax 3355, 2976, 1744 (C=O), 1705 
(C=O), 1512, 1365, 1245, 1162, 1015 cm-1. 
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Methyl 5-tert-butoxycarbonylamino-5-(4-cyano-phenyl)-3-oxo-pentanoate (126j) 
Following general procedure B with sulfone 122j (2.00 g, 5.38 mmol), NaH (60% dispersion in 
mineral oil, 0.644 g, 16.1 mmol), methyl acetoacetate (1.74 mL, 16.1 mmol), diisopropylamine 
(4.55 mL, 32.3 mmol) and n-BuLi (2.5 M in hexanes, 12.9 mL, 32.3 mmol). The residue was 
purified by column chromatography (15-25% EtOAc/hexane) to give the title compound (1.26 
g, 3.64 mmol, 68% yield) as a white solid. Mp 93-95.5 °C; 1H NMR (400 MHz, CDCl3): δ 7.66-
7.59 (2H, m, H-7), 7.45-7.40 (2H, m, H-6), 5.53 (1H, br. s, NH), 5.13 (1H, br.s, H-5), 3.70 (3H, s, 
OCH3), 3.43 (1H, d, J = 15.5 Hz, H-2), 3.38 (1H, d, J = 15.5 Hz, H-2), 3.22 (1H, dd, J = 17.5, 4.5 
Hz, H-4), 3.05 (1H, dd, J = 17.5, 4.5 Hz, H-4), 1.41 (9H, s, (CH3)3) ppm; 13C-NMR (101 MHz, 
CDCl3): δ 200.3 (C=O), 167.3 (C=O), 155.1 (C=O), 147.0 (C), 132.6 (CH), 127.2 (CH), 118.8 (CN), 
111.4 (C), 80.4 (C), 52.7 (CH3), 50.5 (CH), 49.3 (CH2), 47.9 (CH2), 28.4 (CH3) ppm; HRMS (ESI) 
369.1421 (M + Na+. C18H22N2NaO5 requires 369.1421); IR (ATR): νmax 3343, 2995, 2955, 2228 
(CN), 1751 (C=O), 1707 (C=O), 1676 (C=O), 1525, 1271, 1249, 1166, 1152 cm-1. 
 
 
Methyl 6-methyl-4-oxo-2-phenyl-piperidine-3-carboxylate (129) 
Following general procedure C with TFA salt 128a (60 mg, 0.308 mmol), benzaldehyde (156 
μL, 1.54 mmol) and NaHCO3 (129 mg, 1.54 mmol) to give the title compound as a mixture of 
diastereomers (62.5 mg, 0.253 mmol, 82% yield) as a yellow oil after column chromatography 
(20% EtOAc/hexane then 100% EtOAc). Data presented is for the major diastereomer. 1H NMR 
(500 MHz, CDCl3): δ 7.44-7.40 (2H, m, ArH), 7.36-7.27 (3H, m, ArH), 4.28 (1H, d, J = 11.0 Hz, H-
2), 3.57 (1H, dd, J = 11.0, 1.0 Hz, H-3), 3.57 (3H, s, OCH3), 3.21 (1H, dqd, J = 11.5, 6.0, 3.0 Hz, 
H-6), 2.52 (1H, dd, J = 14.0, 3.0 Hz, H-5), 2.28 (1H, ddd, J = 14.0, 11.5, 1.0 Hz, H-5), 1.25 (3H, 
139 
 
d, J = 6.0 Hz, CH3) ppm; HRMS (ESI) 248.1272 (M + H+. C14H18NO3 requires 248.1281), 270.1096 
(M + Na+. C14H17NNaO3 requires 270.1101). 1H data was in agreement with literature.95 
 
 
2-Methylpiperidine-4,6-dione (130a) 
To a stirred solution of TFA salt 128a (70 mg 0.320 mmol) in CH2Cl2 (0.7 mL) was added sat. 
aq. NaHCO3 (0.35 mL). The reaction was stirred at rt for 1h then acidified to pH 3 with 2M HCl. 
The layers were separated and the aqueous was extracted with EtOAc (2 x 5 mL). The organics 
were combined, dried (MgSO4), filtered and concentrated in vacuo. The residue was purified 
by column chromatography (4% MeOH/CH2Cl2) to give the title compound (12 mg, 0.096 
mmol, 30% yield) as a sticky yellow oil. 1H NMR (400 MHz, CDCl3): δ 3.89-3.76 (1H, m, H-2), 
3.30 (1H, d, J = 20.1 Hz, H-5), 3.24 (1H, d, J = 20.1 Hz, H-5), 2.68 (1H, dd, J = 16.5, 4.1 Hz, H-3), 
2.33 (1H, dd, J = 16.5, 9.6 Hz, H-3), 1.33 (3H, d, J = 6.5 Hz, H-7) ppm. 1H NMR data was in 
agreement with literature.206 
 
 
2-Phenylpiperidine-4,6-dione (130b) 
To a stirred solution of TFA salt 128b (190 mg 0.676 mmol) in CH2Cl2 (2.5 mL) was added sat. 
aq. NaHCO3 (1.25 mL). The reaction was stirred at rt for 1h then acidified to pH 3 with 2M HCl. 
The layers were separated and the aqueous was extracted with EtOAc (2 x 5 mL). The organics 
were combined, dried (MgSO4), filtered and concentrated in vacuo. The residue was purified 
by column chromatography (4% MeOH/CH2Cl2) to give the title compound (83 mg, 0.439 
mmol, 65% yield) as a sticky oil. 1H NMR (400 MHz, CDCl3): δ 7.47-7.28 (5H, m, ArH), 4.81 (1H, 
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ddd, J = 9.0, 4.3, 1.0 Hz, H-2), 3.38 (2H, s, H-5), 2.89 (1H, dd, J = 16.0, 4.3 Hz, H-3), 2.76 (1H, 
dd, J = 16.0, 9.0 Hz, H-3) ppm. 1H NMR data was in agreement with literature.206 
 
General Procedure C – Synthesis of 2-spiropiperidines from N-Boc-δ-amino-β-ketoesters 
N-Boc protected δ-amino-β-ketoester (3.00 mmol) was stirred in 4M HCl in dioxane (11.5 mL) 
for 3h at room temperature. The mixture was concentrated in vacuo to afford the δ-amino-
β-ketoester hydrochloride salt which was used without further purification. To a suspension 
of the δ-amino-β-ketoester hydrochloride salt (0.308 mmol) and ketone (1.54 mmol) in CH2Cl2 
(1 mL), was added NaHCO3 (129 mg, 1.54 mmol). The reaction was stirred for 16h at room 
temperature, then filtered and concentrated in vacuo. The residue was purified by column 
chromatography to afford 2-spiropiperidin-4-ones. 
 
 
Methyl 2,2,6-trimethyl-4-oxo-piperidine-3-carboxylate (134a) 
Following general procedure C with the hydrochloride salt of 126a (60 mg, 0.308 mmol), 
acetone (113 µL, 1.54 mmol) and NaHCO3 (129 mg, 1.54 mmol) to give the title compound as 
a mixture of diastereomers (52 mg, 0.246 mmol, 85% yield, 2.5:1 dr) as a yellow oil without 
further purification. Data presented is for the major diastereomer. 1H NMR (500 MHz, CDCl3): 
δ 3.69 (3H, s, OCH3), 3.22 (1H, d, J = 1.0 Hz, H-3), 3.18 (1H, dqd, J = 10.5, 6.5, 3.5 Hz, H-6), 2.47 
(1H, dd, J = 13.5, 10.5 Hz, H-5), 2.32 (1H, ddd, J = 13.5, 3.5, 1.0 Hz, H-5), 1.26 (3H, d, J = 6.3 Hz, 
H-7), 1.18 (3H, s, H-8), 1.09 (3H, s, H-8) ppm; 13C NMR (101 MHz, CDCl3): δ 205.7 (C=O), 169.7 
(C=O), 66.8 (CH), 57.9 (C), 52.3 (CH3), 48.4 (CH), 46.9 (CH2), 28.2 (CH3), 26.1 (CH3), 22.8 (CH3) 
ppm; HRMS (ESI) 200.1289 (M + H+. C10H18NO3 requires 200.1281); IR (ATR): νmax 2967, 1705 
(C=O), 1610, 1534, 1434, 1136 cm-1. 
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Methyl 6-(4-fluorophenyl)-2,2-dimethyl-4-oxo-piperidine-3-carboxylate (134b) 
Following general procedure C with the hydrochloride salt of 126e (110 mg, 0.399 mmol), 
acetone (146 µL, 1.99 mmol) and NaHCO3 (167 mg, 1.99 mmol) to give the title compound as 
a mixture of diastereomers (108 mg, 0.387 mmol, 97% yield, 1.8:1) as a yellow oil without 
further purification. Data presented is for the major diastereomer. 1H NMR (500 MHz, CDCl3): 
δ 7.44 (2H, m, H-7), 7.06 (2H, t, J = 8.5 Hz, H-8), 4.16 (1H, dd, J = 11.5, 3.5 Hz, H-6), 3.75 (3H, 
s, OCH3), 3.33 (1H, d, J = 1.0 Hz, H-3), 3.00 (1H, dd, J = 13.5, 11.5 Hz, H-5), 2.50 (1H, ddd, J = 
13.5, 3.5, 1.0 Hz, H-5), 1.24 (3H, s, CH3), 1.21 (3H, s, CH3) ppm; 13C NMR (101 MHz, CDCl3): δ 
204.7 (C=O), 169.7 (C=O), 162.4 (d, JF = 247.0 Hz, CF), 137.9 (d, JF = 3.5 Hz, C), 128.3 (d, JF = 8.5 
Hz, CH), 115.8 (d, JF = 21.5 Hz, CH), 67.1 (CH), 58.0 (C), 56.2 (CH), 52.4 (CH3), 46.0 (CH2), 28.4 
(CH3), 26.0 (CH3) ppm; 19F NMR (376 MHz, CDCl3): δ -114.42 ppm; HRMS (ESI) 280.1342 (M + 
Na+. C15H19FNO3 requires 280.1343); IR (ATR): νmax 2969, 1748 (C=O), 1705 (C=O), 1603, 1509, 
1222, 1195, 1152, 1125 cm-1. 
 
 
Methyl 6-(3-pyridyl)-2,2-dimethyl-4-oxo-piperidine-3-carboxylate (134c) 
Following general procedure C with the hydrochloride salt of 126g (80 mg, 0.310 mmol), 
acetone (114 µL, 1.55 mmol) and NaHCO3 (130 mg, 1.55 mmol) to give the title compound as 
a mixture of diastereomers (69.8 mg, 0.266 mmol, 86% yield, 1.5:1) as a yellow oil without 
further purification. Data presented is for the major diastereomer. 1H NMR (500 MHz, CDCl3): 
δ 8.65 (1H, d, J = 2.0 Hz, H-10), 8.55 (1H, dd, J = 4.5, 2.0 Hz, H-9), 7.80 (1H, dt, J = 8.0, 2.0 Hz, 
H-7), 7.31 (1H, dd, J = 8.0, 4.5 Hz, H-8), 4.21 (1H, dd, J = 11.5, 4.0 Hz, H-6), 3.73 (3H, s, OCH3), 
3.13 (1H, d, J = 1.0 Hz, H-3), 3.01 (1H, dd, J = 13.5, 11.5 Hz, H-5), 2.52 (1H, ddd, J = 13.5, 4.0, 
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1.0 Hz, H-5), 1.24 (3H, s, CH3), 1.22 (3H, s, CH3) ppm; 13C NMR (101 MHz, CDCl3): δ 204.3(C=O), 
169.7 (C=O), 149.5 (CH), 148.8 (CH), 137.4 (C), 134.1 (CH), 123.9 (CH), 66.9 (CH), 58.0 (C), 54.2 
(CH), 52.2 (CH3), 45.4 (CH2), 28.3 (CH3), 25.8 (CH3) ppm; HRMS (ESI) 263.1393 (M + Na+. 
C14H19N2O3 requires 263.1390); IR (ATR): νmax 2969, 1707, 1429, 1197, 1153 cm-1. 
 
 
Methyl 6-methyl-4-oxo-1-aza-spiro[5.5]undecane-3-carboxylate (135a) 
Following general procedure C with the hydrochloride salt of 126a (60 mg, 0.308 mmol), 
cyclohexanone (159 µL, 1.54 mmol) and NaHCO3 (129 mg, 1.54 mmol). The crude residue was 
dissolved in EtOAc (5 mL), washed with 2M NaOH (5 mL) and concentrated in vacuo to give 
the title compound as a mixture of diastereomers (63.4 mg, 0.265 mmol, 86% yield, 7:1 dr) as 
a yellow oil. Data presented is for the major diastereomer. 1H NMR (500 MHz, CDCl3): δ 3.67 
(3H, s, OCH3), 3.34 (1H, br. s, H-3), 3.15 (1H, dqd, J = 10.5, 6.5, 3.5 Hz, H-6), 2.51 (1H, dd, J = 
13.5, 10.5 Hz, H-5), 2.30 (1H, ddd, J = 13.5, 3.5, 1.0 Hz, H-5), 1.60-1.30 (10H, m, cyclohexyl), 
1.25 (3H, d, J = 6.5 Hz, CH3) ppm; 13C NMR (101 MHz, CDCl3): δ 206.1 (C=O), 169.5 (C=O), 65.8 
(CH), 60.3 (C), 52.1 (CH3), 47.5 (CH2), 47.2 (CH), 36.6 (CH2), 33.7 (CH2), 25.8 (CH2), 22.9 (CH3), 
21.6 (CH2), 21.1 (CH2) ppm; HRMS (ESI) 240.1592 (M + H+. C13H22NO3 requires 240.1594); IR 
(ATR): νmax 2930, 2856, 1703 (C=O), 1434, 1327, 1161 cm-1. 
 
 
Methyl 4-oxo-6-phenyl-1-aza-spiro[5.5]undecane-3-carboxylate (135b) 
Following general procedure C with the hydrochloride salt of 126d (116 mg, 0.451 mmol), 
cyclohexanone (234 μL, 2.26 mmol) and NaHCO3 (190 mg, 2.26 mmol). The residue was 
dissolved in EtOAc (10 mL), washed with water (15 x 5 mL) and concentrated in vacuo to give 
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the title compound as a mixture of diastereomers (105 mg, 0.352 mmol, 78% yield, 7:1 dr) as 
a yellow oil. Data presented is for the major diastereomer. 1H NMR (400 MHz, CDCl3): δ 7.48-
7.27 (5H, m, ArH), 4.11 (1H, dd, J = 11.0, 4.0 Hz, H-6), 3.72 (3H, s, OCH3), 3.41 (1H, br s, H-3), 
3.08 (1H, dd, J = 13.5, 11.0 Hz, H-5), 2.53 (1H, ddd, J = 13.5, 4.0, 1.0 Hz, H-5), 1.76-1.29 (10H, 
m, cyclohexyl) ppm; 13C NMR (101 MHz, CDCl3): δ 205.4 (C=O), 169.5 (C=O), 142.5 (C), 128.9 
(CH), 127.8 (CH), 126.7 (CH), 66.6 (CH), 60.4 (C), 55.5 (CH), 52.2 (CH3), 46.3 (CH2), 36.6 (CH2), 
33.3 (CH2), 25.7 (CH2), 21.5 (CH2), 21.0 (CH2) ppm; HRMS (ESI) 302.1754 (M + H+. C18H24NO3 
requires 302.1751); IR (ATR): νmax 2930, 2855, 1702, 1434, 1327, 1192, 1162 cm-1. 
 
 
Methyl 6-(4-fluorophenyl)-4-oxo-1-aza-spiro[5.5]undecane-3-carboxylate (135c) 
Following general procedure C with the hydrochloride salt of 126e (68.5 mg, 0.248 mmol) 
cyclohexanone (128 µL, 1.24 mmol) and NaHCO3 (104 mg, 1.24 mmol). The crude residue was 
dissolved in EtOAc (10 mL), washed with water (5 x 10 mL) and brine (10 mL), dried (MgSO4), 
filtered and concentrated in vacuo to give the title compound as a mixture of diastereomers 
(59.0 mg, 0.185 mmol, 75% yield, 5:1 dr) as a yellow oil. Data presented is for the major 
diastereomer. 1H NMR (400 MHz, CDCl3): δ 7.46-7.39 (2H, m, H-7), 7.10-7.03 (2H, m, H-8), 
4.10 (1H, dd, J = 11.5, 4.0 Hz, H-6), 3.73 (3H, s, OCH3), 3.41 (1H, br. s, H-3), 3.04 (1H, dd, J = 
13.5, 11.5 Hz, H-5), 2.52 (1H, ddd, J = 13.5, 4.0, 1.0 Hz, H-5), 1.80-1.29 (10H, m, cyclohexyl) 
ppm; 13C NMR (101 MHz, CDCl3): δ 205.1 (C=O), 169.6 (C=O), 162.3 (d, J = 247 Hz, CF), 138.4 
(C, d, J = 3.0 Hz), 128.4 (CH, d, J = 8.0 Hz), 115.8 (CH, d, J = 21 Hz), 66.5 (CH), 60.3 (C), 54.8 
(CH3), 52.3 (CH), 46.3 (CH2), 36.6 (CH2), 33.4 (CH2), 25.7 (CH2), 21.6 (CH2), 21.1 (CH2) ppm; 19F 
NMR (376 MHz, CDCl3): δ  -114.7 ppm; HRMS (ESI) 320.1645 (M + H+. C18H23FNO3 requires 
320.1656; IR (ATR): νmax 2933, 2856, 1705 (C=O), 1600, 1510, 1439, 1329, 1224, 1159 cm-1. 
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Methyl 6-methyl-4-oxo-1-aza-spiro[4.5]decane-3-carboxylate (136) 
Following general procedure C with the hydrochloride salt of 126a (65.8 mg, 0.337 mmol), 
cyclopentanone (149 µL, 1.69 mmol) and NaHCO3 (142 mg, 1.69 mmol). The residue was 
purified by column chromatography (triethylamine deadened silica, 5% MeOH/CH2Cl2) to give 
the title compound as a mixture of diastereomers (32.4 mg, 0.144 mmol, 43% yield, 5:1 dr) as 
a pink oil. Data presented is for the major diastereomer. 1H NMR (400 MHz, CDCl3): δ 3.69 
(3H, s, OCH3), 3.24 (1H, d, J = 1.0 Hz, H-3), 3.06 (1H, dqd, J = 10.5, 6.5, 3.5 Hz, H-6), 2.43 (1H, 
dd, J = 13.5, 10.5 Hz, H-5), 2.31 (1H, ddd, J = 13.5, 3.5, 1.0 Hz, H-5), 1.82-1.50 (7H, m, 
cyclopentyl), 1.36 (1H, m, cyclopentyl), 1.24 (3H, d, J = 6.5 Hz) ppm; 13C NMR (101 MHz, CDCl3): 
δ 205.3 (C=O), 169.9 (C=O), 69.2 (C), 66.1 (CH), 52.3 (CH3), 49.6 (CH), 47.6 (CH2), 39.2 (CH2) 
36.1 (CH2), 24.3 (CH2), 23.7 (CH2), 22.3 (CH3) ppm; HRMS (ESI) 226.1440 (M + H+. C12H20NO3 
requires 226.1438); IR (ATR): νmax 2957, 1704 (C=O), 1435, 1329, 1268, 1192, 1158 cm-1. 
 
 
Methyl 6-methyl-4-oxo-1-aza-spiro[3.5]nonane-3-carboxylate (137a) 
Following general procedure C with the hydrochloride salt of 126a (72.4 mg, 0.371 mmol), 
cyclobutanone (139 µL, 1.86 mmol) and NaHCO3 (156 mg, 1.86 mmol). The residue was 
purified by column chromatography (triethylamine deadened silica, 5% MeOH/CH2Cl2) to give 
the title compound as a mixture of diastereomers (52.6 mg, 0.249 mmol, 67% yield, 2.5:1 dr) 
as a yellow oil. Data presented is for the major diastereomer. 1H NMR (400 MHz, CDCl3): δ 
3.70 (3H, s, OCH3), 3.55 (1H, d, J = 1 Hz, H-3), 2.98 (1H, dqd, J = 10.5, 6.5, 4.0 Hz, H-6), 2.34 
(1H, dd, J = 13.5, 10.5 Hz, H-5), 2.27 (1H, ddd, J = 13.5, 4.0, 1.0 Hz, H-5), 2.01-1.75 (6H, m, 
cyclobutyl), 1.23 (3H, d, J = 6.5 Hz, CH3) ppm; 13C NMR (101 MHz, CDCl3): δ 204.4 (C=O), 169.1 
(C=O), 65.4 (CH), 63.0 (C), 52.3 (CH3), 48.4 (CH), 48.1 (CH), 32.4 (CH2), 31.6 (CH2), 22.5 (CH3), 
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14.4 (CH2) ppm; HRMS (ESI) 212.1275 (M + H+. C11H18NO3 requires 212.1281); IR (ATR): νmax 
2956, 1705 (C=O), 1434, 1329, 1193, 1166 cm-1. 
 
 
Methyl 6-(4-cyano-phenyl)-4-oxo-1-aza-spiro[3.5]nonane-3-carboxylate (137b) 
Following general procedure C with the hydrochloride salt of 126j (102 mg, 0.362 mmol), 
cyclobutanone (133 μL, 1.81 mmol) and NaHCO3 (152 mg, 1.81 mmol). The residue was 
purified by column chromatography (33% EtOAc/hexane) to give the title compound as a 
mixture of diastereomers (67.5 mg, 0.224 mmol, 63% yield, 1:1 dr) as a yellow oil. Data 
presented is for the major diastereomer. 1H NMR (400 MHz, CDCl3): δ 7.69-7.64 (2H, m, H-8), 
7.57-7.50 (2H, m, H-7), 4.04 (1H, dd, J = 11.5, 3.5 Hz, H-6), 3.76 (3H, s, OCH3), 3.65 (1H, d, J = 
1.0 Hz, H-3), 2.86 (1H, dd, J = 13.5, 11.5 Hz, H-5), 2.52 (1H, ddd, J = 13.5, 3.5, 1.0 Hz, H-5), 2.29-
2.20 (1H, m, H-9), 2.15-2.05 (1H, m, H-9), 2.04-1.86 (4H, m, H-9 and H-10) ppm; 13C-NMR 
(101 MHz, CDCl3): δ 202.9 (C=O), 169.0 (C=O), 147.1 (C), 132.8 (CH), 127.5 (CH), 118.7 (CN), 
111.8 (C), 65.1 (CH), 63.0 (C), 56.0 (CH), 52.5 (CH3), 46.8 (CH2), 32.6 (CH2), 31.7 (CH2), 14.2 
(CH2) ppm; HRMS (ESI) 299.1383 (M + H+. C17H19N2O3 requires 299.1390); IR (ATR): νmax 3313, 
2952, 2227 (CN), 1707 (C=O), 1607, 1435, 1290, 1197, 1165 cm-1. 
 
 
Methyl 6-methyl-4-oxo-9-oxa-1-aza-spiro[5.5]undecane-3-carboxylate (138a) 
Following general procedure C with the hydrochloride salt of 126a (280 mg, 1.44 mmol), 
tetrahydro-4H-pyran-4-one (664 µL, 7.20 mmol) and NaHCO3 (605 mg, 7.20 mmol). The 
residue was purified by column chromatography (8-50% EtOAc/CH2Cl2) to give the title 
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compound as a mixture of diastereomers (233 mg, 0.967 mmol, 67% yield, 4.5:1 dr) as a 
colourless oil. Data presented is for the major diastereomer. 1H NMR (400 MHz, CDCl3): δ 3.88 
(1H, ddd, J = 11.5, 10.0, 3.0 Hz, H-9), 3.72 (1H, ddd, J = 11.5, 10.0, 3.0 Hz, H-9), 3.67 (3H, s, 
OCH3), 3.63 (1H, ddd, J = 11.5, 11.5, 4.0 Hz, H-9), 3.56 (1H, ddd, J = 11.5, 11.5, 4.0 Hz, H-9), 
3.26 (1H, d, J = 1.0 Hz, H-3), 3.06 (1H, dqd, J = 10.5, 6.0 Hz, 3.7 Hz, H-6), 2.48 (1H, dd, J = 13.5, 
10.5 Hz, H-5), 2.30 (1H, ddd, J = 13.5, 3.5, 1.0 Hz, H-5), 1.67-1.54 (2H, m, H-8), 1.48-1.36 (2H, 
m, H-8), 1.25 (3H, d, J = 6.0 Hz, H-7) ppm; 13C NMR (101 MHz, CDCl3): δ 205.0 (C=O), 168.9 
(C=O), 66.8 (CH), 63.3 (CH2), 62.8 (CH2), 58.2 (C), 52.3 (CH3), 47.5 (CH2), 46.9 (CH), 36.5 (CH2), 
33.6 (CH2), 22.8 (CH3) ppm; HRMS (ESI) 242.1386 (M + H+. C12H20NO4 requires 242.1387); IR 
(ATR): νmax 2956, 2867, 1703 (C=O), 1435, 1333, 1162 cm-1. 
 
 
Methyl 6-(4-fluorophenyl)-4-oxo-9-oxa-1-aza-spiro[5.5]undecane-3-carboxylate (138b) 
Following general procedure C with the hydrochloride salt of 126e (129 mg, 0.468 mmol), 
tetrahydro-4H-pyran-4-one (216 µL, 2.34 mmol) and NaHCO3 (196 mg, 2.34 mmol). The 
residue was purified by column chromatography (triethylamine deadened silica, 20% 
EtOAc/CH2Cl2) to give the title compound as a mixture of diastereomers (84.5 mg, 0.263 
mmol, 56% yield, 2:1 dr) as a white solid. Data presented is for the major diastereomer. Mp 
110.5-113 oC; 1H NMR (400 MHz, CDCl3): δ 7.46-7.38 (2H, m, H-7), 7.13-7.04 (2H, m, H-8), 4.09 
(1H, dd, J = 11.5, 3.5 Hz, H-6), 3.90 (1H, td, J = 11.5, 3.0 Hz, H-10), 3.81 (1H, td, J = 11.5, 3.0 
Hz, H-10), 3.74 (3H, s, OCH3), 3.72-3.64 (2H, m, H-10), 3.41 (1H, d, J = 1.0 Hz), 3.06 (1H, dd, J = 
13.5, 11.5 Hz, H-5), 2.57 (1H, ddd, 13.5, 3.5, 1.0 Hz, H-5), 2.15 (1H, br. s, NH), 1.81-1.68 (2H, 
m, H-9), 1.63-1.54 (1H, m, H-9), 1.53-1.45 (1H, m, H-9) ppm; 13C NMR (101 MHz, CDCl3): δ 
204.2 (C=O), 169.0 (C=O), 162.1 (d, JF = 245 Hz, CF), 138.8 (d, JF = 3.0 Hz, C), 128.3 (d, JF = 14.0 
Hz, CH), 115.8 (d, JF = 21.5 Hz, CH), 67.0 (CH), 63.4 (CH2), 62.8 (CH2), 58.3 (C), 54.9 (CH), 52.5 
(CH3), 46.1 (CH2), 36.7 (CH2), 33.4 (CH2) ppm; 19F NMR (376 MHz, CDCl3): δ -114.0 ppm; HRMS 
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(ESI) 322.1445 (M + H+. C17H21FNO4 requires 322.1449), 344.1269 (M + Na+. C17H21FNO4 
requires 344.1269); IR (ATR): νmax 2963, 2868, 1706 (C=O), 1603, 1511, 1223, 1160 cm-1. 
 
 
Methyl 6-(4-methoxyphenyl)-4-oxo-9-oxa-1-azaspiro[5.5]undecane-3-carboxylate (138c) 
Following general procedure C with the hydrochloride salt of 126f (757 mg, 2.63 mmol), 
tetrahydro-4H-pyran-4-one (1.22 mL, 13.2 mmol) and NaHCO3 (1.11 g, 13.2 mmol). The 
residue was purified by column chromatography (0-80% EtOAc/cyclohexane) to afford the 
title compound as a mixture of diastereomers (290 mg, 0.870 mmol, 33% yield, 2:1 dr) as a 
red oil that solidified on standing. Data presented is for the major diastereomer. Mp 118-121 
oC; 1H NMR (400 MHz, CDCl3): δ 7.43-7.36 (2H, m, H-7), 6.98-6.92 (2H, m, H-8), 4.08 (1H, dd, J 
= 11.0, 3.5 Hz, H-6), 4.03-3.64 (4H, m, H-11), 3.84 (3H, s, H-9), 3.76 (3H, s, OCH3), 3.42 (1H, d, 
J = 1.0 Hz, H-3), 3.10 (1H, dd, J = 13.5, 11.0 Hz, H-5), 2.57 (1H, ddd, J = 13.5, 3.5, 1.0 Hz, H-5), 
2.15 (1H, br. s, NH), 1.85-1.70 (2H, m, H-10), 1.65-1.44 (2H, m, H-10) ppm; 13C-NMR (101 MHz, 
CDCl3): δ 204.4 (C=O), 168.9 (C=O), 159.2 (C), 134.1 (C), 127.7 (CH), 114.2 (CH), 67.0 (CH), 63.3 
(CH2), 62.7 (CH2), 58.2 (C), 55.3 (CH3), 54.9 (CH), 52.3 (CH3), 46.2 (CH2), 36.6 (CH2), 33.3 (CH2); 
HRMS (ESI) 334.1637 (M + H+. C18H24NO5 requires 334.1649); IR (ATR): νmax 3318, 2965, 2947, 
2865, 1732 (C=O), 1701 (C=O), 1515, 1297, 1243,1159, 1024 cm-1.  
 
 
Methyl 4-oxo-6-pyridin-3-yl-9-oxa-1-aza-spiro[5.5]undecane-3-carboxylate (138d) 
Following general procedure C with the hydrochloride salt of 126g (1.50 g, 5.81 mmol), 
tetrahydro-4H-pyran-4-one (2.68 mL, 29.1 mmol) and NaHCO3 (2.44 g, 29.1 mmol). The 
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residue was purified by column chromatography (50% EtOAc/CH2Cl2 then 100% EtOAc) to give 
the title compound as a mixture of diastereomers (1.40 g, 4.61 mmol, 79% yield, 1.5:1 dr) as 
a yellow oil. Data presented is for the major diastereomer. 1H NMR (400 MHz, CDCl3): δ 8.66 
(1H, d, J = 2.0 Hz, H-10), 8.55 (1H, dd, J = 5.0, 2.0 Hz, H-9), 7.79 (1H, ddd, J = 8.0, 2.0, 2.0 Hz, 
H-7), 7.31 (1H, dd, J = 8.0, 5.0 Hz, H-8), 4.14 (1H, dd, J = 11.5, 3.5 Hz, H-6), 3.87 (1H, ddd, J = 
11.5, 11.5, 2.5 Hz, H-12), 3.78 (1H, ddd, J = 11.5, 11.5, 2.5 Hz, H-12), 3.71 (3H, s, OCH3), 3.70-
3.60 (2H, m, H-12), 3.38 (1H, br. s, H-3), 3.06 (1H, dd, J = 13.5, 11.5 Hz, H-5), 2.58 (1H, dd, J = 
13.5, 3.5 Hz, H-5) ppm; 13C NMR (101 MHz, CDCl3): δ 203.5 (C=O), 168.9 (C=O), 149.4 (CH), 
148.7 (CH), 137.2 (C), 134.0 (CH), 123.8 (CH), 67.0 (CH), 63.3 (CH2), 62.7 (CH2), 58.3 (C), 53.1 
(CH3), 52.5 (CH), 45.3 (CH2), 36.5 (CH2), 33.2 (CH2) ppm; HRMS (ESI) 305.1486 (M + H+. 
C16H21N2O4 requires 305.1496); IR (ATR): νmax 2952, 2872, 1706 (C=O), 1428, 1337, 1195, 1166 
cm-1. 
 
 
Methyl 6-(4-methyl-thiazol-5-yl)-4-oxo-9-oxa-1-aza-spiro[5.5]undecane-3-carboxylate 
(138e) 
Following general procedure C with the hydrochloride salt of 126h (99 mg, 0.356 mmol), 
tetrahydro-4H-pyran-4-one (164 µL, 1.78 mmol) and NaHCO3 (150 mg, 1.78 mmol). The 
residue was purified by column chromatography (50% EtOAc/CH2Cl2 then 100% EtOAc) to give 
the title compound as a mixture of diastereomers (86 mg, 0.265 mmol, 75% yield, 1:1 dr) as 
a white solid. Data presented is for the major diastereomer. Mp 98-101 oC; 1H NMR (400 MHz, 
CDCl3): δ 8.67 (1H, s, H-7), 4.41 (1H, dd, J = 11.0, 3.5 Hz, H-6), 3.90-3.76 (2H, m, H-10), 3.73 
(3H, s, OCH3), 3.71-3.64 (2H, m, H-10), 3.38 (1H, br. s, H-3), 3.05 (1H, dd, J = 13.5, 11.0 Hz, H-
5), 2.63 (1H, ddd, J = 13.5, 3.5, 1.0 Hz, H-5), 2.47 (3H, s, H-8), 1.80-1.54 (3H, m, H-9), 1.51-1.41 
(1H, m, H-9) ppm; 13C NMR (101 MHz, CDCl3): δ 202.5 (C=O), 168.7 (C=O), 150.2 (CH), 149.9 
(C), 133.0 (C), 66.8 (CH), 63.3 (CH2), 62.7 (CH2), 58.1 (C), 52.6 (CH3), 48.8 (CH), 47.1 (CH2), 36.5 
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(CH2), 33.4 (CH2), 16.6 (CH3) ppm; HRMS (ESI) 325.1201 (M + H+. C15H21N2O4S requires 
325.1217); IR (ATR): νmax 2953, 2865, 1706 (C=O), 1435, 1338, 1255, 1196, 1165 cm-1. 
 
 
Methyl 6-(1-methyl-1H-pyrazol-4-yl)-4-oxo-9-oxa-1-azaspiro[5.5]undecane-3-carboxylate 
(138f) 
Following general procedure C with the hydrochloride salt of 126i (203 mg, 0.776 mmol), 
tetrahydro-4H-pyran-4-one (358 µL, 3.88 mmol) and NaHCO3 (326 mg, 3.88 mmol). The 
residue was purified by column chromatography (0-50% EtOH/EtOAc) to give the title 
compound as a mixture of diastereomers (119 mg, 0.387 mmol, 50% yield, 2.5:1 dr) as a 
yellow oil. Data presented is for the major diastereomer. 1H NMR (400 MHz, CDCl3): δ 7.52 
(1H, s, H-7), 7.40 (1H, s, H-8), 4.13 (1H, dd, J = 11.0, 3.5 Hz, H-6), 4.00-3.63 (4H, m, H-11), 3.91 
(3H, s, H-9), 3.72 (3H, s, OCH3),  3.38 (1H, d, J = 1.0 Hz, H-3), 2.97 (1H, dd, J = 13.5, 11.0 Hz, H-
5), 2.63 (1H, ddd, J = 13.5, 3.5, 1.0 Hz, H-5), 1.80-1.67 (2H, m, H-10), 1.61-1.44 (2H, m, H-10) 
ppm; 13C-NMR (101 MHz, CDCl3): δ 203.7 (C=O), 168.7 (C=O), 137.1 (CH), 127.6 (CH), 123.8 
(C), 67.1 (CH), 63.2 (CH2), 62.7 (CH2), 58.0 (C), 52.3 (CH3), 47.4 (CH), 46.1 (CH2), 39.0 (CH3), 
36.5 (CH2), 33.3 (CH2) ppm; HRMS (ESI) 308.1594 (M + H+. C15H22N3O4 requires 308.1605); IR 
(ATR): νmax 3282, 3248, 1704 (C=O), 1562, 1435, 1296, 1218, 1159 cm-1. 
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Methyl 6-(4-fluoro-phenyl)-4-oxo-9-thia-1-aza-spiro[5.5]undecane-3-carboxylate (139a) 
Following general procedure C with the hydrochloride salt of 126e (189 mg, 0.686 mmol), 
tetrahydro-4H-thiopyran-4-one (398 mg, 3.43 mmol) and NaHCO3 (288 mg, 3.43 mmol). The 
residue was purified by column chromatography (triethylamine deadened silica, 10-20% ethyl 
acetate/hexane) to give the title compound as a mixture of diastereomers (171 mg, 0.432 
mmol, 63% yield, 1:1 dr) as a yellow oil. Data presented is for the major diastereomer. 1H NMR 
(400 MHz, CDCl3): δ 7.45-7.39 (2H, m, H-7), 7.11-7.04 (2H, m, H-8), 4.04 (1H, dd, J = 11.0, 4.0 
Hz, H-6), 3.73 (3H, s, OCH3), 3.33 (1H, br s, H-3), 3.22-3.12 (1H, m, H-10), 3.04 (1H, dd, J = 13.5, 
11.0 Hz, H-5), 3.06-2.93 (1H, m, H-10), 2.56 (1H, ddd, J = 13.5, 4.0, 0.5 Hz, H-5), 2.41-2.32 (2H, 
m, H-10), 2.12-1.93 (2H, m, H-9 and NH), 1.84-1.77 (2H, m, H-9), 1.70 (1H, ddd, J = 14.5, 11.5, 
14.5 Hz, H-9) ppm; 13C NMR (101 MHz, CDCl3): δ 204.3 (C=O), 169.0 (C=O), 162.4 (d, JF = 247.5 
Hz, CF), 137.8 (d, JF = 3.5 Hz, C), 128.3 (d, JF = 8.0 Hz, CH), 115.8 (d, JF = 21.5 Hz, CH), 67.4 (CH), 
59.3 (C), 54.4 (CH), 52.5 (CH3), 45.7 (CH2), 37.3 (CH2), 34.3 (CH2), 23.4 (CH2), 22.8 (CH2) ppm; 
19F NMR (376 MHz, CDCl3): δ -114.3 ppm; HRMS (ESI) 338.1205 (M + H+. C17H21FNO3S requires 
338.1221); IR (ATR): νmax 2962, 2922, 1705 (C=O), 1510, 1226, 1196, 1161 cm-1. 
 
 
Methyl 4-oxo-6-pyridin-3-yl-9-thia-1-aza-spiro[5.5]undecane-3-carboxylate (139b) 
Following general procedure C with the hydrochloride salt of 126g (104 mg, 0.402 mmol), 
tetrahydro-4H-thiopyran-4-one (233 mg, 2.01 mmol) and NaHCO3 (169 mg, 2.01 mmol). The 
residue was purified by column chromatography (50% ethyl acetate/hexane then 100% 
EtOAc) to give the title compound as a mixture of diastereomers (77.5 mg, 0.302 mmol, 75% 
yield, 0.95:1 dr) as a yellow oil. Data presented is for the major diastereomer. 1H NMR (400 
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MHz, CDCl3): δ 8.68-8.64 (1H, m, H-10), 8.56 (1H, dd, J = 5.0, 1.5 Hz, H-9), 7.79 (1H, ddd, 8.0, 
2.0, 2.0 Hz, H-7), 7.35-7.28 (1H, m, H-8), 4.10 (1H, br s, H-6), 3.71 (3H, s, OCH3), 3.33 (1H, d, 
1.0 Hz, H-3), 3.20-3.09 (1H, m, H-12), 3.05 (1H, dd, 13.5, 11.5 Hz, H-5), 3.06-2.90 (1H, m, H-
12), 2.58 (1H, ddd, 13.5, 4.0, 1.0 Hz, H-5), 2.40-2.28 (2H, m, H-12), 2.12-2.05 (1H, m, H-11), 
1.82-1.77 (2H, m, H-11), 1.70 (1H, ddd, J = 14.5, 11.5, 3.0, H-11) ppm; 13C NMR (101 MHz, 
CDCl3): δ 203.6 (C=O), 168.9 (C=O), 149.5 (CH), 148.7 (CH), 137.1 (C), 134.0 (CH), 123.8 (CH), 
67.4 (CH), 59.3 (C), 52.7 (CH), 52.5 (CH3), 44.9 (CH2), 37.2 (CH2), 34.2 (CH2), 23.3 (CH2), 22.7 
(CH2) ppm; HRMS (ESI) 321.1260 (M + H+. C16H21N2O3S requires 321.1267); IR (ATR): νmax 3310, 
2952, 2920, 1703 (C=O), 1424, 1268, 1195, 1162 cm-1. 
 
 
4-Oxo-6-pyridin-3-yl-1,9-diaza-spiro[5.5]undecane-3,9-dicarboxylic acid 9-benzyl ester 3-
methyl ester (140) 
Following general procedure C with the hydrochloride salt of 126g (145 mg, 0.562 mmol), 1-
Z-4-piperidone (655 mg, 2.81 mmol) and NaHCO3 (236 mg, 2.81 mmol). The residue was 
purified by column chromatography (50% EtOAc/CH2Cl2 then 100% EtOAc) to give the title 
compound as a mixture of diastereomers (145 mg, 0.376 mmol, 67% yield, 2:1 dr) as a yellow 
oil. Data presented is for the major diastereomer. 1H NMR (400 MHz, CDCl3): δ 8.66 (1H, br. 
s, H-10), 8.56 (1H, dd, J = 5.0, 1.5 Hz, H-9), 7.78 (1H, ddd, J = 8.0, 1.5, 1.5 Hz, H-7), 7.37-7.26 
(6H, m, H-8 and ArH), 5.10 (2H, s, H-13), 4.20-4.06 (1H, m, H-6), 3.92-3.75 (2H, m, H-12), 3.71 
(3H, s, OCH3), 3.45-3.16 (2H, m, H-12), 3.30 (1H, d, J = 0.5 Hz, H-3), 3.07 (1H, dd, J = 13.5, 11.5 
Hz, H-5), 2.60 (1H, dd, J = 13.5, 3.0 Hz, H-5), 1.91-1.34 (4H, m, H-11) ppm; 13C NMR (101 MHz, 
CDCl3): δ 203.1 (C=O), 168.8 (C=O), 155.2 (C=O), 149.5 (CH), 148.6 (CH), 137.0 (C), 136.7 (C), 
133.9 (CH), 128.6 (CH), 128.1 (CH), 127.9 (CH), 123.8 (CH), 67.2 (CH2), 66.8 (CH), 58.8 (C), 53.2 
(CH), 52.5 (CH3) 45.0 (CH2), 39.5 (CH2), 39.0 (CH2), 35.5 (CH2), 32.3 (CH2) ppm; HRMS (ESI) 
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438.2032 (M + H+. C24H28N3O5 requires 438.2023); IR (ATR): νmax 2951, 1694 (C=O), 1427, 1246, 
1164 cm-1. 
 
 
Methyl 6-(4-cyano-phenyl)-4-oxo-8-oxa-1-aza-spiro[3.5]nonane-3-carboxylate (141) 
Following general procedure C with the hydrochloride salt of 126j (93 mg, 0.330 mmol), 3-
oxetanone (97 μL, 1.65 mmol) and NaHCO3 (139 mg, 1.69 mmol). The residue was purified by 
column chromatography (60% EtOAc/hexane) to give the title compound as a mixture of 
diastereomers (42.8 mg, 0.142 mmol, 43% yield, 1.6:1 dr) as a yellow oil. Data presented is 
for the major diastereomer. 1H NMR (400 MHz, CDCl3): δ 7.70-7.66 (2H, m, H-8), 7.57-7.51 
(2H, m, H-7), 4.92 (1H, d, J = 7.5 Hz, H-9), 4.61 (1H, d, J = 7.5 Hz, H-9), 4.56 (1H, d, J = 6.5 Hz, 
H-9), 4.50 (1H, d, J = 6.5 Hz, H-9), 4.02 (1H, dd, J = 11.5, 3.5 Hz, H-6), 3.93 (1H, d, J = 1.5 Hz, H-
3), 3.79 (3H, s, OCH3), 2.72 (1H, dd, J = 13.5, 11.5 Hz, H-5), 2.56 (1H, ddd, J = 13.5, 3.5, 1.5 Hz, 
H-5) ppm; 13C-NMR (101 MHz, CDCl3): δ 200.9 (C=O), 167.9 (C=O), 146.3 (C), 132.9 (CH), 127.5 
(CH), 118.6 (CN), 112.3 (C), 80.9 (CH2), 80.1 (CH2), 62.9 (CH), 62.4 (C), 56.1 (CH), 53.0 (CH3), 
47.5 (CH2) ppm; HRMS (ESI) 301.1179 (M + H+. C16H17N2O4 requires 301.1183); IR (ATR): νmax 
3302, 2874, 2228 (CN), 1717 (C=O), 1608, 1441, 1345, 1297 1225 cm-1. 
 
 
Ethyl 2,2-dimethyl-4-oxo-piperidine-3-carboxylate (145) 
Following general procedure C with the hydrochloride salt of 144 (101 mg, 0.513 mmol), 
acetone (192 μL, 2.59 mmol) and NaHCO3 (218 mg, 2.59 mmol) to give the title compound 
(85 mg, 0.425 mmol, 83% yield) as a colourless oil without further purification. 1H NMR (400 
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MHz, CDCl3): δ 4.21-4.10 (2H, m, H-8), 3.32 (1H, ddd, J = 14.0, 7.5, 2.8 Hz, H-6), 3.27 (1H, d, J 
= 1.0 Hz, H-3), 3.10 (1H, ddd, J = 14.0, 10.0, 4.5 Hz, H-6), 2.76 (1H, ddd, J = 14.0, 10.0, 7.5 Hz, 
H-5), 2.25 (1H, dddd, J = 14.0, 4.5, 2.8, 1.0 Hz, H-5), 1.26 (3H, t, J = 7.5 Hz, H-9), 1.20 (3H, s, H-
7), 1.11 (3H, s, H-7) ppm; 13C NMR (101 MHz, CDCl3): δ 205.3 (C=O), 169.1 (C=O), 68.3 (CH), 
61.3 (CH2), 58.3 (C), 41.9 (CH2), 39.8 (CH2), 27.1 (CH3), 26.1 (CH3), 14.3 (CH3) ppm; HRMS (ESI) 
200.1288 (M + H+. C10H18NO3 requires 200.1281); IR (ATR): νmax 3299, 2974, 2935, 1703 (C=O), 
1652 (C=O), 1600, 1238, 1164, 1144, 1127 cm-1. 
 
 
Ethyl 4-oxo-1-aza-spiro[3.5]nonane-3-carboxylate (146) 
Following general procedure C with the hydrochloride salt of 144 (100 mg, 0.513 mmol), 
cyclobutanone (192 μL, 2.57 mmol) and NaHCO3 (215 mg, 2.57 mmol). The residue was 
purified by column chromatography (100% EtOAc) to give the title compound (53 mg, 0.251 
mmol, 49% yield) as a colourless oil. 1H NMR (400 MHz, CDCl3): δ 4.21-4.07 (2H, m, H-9), 3.54 
(1H, d, J = 1.5 Hz, H-3), 3.26 (1H, ddd, J = 13.5, 7.2, 2.0 Hz, H-6), 2.89 (1H, ddd, J = 13.5, 11.8, 
3.5 Hz, H-6), 2.63 (1H, ddd, J = 13.5, 11.8, 7.2 Hz, H-5), 2.35 (1H, br. s, NH), 2.20 (1H, dddd, J = 
13.5, 3.5, 2.0, 1.5 Hz, H-5), 2.13-1.74 (6H, m, H-7 and H-8) ppm; 13C NMR (101 MHz, CDCl3): δ 
204.1 (C=O), 168.5 (C=O), 67.0 (CH), 63.8 (C), 61.4 (CH2), 41.8 (CH2), 40.7 (CH2), 32.1 (CH2), 
30.9 (CH2), 14.5 (CH2), 14.3 (CH3) ppm; HRMS (ESI) 212.1284 (M + H+. C11H18NO3 requires 
212.1281); IR (ATR): νmax 3326, 2978, 2937, 2874, 1701 (C=O), 1453, 1294, 1174, 1095 cm-1. 
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Methyl 4-oxo-6-pyridin-3-yl-1,9-diaza-spiro[5.5]undecane-3-carboxylate (142) 
A mixture of 2-spiropiperidine 140 (71 mg, 0.162 mmol) and 10% Pd/C (7 mg, 6.86 μmol) in 
MeOH (3 mL) was evacuated and subjected to a balloon of H2. The reaction was stirred for 5h 
before the addition of extra 10% Pd/C (4 mg, 3.92 μmol). The reaction was stirred overnight 
at rt, then filtered through Celite. The volatiles were removed in vacuo to give the title 
compound (44.2 mg, 0.146 mmol, 90% yield) as a yellow oil. Data presented is for the major 
diastereomer. 1H NMR (400 MHz, CDCl3): δ 8.69 (1H, d, J = 1.8 Hz, H-10), 8.58 (1H, dd, J = 4.6, 
1.8 Hz, H-9), 7.82 (1H, ddd, J = 7.8, 1.8, 1.8 Hz, H-7), 7.34 (1H, dd, J = 7.8, 4.6 Hz, H-8), 4.19 
(1H dd, J = 11.0, 3.8 Hz, H-6), 3.74 (3H, s, OCH3), 3.42 (1H, br. s, H-3), 3.14-3.05 (1H, m, H-12), 
3.09 (1H, dd, J = 13.5, 11.0, H-5), 3.04-2.97 (1H, m, H-12), 2.88-2.77 (2H, m, H-12), 2.60 (1H, 
ddd, J = 13.5, 3.8, 1.0 Hz, H-5), 2.15 (1H, d, J = 11.9 Hz, NH), 1.84-1.75 (1H, m, H-9), 1.69-1.58 
(1H, m, H-9), 1.56-1.46 (2H, m, H-9) ppm;  13C NMR (101 MHz, CDCl3): δ 203.2 (C=O), 168.9 
(C=O), 149.6 (CH), 148.6 (CH), 137.0 (C), 134.1 (CH), 123.9 (CH), 66.8 (CH), 58.5 (C), 53.1 (CH), 
52.6 (CH3), 45.2 (CH2), 40.9 (CH2), 40.4 (CH2), 35.2 (CH2), 31.8 (CH2) ppm; HRMS (ESI) 304.1653 
(M + H+. C16H22N3O3 requires 304.1656). 
 
General Procedure D – Decarboxylation of the 2-spiropiperidines 
Water (3.5 mL) was added to a suspension of 2-spiropiperidine (0.358 mmol) and LiOH (3.58 
mmol) in THF (3.5 mL). The reaction was stirred for 16 hours at room temperature. The 
mixture was diluted with EtOAc (20 mL) and layers were separated. The aqueous was 
extracted with EtOAc (5 x 10 mL). Organics were combined, concentrated in vacuo and 
purified by column chromatography. 
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6-(4-Fluoro-phenyl)-9-oxa-1-aza-spiro[5.5]undecan-4-one (147b) 
Following general procedure D with 2-spiropiperidine 138b (115 mg, 0.358 mmol) and LiOH 
(86 mg, 3.58 mmol) gave the title compound (59.7 mg, 0.229 mmol, 64% yield) as a yellow oil. 
1H NMR (400 MHz, CDCl3): δ 7.43-7.37 (2H, m, H-7), 7.08-7.04 (2H, m, H-8), 4.18 (1H, dd, J = 
11.5, 3.5 Hz, H-6), 3.86-3.72 (2H, m, H-10), 3.70-3.59 (2H, m, H-10), 2.58 (1H, dd, J = 13.5, 1.75 
Hz, H-3), 2.53 (1H, ddd, J = 13.5, 3.5, 1.75 Hz, H-5), 2.44 (1H, dd, J = 13.5, 11.5 Hz, H-5), 2.35 
(1H, J = 13.5 Hz, H-3), 1.83-1.71 (2H, m, H-9), 1.70-1.57 (3H, m, H-9 and N-H) ppm; 13C NMR 
(101 MHz, CDCl3): δ 208.6 (C=O), 169.0 (C=O), 162.1 (d, JF = 247 Hz, CF), 138.4 (d, JF = 3.0 Hz, 
C), 128.3 (d, JF = 8.5 Hz, CH), 115.8 (d, JF = 21.5 Hz, CH), 63.9 (CH2), 63.6 (CH2), 54.0 (CH), 53.7 
(C), 51.8 (CH2), 50.2 (CH2), 40.4 (CH2), 33.9 (CH2) ppm; 19F NMR (376 MHz, CDCl3): δ -114.2 
ppm; HRMS (ESI) 264.1394 (M + H+. C15H19FNO2 requires 264.1394); IR (ATR): νmax 2935, 2857, 
1707 (C=O), 1509, 1221, 1101 cm-1. 
 
 
6-(4-Fluorophenyl)-9-thia-1-aza-spiro[5.5]undecan-4-one (147c) 
Following general procedure D with spirocycle 139a (49 mg, 0.145 mmol) and LiOH (35 mg, 
1.45 mmol) gave the title compound (28.2 mg, 0.101 mmol, 70% yield) as a colourless oil after 
column chromatography (20 % ethyl acetate/hexane). 1H NMR (400 MHz, CDCl3): δ 7.43-7.36 
(2H, m, H-7), 7.10-7.01 (2H, m, H-8), 4.13 (1H, dd, J = 11.5, 3.5 Hz, H-6), 2.90 (1H, ddd, J = 14.0, 
9.5, 4.5 Hz, H-10), 2.76 (1H, ddd, J = 13.5, 10.5, 3.0 Hz, H-10), 2.57-2.44 (3H, m, H-5 and H-10), 
2.41 (1H, dd, J = 13.5, 2.0 Hz, H-3), 2.41 (1H, dd, J = 13.5, 11.5 Hz, H-5), 2.27 (1H, d, J = 13.5 
Hz, H-3), 2.05-1.86 (3H, m, H-9), 1.82 (1H, ddd, J = 13.5, 10.5, 3.0 Hz, H-9) ppm; 13C NMR 
(101 MHz, CDCl3): δ 208.6 (C=O), 162.4 (d, JF = 248.0 Hz, CF), 138.3 (d, JF = 3.0 Hz, C), 128.3 (d, 
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JF = 8.0 Hz, CH), 115.7 (d, JF = 21.5 Hz, CH), 54.6 (C), 53.8 (CH2), 53.5 (CH2), 50.0 (CH2), 41.1 
(CH2), 33.8 (CH2), 23.6 (CH2), 23.6 (CH2) ppm; 19F NMR (376 MHz, CDCl3): δ -114.2 ppm; HRMS 
(ESI) 280.1170 (M + H+. C15H19FNOS requires 280.1166); IR (ATR): νmax 3302, 2924, 2847, 1707 
(C=O), 1509, 1274, 1221 cm-1. 
 
 
4-(8-Oxo-5-aza-spiro[3.5]non-6-yl)-benzonitrile (147d) 
Following general procedure D with spirocycle 137b (56 mg, 0.188 mmol) and LiOH (45 mg, 
1.88 mmol) gave the title compound (30.2 mg, 0.126 mmol, 67% yield) as a colourless oil after 
column chromatography (60% ethyl acetate/hexane). 1H NMR (400 MHz, CDCl3): δ 7.65 (2H, 
d, J = 8.0 Hz, H-7), 7.53 (2H, d, J = 8.0 Hz, H-8), 4.04 (1H, dd, J = 9.0, 6.0 Hz, H-6), 2.69 (1H, d, J 
= 13.5 Hz, H-3), 2.51 (1H, d, J = 13.5 Hz, H-3), 2.45-2.35 (2H, m, H-5), 2.18-2.02 (3H, m, H-9), 
1.92-1.76 (4H, m, H-9 and H-10) ppm; 13C NMR (101 MHz, CDCl3): δ 207.6 (C=O), 147.9 (C), 
132.8 (CH), 127.5 (CH), 118.7 (CN), 111.9 (C), 59.8 (C), 56.2 (CH), 51.3 (CH2), 49.7 (CH2), 35.8 
(CH2), 33.7 (CH2), 13.0 (CH2) ppm; HRMS (ESI) 241.1336 (M + H+. C15H17N2O requires 
241.1335); IR (ATR): νmax 3310, 2960, 2929, 2227, 1710 (C=O), 1297 cm-1. 
 
 
6-(4-Methyl-thiazol-5-yl)-9-oxa-1-aza-spiro[5.5]undecane-4-one (147e) 
Following general procedure D with spirocycle 138e (160 mg, 0.494 mmol) and LiOH (119 mg, 
4.94 mmol) gave the title compound (52 mg, 0.198 mmol, 40% yield) as a colourless oil. 1H 
NMR (400 MHz, CDCl3): δ 8.65 (1H, s, H-7), 4.53 (1H, dd, J = 11.2, 3.5 Hz, H-6), 3.83-3.71 (2H, 
m, H-10), 3.68-3.57 (2H, m, H-10), 2.63-2.51 (2H, m, H-3 and H-5), 2.47-2.33 (2H, m, H-3 and 
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H-5), 2.41 (3H, s, H-8), 1.81-1.71 (2H, m, H-9), 1.69-1.58 (2H, m, H-9) ppm; 13C NMR (101 MHz, 
CDCl3): δ 207.1 (C=O), 151.1 (CH), 148.7 (C), 134.2 (C), 63.9 (CH2), 63.6 (CH2), 53.7 (C), 51.2 
(CH2), 50.4 (CH2), 47.9 (CH), 40.1 (CH2), 34.1 (CH2), 15.5 (CH3) ppm; HRMS (ESI) 280.1170 (M + 
H+. C15H19FNOS requires 280.1166); IR (ATR): νmax 2924, 2854, 1709 (C=O), 1414, 1357, 1238, 
1101 cm-1. 
 
General Procedure E – Ketone reduction of the 2-spiropiperidines  
Sodium borohydride (2.74 mmol) was added portionwise to a solution of 2-spiropiperidine 
(2.28 mmol) in methanol (11 mL) at 0 °C. The reaction was stirred at room temperature for 
1h then quenched with acetone (11.4 mmol). Volatiles were removed in vacuo, and the 
residue was purified by column chromatography to give the 4-hydroxy-2-spiropiperidine. 
 
 
Methyl 4-hydroxy-6-methyl-9-oxa-1-aza-spiro[5.5]undecane-3-carboxylate (148a) 
Following general procedure E with spirocycle 138a (48.2 mg, 0.200 mmol) and sodium 
borohydride (9.1 mg, 0.240 mmol). The residue was purified by column chromatography (50% 
EtOAc/CH2Cl2 followed by 50% EtOAc/MeOH) to give the title compound as a mixture of 
diastereomers (39.5 mg, 0.162 mmol, 81% yield) as a colourless oil. Data presented is for the 
major diastereomer. 1H NMR (400 MHz, CDCl3): δ 4.27 (1H, dd, J = 6.5, 3.0 Hz, H-4), 3.94-3.79 
(2H, m, H-9), 3.67 (3H, s, OCH3), 3.65-3.55 (2H, m, H-9), 3.13 (1H, dqd, J = 13.0, 6.5, 3.5 Hz, H-
6), 2.60 (1H, d, J = 2.0 Hz, H-3), 2.26 (1H, m, H-5), 1.85 (1H, ddd, J = 14.0, 10.0, 4.0 Hz, H-8), 
1.76 (1H, ddd, J = 14.5, 11.5, 3.5 Hz, H-5), 1.65-1.55 (2H, m, H-8), 1.32-1.22 (1H, m, H-8), 1.12 
(3H, d, H-7) ppm; 13C NMR (101 MHz, CDCl3): δ 173.0 (C=O), 68.1 (CH), 63.6 (CH2), 63.1 (CH2), 
53.2 (CH), 51.6 (CH3), 51.4 (C), 40.0 (CH), 37.9 (CH2), 37.8 (CH2), 36.0 (CH2), 22.9 (CH3) ppm; 
HRMS (ESI) 244.1546 (M + H+. C12H22NO4 requires 244.1543); IR (ATR): νmax 3407, 2952, 2866, 
1722 (C=O), 1434, 1199, 1147, 1103 cm-1. 
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Methyl 6-(4-fluorophenyl)-4-hydroxy-9-oxa-1-aza-spiro[5.5]undecane-3-carboxylate (148b) 
Following general procedure E with spirocycle 138b (107 mg, 0.333 mmol) and sodium 
borohydride (15.2 mg, 0.400 mmol). The residue was purified by column chromatography (60-
100% EtOAc/hexane) to give the title compound as a mixture of diastereomers (69 mg, 0.213 
mmol, 64% yield) as a yellow oil. Data presented is for the major diastereomer. 1H NMR (400 
MHz, CDCl3): 7.43-7.36 (2H, m, H-7), 7.03 (2H, dd, J = 3.0, 8.5 Hz, H-8), 4.38 (1H, dd, J = 6.0, 
3.0 Hz, H-4), 4.15 (1H, dd, J = 12.0, 3.0 Hz, H-6), 3.92-3.84 (2H, m, H-10), 3.69 (3H, s, OCH3), 
3.70-3.58 (2H, m, H-10), 2.66 (1H, d, J = 2.0 Hz, H-3), 2.45-2.36 (1H, m, H-5), 2.25 (1H, ddd, J = 
15.5, 12.0, 3.5 Hz, H-5), 1.93-1.80 (2H, m, H-9), 1.69 (1H, ddd, J = 15.0, 10.5, 4.5 Hz, H-9), 1.29-
1.21 (1H, m, H-9) ppm; 13C NMR (101 MHz, CDCl3): δ 172.9 (C=O), 162.0 (d, JF = 246 Hz, CF), 
140.0 (d, JF = 3.0 Hz, C), 128.4 (d, JF = 8.0 Hz, CH), 115.3 (d, JF = 21.0 Hz, CH), 67.9 (CH), 63.5 
(CH2), 63.0 (CH2), 53.6 (CH), 51.7 (CH3), 47.5 (CH), 37.8 (CH2), 35.9 (CH2), 35.8 (CH2) ppm; HRMS 
(ESI) 324.1614 (M + H+. C17H23FNO4 requires 324.1606); IR (ATR): νmax 3395, 2951, 2867, 1720 
(C=O), 1509, 1221, 1076 cm-1. 
 
 
Methyl 4-hydroxy-6-(4-methoxyphenyl)-9-oxa-1-azaspiro[5.5]undecane-3-carboxylate 
(148c) 
Following general procedure E with spirocycle 138c (102 mg, 0.306 mmol) and sodium 
borohydride (17.4 mg, 0.459 mmol). The residue was purified by column chromatography (0-
100% EtOAc/cyclohexane) to give the title compound as a mixture of diastereomers (58 mg, 
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0.173 mmol, 57% yield) as a yellow oil. Data presented is for the major diastereomer. 1H NMR 
(400 MHz, CDCl3): δ 7.39-7.33 (2H, m, H-7), 6.94-6.87 (2H, m, H-8), (1H, q, J  = 3.0 Hz, H-4), 
(1H, dd, J = 12.0, 3.0 Hz, H-6), 3.91 (2H, td, J = 11.0, 2.5 Hz, H-11), 3.82 (3H, s, H-9), 3.70 (3H, 
s, OCH3), 3.69-3.59 (2H, m, H-11), 2.67 (1H, d, J = 2.0 Hz, H-3), 2.46-2.37 (1H, m, H-10), 2.27 
(1H, ddd, J = 14.0, 12.0, 3.5 Hz, H-5), 1.94-1.86 (1H, m, H-10), 1.83 (1H, dt, J = 14.0, 3.0 Hz, H-
5), 1.31-1.23 (1H, m, H-10) ppm; 13C-NMR (101 MHz, CDCl3): δ 172.8 (C=O), 158.6 (C), 136.4 
(C), 127.7 (CH), 113.8 (CH), 67.8 (CH), 63.3 (CH2), 62.9 (CH2), 55.3 (CH3), 53.5 (CH), 51.5 (CH3), 
51.4 (C), 47.4 (CH), 37.7 (CH2), 35.8 (CH2), 35.7 (CH2) ppm. HRMS (ESI) 336.1789 (M + H+. 
C18H25NO5 requires 336.1806); IR (ATR): νmax 3341, 2966, 2867, 1720 (C=O), 1427, 1306, 1193, 
1161, 1139, 1101, 1079, 1026 cm-1. 
 
 
Methyl 4-hydroxy-6-pyridin-3-yl-9-oxa-1-aza-spiro[5.5]undecane-3-carboxylate (148d) 
Following general procedure E with spirocycle 138d (694 mg, 2.28 mmol) and sodium 
borohydride (104 mg, 2.74 mmol). The residue was purified by column chromatography (7.5-
10% methanol/ethyl acetate) to give the title compound as a mixture of diastereomers (538 
mg, 1.76 mmol, 77% yield) as a yellow oil. Data presented is for the major diastereomer. 1H 
NMR (400 MHz, CDCl3): 8.65 (1H, d, J = 2.0 Hz, H-10), 8.49 (1H, dd, J = 4.5, 1.0 Hz, H-9), 7.83-
7.78 (1H, m, H-7), 7.30 (1H, dd, J = 8.0, 4.5 Hz, H-8), 4.44-4.40 (1H, m, H-4), 4.27 (1H, dd, 12.0, 
3.0 Hz, H-6), 3.94-3.83 (2H, m, H-12), 3.69-3.60 (2H, m, H-12), 3.68 (3H, s, OCH3), 2.72 (1H, d, 
J = 2.0 Hz, H-3), 2.54-2.44 (1H, m, H-5), 2.30-2.17 (1H, m, H-5), 1.99-1.86 (2H, m, H-5 and H-
11), 1.75-1.65 (1H, m, H-11), 1.31-1.22 (1H, m, H-11) ppm; 13C NMR (101 MHz, CDCl3): δ 173.0 
(C=O), 148.6 (CH), 148.1 (CH), 139.9 (C), 134.6 (CH), 123.7 (CH), 67.3 (CH), 63.4 (CH2), 62.9 
(CH2), 53.4 (CH), 52.6 (C), 51.6 (CH3), 46.1 (CH), 37.9 (CH2), 35.6 (CH2), 35.4 (CH2) ppm; HRMS 
(ESI) 307.1644 (M + H+. C16H23N2O4 requires 307.1652); IR (ATR): νmax 3290, 2948, 2863, 1720 
(C=O), 1426, 1192, 1139, 1101, 1078, 1025 cm-1. 
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6-(4-Fluorophenyl)-9-oxa-1-aza-spiro[5.5]undecan-4-ol (149) 
Method A: To a stirred solution of ketone 147b (52.5 mg, 0.200 mmol) in MeOH (1 mL) at 0 
oC was added NaBH4 (9.1 mg, 0.240 mmol). The reaction was stirred for 1h at rt, then 
quenched with acetone (73 μL, 1.00 mmol). Volatiles were removed in vacuo, and the residue 
was purified by column chromatography (10% MeOH/EtOAc) to give the title compound as a 
mixture of diastereomers (35 mg, 0.132 mmol, 66% yield, 2:1 dr) as a yellow oil. 
Method B: To a stirred solution of ketone 147b (35.6 mg, 0.135 mmol) in THF (5 mL) at -78 oC 
was added L-Selectride (1M in THF, 169 μL, 0.169 mmol). The reaction was stirred for 20 mins 
then quenched with MeOH (0.35 mL). The mixture was warmed to rt, and water (2.5 mL) was 
added. The Organic layer was extracted with CH2Cl2 (5 x 10 mL). The organics were combined 
and passed through a phase separator and concentrated in vacuo. The residue was purified 
by column chromatography (5% MeOH/CH2Cl2) to give the title compound (16 mg, 0.0581 
mmol, 43% yield, >20:1 dr) as a yellow oil. Data presented is for the major diastereomer. 1H 
NMR (400 MHz, CDCl3): δ 7.45-7.36 (2H, m, H-7), 7.06-6.97 (2H, m, H-8), 4.37-4.32 (1H, m, H-
4), 4.28 (1H, dd, J = 11.5, 1.8 Hz, H-6), 3.81-3.61 (4H, m, H-10), 2.29-2.16 (1H, m, H-9), 2.12-
1.96 (2H, m, H-3 and H-9), 1.91-1.84 (1H, m, H-5), 1.83-1.59 (1H, m, H-5 and H-9), 1.48 (1H, 
dd, J = 14.5, 3.0 Hz, H-3), 1.44-1.35 (1H, m, H-9) ppm; 13C NMR (125 MHz, CDCl3): δ 163.1 (d, 
JF = 243 Hz, CF), 140.6 (C), 128.6 (d, JF = 7.8 Hz, CH), 115.3 (d, JF = 21.0 Hz, CH), 66.7 (CH), 64.4 
(CH2), 63.7 (CH2), 49.9 (CH2), 48.5 (CH), 41.8 (CH2), 41.7 (CH2), 35.6 (CH2) ppm; 19F NMR (376 
MHz, CDCl3): δ -115.4 ppm; HRMS (ESI) 266.1545 (M + H+. C15H21FNO2 requires 266.1551); IR 
(ATR): νmax 3391, 2925, 2858, 1604, 1510, 1424, 1300, 1222, 1159, 1099 cm-1. 
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General Procedure F – Direct amidation of the 2-spiropiperidines 
A mixture of amine (1.19 mmol) and DABAL.Me3 (0.796 mmol) in THF (2.5 mL) was heated to 
40 °C for 1h. A solution of 4-hydroxy-2-spiropiperidine (0.199 mmol) in THF (1 mL) was added 
and the reaction was heated under reflux for 16 hours. Upon cooling to room temperature, 
the reaction was quenched with water (1 mL) and diluted with CH2Cl2 (10 mL). The mixture 
was passed through a phase separator, washing with CH2Cl2 (2 x 5 mL), and concentrated in 
vacuo. The residue was purified by column chromatography. 
 
 
N-Butyl-4-hydroxy-6-(4-methoxyphenyl)-9-oxa-1-azaspiro[5.5]undecane-3-carboxamide 
(150a) 
Following general procedure F with spirocycle 148c (40 mg, 0.119 mmol), butylamine (71 μL, 
0.716 mmol) and DABAL.Me3 (122 mg, 0.477 mmol). The residue was purified by column 
chromatography (0-30% EtOH/EtOAc) to give the title compound as a mixture of 
diastereomers (19.9 mg, 0.053 mmol, 44% yield) as a yellow oil. Data presented is for the 
major diastereomer. Mp 148-151 oC; 1H NMR (400 MHz, CDCl3): δ 8.47-8.36 (1H, m, NH), 7.32-
7.27 (2H, m, H-7), 6.94-6.89 (2H, m, H-8), 4.39-4.35 (1H, m, H-4), 4.33 (1H, dd, J = 12.0, 3.0 Hz, 
H-6), 3.83 (3H, s, H-9), 3.79-3.67 (4H, m, H-11), 3.40-3.18 (2H, m, H-12), 2.83 (1H, br. s, H-3), 
2.58-2.47 (1H, m, H-5), 2.20-2.06 (2H, m, H-5 and H-10), 1.92-1.83 (2H, m, H-10), 1.61-1.47 
(3H, m, H-10 and H-13), 1.41 (2H, app. sext, J = 7.0 Hz, H-14), 0.96 (3H, t, J = 7.0 Hz, H-15) 
ppm; 13C-NMR (101 MHz, CDCl3): δ 172.5 (C=O), 159.1 (C), 136.2 (C), 127.7 (CH), 114.1 (CH), 
68.6 (CH), 64.0 (CH2), 63.4 (CH2), 55.3 (CH3), 54.8 (CH), 51.5 (C), 48.7 (CH), 38.9 (CH2), 38.1 
(CH2), 37.7 (CH2), 35.8 (CH2), 31.6 (CH2), 20.4 (CH2) 13.7 (CH3) ppm; HRMS (ESI) 377.2429 (M 
+ H+. C21H33N2O4 requires 377.2435); IR (ATR): νmax 3301, 2965, 2931, 2871, 1638 (C=O), 1514, 
1247, 1102 cm-1. 
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N-Butyl-4-hydroxy-6-pyridin-3-yl-9-oxa-1-aza-spiro[5.5]undecane-3-carboxamide (150b) 
Following general procedure F with spirocycle 148d (61 mg, 0.199 mmol), butylamine (117 
μL, 1.19 mmol) and DABAL.Me3 (204 mg, 0.796 mmol). The residue was purified by column 
chromatography (7.5-10% MeOH/EtOAc) to give the title compound as a mixture of 
diastereomers (61 mg, 0.175 mmol, 88% yield) as an off-white solid. Data presented is for the 
major diastereomer. Mp 147-149 oC; 1H NMR (400 MHz, CDCl3): δ 8.65 (1H, d, J = 2.0 Hz, H-
10), 8.55 (1H, dd, J = 5.0, 1.5 Hz, H-9), 7.86 (1H, br s, NH), 7.69 (1H, ddd, J = 8.0, 2.0, 2.0 Hz, H-
7), 7.31 (1H, dd, 8.0, 5.0 Hz, H-8), 4.42-4.36 (2H, m, H-4 and H-6), 3.83-3.62 (4H, m, H-12), 
3.37-3.18 (2H, m, H-13), 2.76 (1H, br s, H-3) 2.50-2.38 (1H, m, H-11), 2.23-2.07 (2H, m, H-5 
and H-11), 1.97-1.81 (2H, m, H-5 and H-11), 1.60-1.45 (H-11 and H-14), 1.38 (2H, dddd, J = 
15.0, 7.5, 7.5, 7.5 Hz, H-15), 0.94 (3H, d, J = 7.5 Hz, H-16) ppm; 13C-NMR (101 MHz, CDCl3): δ 
172.2 (C=O), 149.2 (CH), 148.8 (CH), 139.5 (C), 134.4 (CH), 123.8 (CH), 68.5 (CH), 64.0 (CH2), 
63.5 (CH2), 54.5 (CH), 51.7 (C), 47.3 (CH), 39.1 (CH2), 38.1 (CH2), 37.5 (CH2), 35.9 (CH2), 31.8 
(CH2), 20.5 (CH2), 13.9 (CH3) ppm; HRMS (ESI) 348.2265 (M + H+. C19H30N3O3 requires 
348.2282); IR (ATR): νmax 3280, 2955, 2930, 2864, 1637 (C=O), 1547, 1425, 1225, 1101, 1079 
cm-1. 
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N-propargyl-4-hydroxy-6-pyridin-3-yl-9-oxa-1-aza-spiro[5.5]undecane-3-carboxamide 
(150c) 
Following general procedure F with spirocycle 148d (104 mg, 0.340 mmol), propargylamine 
(130 μL, 2.04 mmol) and DABAL.Me3 (348 mg, 1.36 mmol). The residue was purified by column 
chromatography (10% MeOH/EtOAc) to give the title compound as a mixture of 
diastereomers (68.5 mg, 0.207 mmol, 61% yield) as a pale orange solid. Data presented is for 
the major diastereomer. Mp 186-188 oC; 1H NMR (400 MHz, CD2Cl2): δ 8.66 (1H, d, J = 2.0 Hz, 
H-10), 8.54-8.49 (1H, m, H-9), 8.41 (1H, br s, NH), 7.80-7.75 (1H, m, H-7), 7.31 (1H, dd, J = 8.0, 
5.0 Hz, H-8), 4.38 (1H, dd, J = 12.0, 3.0 Hz, H-6), 4.36-4.29 (1H, m, H-4), 4.14-4.05 (1H, m, H-
13), 4.00 (1H, ddd, J = 18.0, 5.0, 2.5 Hz, H-13), 3.78-3.58 (4H, m, H-12), 2.75 (1H, br s, H-3) 
2.48-2.31 (2H, m, H-11 and H-15), 2.25-2.09 (2H, m, H-5 and H-11), 1.92-1.79 (2H, m, H-5 and 
H-11), 1.56-1.45 (1H, m, H-11) ppm; 13C-NMR (101 MHz, CD2Cl2): δ 172.2 (C=O), 149.3 (CH), 
149.2 (CH), 139.8 (C), 134.8 (CH), 124.0 (CH), 80.1 (CH), 71.6 (C), 68.6 (CH), 64.0 (CH2), 63.5 
(CH2), 54.8 (CH), 52.0 (C), 47.6 (CH), 38.1 (CH2), 37.6 (CH2), 35.9 (CH2), 28.9 (CH2) ppm; HRMS 
(ESI) 330.1808 (M + H+. C18H24N3O3 requires 330.1808); IR (ATR): νmax 3286, 2927, 2865, 1648 
(C=O), 1537, 1425, 1101, 1027 cm-1.  
 
 
 
 
164 
 
 
Methyl 4-hydrazono-6-(4-methyl-thiazol-5-yl)-9-oxa-1-aza-spiro[5.5]undecane-3-
carboxylate (151) 
To a solution of 2-spiropiperidine 138e (81.5 mg, 0.251 mmol) in THF (1 mL) in a sealed tube 
was added hydrazine (1M in acetonitrile, 377 μL, 0.377 mmol). The reaction was stirred at 70 
oC for 1h. The mixture was cooled to rt and diluted with EtOAc (10 mL). The layers were 
separated and the organic layer was washed with water (2 mL). The organics were dried 
(MgSO4), filtered and concentrated in vacuo to give the title compound as a mixture of 
diastereomers (49 mg, 0.143 mmol, 58% yield) as a yellow oil, used in the next reaction 
without further purification. Data presented is for the major diastereomer. 1H NMR (400 MHz, 
CDCl3): δ 8.66 (1H, s, H-7), 4.24 (1H, dd, J = 12.0, 4.0 Hz, H-6), 3.93-3.76 (2H, m, H-10), 3.74-
3.63 (2H, m, H-10), 3.71 (3H, s, OCH3), 3.28 (1H, s, H-3), 2.93 (1H, dd, J = 14.0, 4.0 Hz, H-5), 
2.48 (3H, s, H-7), 2.45 (1H, dd, J = 14.0, 12.0 Hz, H-5), 1.92-1.83 (1H, m, H-9), 1.77-1.59 (2H, 
m, H-9), 1.44-1.36 (1H, m, H-9) ppm; HRMS (ESI) 267.1163 (M + H+. C13H19N2O2S requires 
267.1162); IR (ATR): νmax 3377, 2951, 2863, 1721 (C=O), 1643 (C=N), 1433, 1252, 1195, 1096 
cm-1. 
 
 
Methyl 6-(4-fluoro-phenyl)-9-oxa-1-aza-spiro[5.5]undec-3-ene-3-carboxylate (156) 
To a solution of 2-spiropiperidine 148b (19 mg, 0.0588 mmol) in toluene (0.2 mL) in a plastic 
vessel was sequentially added PyFluor (10.4 mg, 0.0647 mmol) and DBU (17.6 μL, 0.118 mmol) 
at rt and the reaction mixture was stirred overnight. Volatiles were removed in vacuo and the 
residue was purified by column chromatography (60% EtOAc/hexane) to give the title 
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compound (5.3 mg, 0.0176 mmol, 30% yield) as a yellow oil. 1H NMR (400 MHz, CDCl3): δ 7.46-
7.39 (2H, m, H-7), 7.11 (1H, dd, J = 6.5, 2.3 Hz, H-4), 7.09-7.02 (2H, m, H-8), 3.96-3.82 (3H, m, 
H-6 and H-10), 3.80-3.72 (2H, m, H-10), 3.76 (3H, s, OCH3), 2.76 (1H, ddd, J = 13.1, 13.1, 5.5 
Hz, H-9), 2.63-2.52 (2H, m, H-5 and H-9), 2.27 (1H, ddd, J = 18.5, 10.8, 2.3 Hz, H-5), 1.66-1.59 
(1H, m, H-9), 1.20-1.12 (1H, m, H-9) ppm; 13C NMR (101 MHz, CDCl3): δ 166.9 (C=O), 162.1 (d, 
J = 247.0 Hz, C), 139.6 (CH), 139.4 (d, J = 3.4 Hz, C), 138.0 (C), 128.2 (d, J = 7.8 Hz, CH), 115.4 
(d, J = 21.2 Hz, CH), 63.4 (CH2), 63.0 (CH2), 53.6 (C), 51.7 (CH3), 49.5 (CH), 36.3 (CH2), 33.8 
(CH2), 32.0 (CH2) ppm; 19F NMR (376 MHz, CDCl3): δ -115.4 ppm; HRMS (ESI) 306.1490 (M + 
H+. C17H21FNO3 requires 306.1500); IR (ATR): νmax 2950, 2923, 2863, 1708 (C=O), 1509, 1434, 
1237, 1220, 1101, 1058 cm-1. 
 
 
Methyl 6-(4-fluorophenyl)-4-hydroxy-1-methyl-9-oxa-1-aza-spiro[5.5]undecane-3-
carboxylate (159) 
Silver (I) oxide (75.8 mg, 0.327 mmol) and iodomethane (20.4 μL, 0.327 mmol) were 
successively added to a solution of spirocycle 148b (35.1 mg, 0.109 mmol) in 1,2-
dichloroethane (0.5 mL) at rt. The mixture was heated to 85 °C in a sealed vial in the darkness 
for 54 hours. Extra iodomethane (20.4 μL, 0.327 mmol) was added at 24 and 48 hours. The 
mixture was cooled to rt, diluted with methanol and passed through a plug of Celite. The 
filtrate was concentrated in vacuo and purified by column chromatography (60% ethyl 
acetate/hexane) to afford the title compound (18.3 mg, 0.0545 mmol, 50% yield) as a yellow 
oil. 1H NMR (400 MHz, CDCl3): δ 7.43-7.37 (2H, m, H-7), 7.03-6.95 (2H, m, H-8), 4.48 (1H, ddd, 
J = 7.2, 7.0, 4.5 Hz, H-4), 4.23 (1H, br t, J = 6.0 Hz, H-6), 3.91-3.83 (1H, m, H-10), 3.72 (3H, s, 
OCH3), 3.73-3.66 (1H, m, H-10), 3.65-3.57 (1H, m, H-10), 3.45 (1H, dt, J = 11.0, 4.0 Hz, H-10), 
2.78 (1H, d, J = 7.0 Hz, H-3), 2.59 (1H, ddd, J = 14.0, 7.2, 4.5 Hz, H-5), 2.31 (3H, s, NCH3), 2.10-
2.01 (1H, m, H-9), 1.91-1.80 (2H, m, H-5 and H-9), 1.57-1.49 (2H, m, H-9) ppm; 13C NMR 
(101 MHz, CDCl3): δ 173.8 (C=O), 161.7 (d, J = 246.0 Hz, C), 139.7 (d, J = 2.5 Hz, C), 129.0 (d, J 
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= 8.0 Hz, CH), 115.1 (d, J = 21.0 Hz, CH), 65.9 (CH), 64.4 (CH2), 63.9 (CH2), 58.0 (CH), 57.4 (C), 
53.5 (CH), 51.8 (CH3), 35.6 (CH3), 34.8 (CH2), 33.2 (CH2), 30.8 (CH2) ppm; 19F NMR (376 MHz, 
CDCl3): δ -116.0 ppm; HRMS (ESI) 338.1753 (M + H+. C18H25FNO4 requires 338.1762); IR (ATR): 
νmax 3407, 2952, 2872, 1727 (C=O), 1603, 1508, 1435, 1222, 1158, 1143, 1017 cm-1. 
 
 
[6-(4-Fluorophenyl)-9-oxa-1-aza-spiro[5.5]undec-4-yl]-prop-2-ynyl-amine (161) 
To a solution of spirocycle 147b (28 mg, 0.106 mmol) and amine (7.5 μL, 0.117 mmol) in 1,2-
dichloromethane (0.4 mL) was added sodium triacetoxyborohydride (35 mg, 0.164 mmol) and 
acetic acid (6 μL, 0.106 mmol). The mixture was stirred for 2 hours at room temperature, then 
quenched with 1M NaOH (0.2 mL). Product was extracted with diethyl ether (3 x 2 mL) and 
volatiles were removed in vacuo. The residue was purified by column chromatography (5% 
methanol/ethyl acetate) to afford the title compound as a single diastereomer (13.3 mg, 
0.0445 mmol, 42% yield) as a yellow oil. 1H NMR (400 MHz, CDCl3): δ 7.41-7.34 (2H, m, H-7), 
7.04-6.97 (2H, m, H-8), 4.20 (1H, dd, J = 11.0, 3.0 Hz, H-6), 3.77-3.58 (4H, m, H-10), 3.45 (1H, 
dd, J = 2.25, 2.25 Hz, H-11), 3.41 (1H, dddd, J = 7.0, 7.0, 3.5, 3.5 Hz, H-4), 2.21 (1H, dd, J = 2.25, 
2.25 Hz, H-11), 2.17-2.04 (2H, m, H-9), 1.82-1.55 (6H, m, H-3, H-5 and H-13), 1.49 (1H, dd, J = 
14.5, 4.5 Hz, H-9), 1.40-1.32 (1H, m, H-9) ppm; 13C NMR (101 MHz, CDCl3): δ 162.0 (d, JF = 
246.0 Hz, CF), 140.8 (C), 128.6 (d, JF = 8.0 Hz, CH), 115.3 (d, JF = 21.0 Hz, CH), 82.3 (C), 71.6 (C), 
64.3 (CH2), 63.8 (CH2), 50.5 (CH), 49.0 (CH), 41.8 (CH2), 38.7 (CH2), 36.1 (CH2), 36.0 (CH2) ppm; 
19F NMR (376 MHz, CDCl3): δ -115.5 ppm; HRMS (ESI) 303.1863 (M + H+. C18H24FN2O requires 
303.1867); IR (ATR): νmax 3297, 2928, 2852, 1603, 1509, 1431, 1221, 1158, 1099 cm-1. 
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6-(4-Fluorophenyl)-4-methylene-9-oxa-1-aza-spiro[5.5]undecane (162) 
To a suspension of methyl triphenylphosphonium bromide (84.0 mg, 0.228 mmol) in THF (1.2 
mL) was added n-BuLi (2.5 M in hexanes, 96 μL, 0.228 mmol) at 0 oC. The mixture was stirred 
at for 1h before the addition of spirocycle 147b (50 mg, 0.190 mmol) in THF (0.2 mL). The 
reaction was stirred at 0 oC for 4h. The volatiles were removed in vacuo and the residue was 
purified by column chromatography (40% EtOAc/petroleum ether (40-60)) to afford the title 
compound (17.7 mg, 0.0684 mmol, 36% yield) as a colourless oil. 1H NMR (400 MHz, CDCl3): 
δ 7.42-7.34 (2H, m, H-7), 7.06-6.97 (2H, m, H-8), 4.83 (1H, br d, J = 1.5 Hz, H-11), 4.74 (1H, br 
d, J = 1.5 Hz, H-11), 3.87 (1H, dd, J = 11.5, 3.0 Hz, H-6), 3.82-3.64 (3H, m, H-10), 3.60 (1H, ddd, 
J = 11.0, 7.5, 3.5 Hz, H-10), 2.45-2.37 (2H, m, H-3), 2.11  (1H, ddd, J = 12.5, 11.5, 1.5 Hz, H-5), 
2.02 (1H, d, J = 12.5 Hz, H-5), 1.79 (1H, ddd, J = 13.5, 7.5, 3.5 Hz, H-9), 1.72-1.60 (2H, m, H-9), 
1.56-1.48 (1H, m, H-9), 1.42 (1H, br s, NH) ppm; 13C NMR (101 MHz, CDCl3): δ 162.1 (d, JF = 
246.5 Hz, CF), 143.9 (C), 140.3 (d, JF = 3.0 Hz, C), 128.4 (d, JF = 8.0 Hz, CH), 115.3 (d, J = 21.0 
Hz, CH), 110.6 (CH2), 64.4 (CH2), 63.9 (CH2), 54.8 (CH), 51.3 (C), 44.6 (CH2), 43.8 (CH2), 40.9 
(CH2), 32.9 (CH2) ppm; 19F NMR (376 MHz, CDCl3): δ -115.4 ppm; HRMS (ESI) 262.1592 (M + 
H+. C16H21FNO requires 262.1602); IR (ATR): νmax 3070, 2936, 2852, 1651, 1603, 1508, 1221, 
1156, 1102, 1014 cm-1. 
 
 
6-(4-Fluorophenyl)-4,9-dioxa-1-aza-dispiro[2.1.5.3]tridecane (163) 
To a suspension of NaH (60% dispersion in mineral oil, 12 mg, 0.304 mmol) in THF (0.5 mL) 
was added trimethylsulfoxonium iodide (67 mg, 0.304 mmol) at rt. After 10 mins, a solution 
of spirocycle 147b (0.152 mmol) in THF (0.5 mL) was added dropwise and the reaction was 
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stirred for 3h at rt. The mixture was diluted with ethyl acetate (10 mL) and quenched with 
water (1 mL). Layers were separated and the aqueous was extracted with ethyl acetate (10 
mL). Organics were combined, dried (MgSO4), filtered and concentrated in vacuo. The crude 
residue was purified by column chromatography (60% EtOAc/petroleum ether (40-60)) to give 
the title compound as a single diastereomer (16.7 mg, 0.0603 mmol, 41% yield) as a colourless 
oil. 1H NMR (400 MHz, CDCl3): δ 7.41-7.31 (2H, m, H-7), 7.06-6.98 (2H, m, H-8), 4.23 (1H, dd, 
J = 12.0, 2.5 Hz, H-6), 3.82-3.73 (2H, m, H-10), 3.62 (2H, dddd, J = 11.5, 9.5, 7.5, 3.5 Hz, H-10), 
2.61 (1H, d, J = 4.5 Hz, H-11),  2.57 (1H, d, J = 4.5 Hz, H-11), 2.15 (1H, ddd, J = 13.0, 7.0, 3.0 Hz, 
H-9), 2.01 (1H, dd, J = 13.5, 12.0 Hz, H-5), 1.92-1.84 (1H, m, H-9), 1.87 (1H, d, J = 13.75, H-3), 
1.66 (1H, dddd, J = 13.5, 7.0, 3.5, 1.5 Hz, H-9), 1.54 (1H, br s, NH), 1.52-1.44 (1H, m, H-9), 1.47 
(1H, dd, J = 13.75, 2.5 Hz, H-3), 1.36 (1H, ddd, J = 13.5, 2.5, 2.5 Hz, H-5) ppm; 13C NMR 
(101 MHz, CDCl3): δ 162.2 (d, JF = 246.5 Hz, CF), 140.0 (d, JF = 3.0 Hz, C), 128.4 (d, JF = 8.0 Hz, 
CH), 115.4 (d, JF = 21.5 Hz, CH), 64.6 (CH2), 63.8 (CH2), 56.5 (C), 51.6 (CH), 51.3 (CH2), 51.2 (C), 
41.6 (CH2), 41.2 (CH2), 41.2 (CH2), 34.3 (CH2) ppm; 19F NMR (376 MHz, CDCl3): δ -115.2 ppm; 
HRMS (ESI) 278.1553 (M + H+. C16H21FNO2 requires 278.1551); IR (ATR): νmax 3293, 2951, 2855, 
1604, 1509, 1221, 1156, 1102 cm-1. 
 
 
Diketene (168) 
Method A: Triethylamine (344 µL, 2.47 mmol) was added to a solution of acetyl chloride (351 
µL, 4.94 mmol) in diethyl ether (5 mL) at rt. The mixture was stirred for 60 mins, then the 
cream precipitate was filtered and washed with diethyl ether (2 x 3 mL). The filtrate was 
carefully blown down with nitrogen to give the title compound (68 mg, 0.809 mmol, 33% 
yield) as a brown oil. 
Method B: Triethylamine (600 μL, 4.31 mmol) was added to a solution of acetyl chloride (255 
μL, 3.59 mmol) in toluene (3.6 mL) at rt. The mixture was stirred for 60 mins then filtered to 
give the title compound (150 mg, 1.80 mmol, 50% yield) as a 4.91 wt% solution in toluene. 1H 
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NMR (400 MHz, CDCl3): δ 4.92-4.89 (1H, m, H-1), 4.52 (1H, dt, J = 4.0, 1.5 Hz, H-1), 3.92 (2H, t, 
J = 1.5 Hz, H-3) ppm. 1H data was consistent with diketene purchased from Sigma Aldrich.207 
 
 
3-Trimethylsilanyloxy-but-2-enoic acid methyl ester (169) 
Trimethylsilyl chloride (15.0 mL, 118 mmol) was added over 20 mins via syringe pump to a 
solution of methyl acetoacetate (11.5 mL, 107 mmol) and triethylamine (17.8 mL, 128 mmol) 
in hexane (220 mL) at rt. The reaction mixture was stirred overnight at rt. The mixture was 
diluted with hexane (150 mL) and passed through Celite, washing with hexane (2 x 100 mL), 
and concentrated in vacuo to afford the title compound (18.7 g, 99.5 mmol, 93% yield) as a 
pale yellow oil that was used in the next step without further purification. 1H NMR (400 MHz, 
CDCl3): δ 5.12 (1H, s, CH), 3.65 (3H, s, OCH3), 2.26 (3H, s, CH3), 0.26 (9H, s, Si(CH3)3) ppm; IR 
(ATR): νmax 2953, 1714 (C=O), 1621, 1435, 1385, 1337, 1286, 1254, 1189, 1132, 1035 cm-1. 1H 
NMR were in agreement with literature.168 
 
 
1-Methoxy-1,3-bis-trimethylsilanyloxy-buta-1,3-diene (Chan’s diene) (170) 
n-BuLi (2.24 M in hexanes, 42.9 mL, 96.1 mmol) was added to a solution of diisopropylamine 
(13.4 mL, 96.1 mmol) in THF (170 mL) at -78 oC. The mixture was stirred for 15 mins at -78 oC 
and 10 mins at rt, before being re-cooled to -78 oC. A solution of 169 (16.4 g, 87.4 mmol) in 
THF (40 mL) was added and the mixture was stirred for 30 mins at -78 oC. Trimethylsilyl 
chloride (15.0 mL, 118 mmol) was carefully added and the reaction was stirred for 1h at 0 oC. 
The mixture was warmed to rt, and volatiles were removed in vacuo. The residue was 
dissolved in hexane (200 mL) and passed through Celite, washing with hexane (2 x 100 mL). 
Organics were combined and concentrated in vacuo to afford the title compound (22.1 g, 85.0 
mmol, 97% yield) as a yellow oil. 1H NMR (400 MHz, CDCl3): δ 4.48 (1H, s, CH), 4.14 (1H, d, J = 
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1.0 Hz, CH2), 3.94 (1H, d, J = 1.0 Hz, CH2), 3.56 (3H, s, OCH3), 0.25 (9H, s, (CH3)3), 0.21 (9H, s, 
(CH3)3) ppm; IR (ATR): νmax 2959, 1718, 1649, 1443, 1385, 1250, 1219, 1168, 1139, 1090, 1017 
cm-1. 1H NMR were in agreement with literature.168 
 
 
Benzylidene-phenylamine (174) 
To a solution of benzaldehyde (2.00 mL, 20.0 mmol) and aniline (1.70 mL, 20.0 mmol) was 
added MgSO4 (4.00 g, 33.3 mmol). The mixture was stirred at rt for 4h, filtered, and 
concentrated in vacuo to afford the title compound (2.04 g, 11.2 mmol, 56% yield) as an off-
white solid. Mp 49.5-50.5 oC; 1H NMR (400 MHz, CDCl3): δ 8.47 (1H, s, NCH), 7.95-7.88 (2H, m, 
ArH), 7.52-7.46 (3H, m, ArH), 7.44-7.39 (2H, m, ArH), 7.28-7.19 (3H, m, ArH) ppm; 13C NMR 
(101 MHz, CDCl3): δ 160.6 (CH), 152.2 (C), 136.3 (C), 131.5 (CH), 129.3 (CH), 128.9 (CH), 128.9 
(CH), 126.1 (CH), 121.0 (CH) ppm; mp 49.5-50.5 °C; HRMS (ESI) 182.0963 (M + H+. C13H12N 
requires 182.0964); IR (ATR): νmax 3060, 2886, 1626, 1590, 1578, 1484, 150, 1312, 1190, 1168 
cm-1. 
 
 
Methyl 3-oxo-5-phenyl-5-phenylamino-pentanoate (175) 
Method A: To a solution of benzylidene-phenylamine 174 (105 mg, 0.580 mmol) in CH2Cl2 (5.5 
mL) at -78 oC was added ZnCl2 (79 mg, 0.580 mmol). The mixture was stirred for 30 mins 
before the addition of Chan’s diene 170 (226 mg, 0.870 mmol). The reaction was stirred for 
1h then quenched with sat. aq. NaHCO3 (5.5 mL). The mixture was warmed to rt and the layers 
were separated. The aqueous was extracted with CH2Cl2 (5 mL). The organics were combined, 
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washed with water (5 mL) and brine (5 mL), dried (MgSO4), filtered and concentrated in vacuo. 
The residue was purified by column chromatography (20 % EtOAc/petroleum ether (40-60)) 
to give the title compound (96 mg, 0.325 mmol, 56% yield) as a yellow oil. 
Method B: To a solution of benzylidene-phenyl-amine 174 (112 mg, 0.619 mmol) in CH2Cl2 (6 
mL) at -78 oC was added TiCl4 (68 μL, 0.619 mmol). Chan’s diene 170 (241 mg, 0.929 mmol) 
was added and the reaction mixture was stirred for 45 mins at -78 oC. The reaction was 
quenched with sat. aq. NaHCO3 (5 mL) and warmed to rt. The layers were separated and the 
aqueous layer was extracted with CH2Cl2 (3 x 5 mL). The organics were combined, washed 
with water (10 mL) and brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo. The 
residue was purified by column chromatography (15% EtOAc/hexane) to give the title 
compound (132 mg, 0.446 mmol, 72% yield) as a yellow oil. 1H NMR (400 MHz, CDCl3): δ 7.40-
7.29 (4H, m, ArH), 7.27-7.22 (1H, m, ArH), 7.13-7.05 (2H, m ArH), 7.13-7.05 (2H, m, ArH), 6.71-
6.64 (1H, m, ArH), 6.58-6.50 (2H, m, ArH), 4.90 (1H, dd, J = 7.8, 5.5 Hz, H-5), 3.70 (3H, s, OCH3), 
3.43 (1H, d, J = 15.5 Hz, H-2), 3.37 (1H, d, J = 15.5 Hz, H-2), 3.09 (1H, dd, J = 16.0, 7.8 Hz, H-4), 
3.01 (1H, dd, J = 16.0, 5.5 Hz, H-4) ppm; 13C NMR (101 MHz, CDCl3): δ 201.1 (C=O), 167.6 (C=O), 
146.8 (C), 142.3 (C), 129.3 (CH), 129.0 (CH), 127.6 (CH), 126.4 (CH), 118.0 (CH), 113.9 (CH), 
54.3 (CH), 52.6 (CH3), 50.6 (CH2), 49.6 (CH2) ppm; HRMS (ESI) 298.1432 (M + H+. C18H20NO3 
requires 298.1438), 320.1252 (M + Na+. C18H19NNaO3 requires 320.1257); IR (ATR): νmax 3401, 
3026, 2952, 1743 (C=O), 1714 (C=O), 1601, 1504, 1451, 1436, 1317, 1266 cm-1. 
 
 
Ethyl (4-methoxy-phenylimino)-acetate (179) 
To a solution of ethyl glyoxylate (50% in toluene, 1.60 mL, 8.13 mmol) and p-anisidine (8.13 
mmol) in toluene (16 mL) was added Na2SO4 (11.5 g, 81.3 mmol) at rt. The reaction was stirred 
for 2h then filtered and concentrated in vacuo. The residue was purified by column 
chromatography (20% EtOAc/hexane) to give the title compound (700 mg, 3.90 mmol, 48% 
yield) as a yellow oil. 1H NMR (400 MHz, CDCl3): δ 7.94 (1H, s, CH), 7.38-7.34 (2H, m, H-1), 
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6.95-6.91 (2H, m, H-2), 4.41 (2H, q, J = 7.0 Hz, CH2), 3.83 (3H, s, OCH3), 1.40 (3H, t, J = 7.0 Hz, 
CH3) ppm; 13C NMR (101 MHz, CDCl3): δ 163.8 (C=O), 160.7 (C), 148.1 (CH), 141.5 (C), 123.8 
(CH), 114.7 (CH), 62.1 (CH2), 55.6 (CH3), 14.4 (CH3) ppm; HRMS (ESI) 208.0958 (M + H+. 
C11H14NO3 requires 208.0968); IR (ATR): νmax 2981, 2936, 1740, 1713, 1590, 1504, 1465, 1370, 
1282, 1248, 1214, 1192, 1160, 1028 cm-1. 
 
 
2-(4-methoxy-phenylamino)-4-oxo-hexanedioic acid 1-ethyl ester 6-methyl ester (180) 
To a solution of (4-methoxy-phenylimino)-acetic acid ethyl ester 179 (100 mg, 0.483 mmol) in 
THF (5 mL) at -78 oC was added ZnCl2 (66 mg, 0.483 mmol). The mixture was stirred for 30 
mins before the addition of Chan’s diene 170 (189 mg, 0.725 mmol). The reaction was stirred 
for 1h then quenched with sat. aq. NaHCO3 (5 mL). The mixture was warmed to rt, diluted 
with EtOAc (15 mL), and the layers were separated. The aqueous was extracted with EtOAc (2 
x 5 mL). The organics were combined, washed with brine (10 mL), dried (MgSO4), filtered and 
concentrated in vacuo. The residue was purified by column chromatography (20 % 
EtOAc/petroleum ether (40-60)) to give the title compound (72 mg, 0.223 mmol, 46% yield) 
as a yellow oil. 1H NMR (400 MHz, CDCl3): δ 6.79-6.73 (2H, m, H-9), 6.66-6.60 (2H, m, H-10), 
4.36 (1H, dd, J = 5.5, 5.5 Hz, H-5), 4.17 (2H, q, J = 7.0 Hz, H-7), 3.73 (3H, s, H-11), 3.70 (3H, s, 
OCH3), 3.50 (1H, d, J = 16.0 Hz, H-2), 3.46 (1H, d, J = 16.0 Hz, H-2), 3.09 (1H, dd, J = 18.1, 5.5 
Hz, H-4), 3.05 (1H, dd, J = 18.1, 5.5 Hz, H-4), 1.23 (3H, t, J = 7.0 Hz, H-8) ppm; 13C NMR 
(101 MHz, CDCl3): δ 200.3 (C=O), 172.6 (C=O), 167.2 (C=O), 153.2 (C), 140.4 (C), 115.9 (CH), 
114.9 (CH), 61.7 (CH2), 55.8 (CH3), 54.3 (CH), 52.5 (CH3), 49.5 (CH2), 45.2 (CH2), 14.2 (CH3) ppm; 
HRMS (ESI) 346.1262 (M + Na+. C15H17NNaO5 requires 346.1261); IR (ATR): νmax 3377, 2954, 
1717 (C=O), 1511, 1438, 1369, 1235, 1158, 1033 cm-1. 
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Ethyl 1-(4-methoxy-phenyl)-2,4-dioxo-piperidine-6-carboxylate (181) 
Isolated from column chromatography of 180 as a yellow oil. 1H NMR (400 MHz, CDCl3): δ 
7.21-7.15 (2H, m, H-9), 6.96-6.90 (2H, m, H-10), 4.57 (1H, dd, J = 6.5, 2.5 Hz, H-6), 4.24 (2H, q, 
J = 7.0 Hz, H-7), 3.81 (3H, s, H-11), 3.65 (1H, d, J = 20.0 Hz, H-3), 3.45 (1H, d, J = 20.0 Hz, H-3), 
3.09 (1H, dd, J = 17.5, 6.5 Hz, H-5), 3.02 (1H, dd, J = 17.5, 2.5 Hz, H-5), 1.27 (3H, t, J = 7.0 Hz, 
H-8) ppm; 13C NMR (101 MHz, CDCl3): δ 201.5 (C=O), 170.5 (C=O), 167.0 (C=O), 159.0 (C), 134.2 
(C), 128.0 (CH), 114.9 (CH), 62.8 (CH2), 60.6 (CH), 55.6 (CH3), 48.6 (CH2), 42.1 (CH2), 14.2 (CH3) 
ppm; HRMS (ESI) 314.0982 (M + Na+. C15H17NNaO5 requires 314.0999); IR (ATR): νmax 2980, 
1735 (C=O), 1672 (C=O), 1510, 1430, 1298, 1243, 1200, 1030 cm-1. 
 
 
4-Hydroxy-1-(4-methoxy-phenyl)-2-phenyl-1,2,5,6-tetrahydro-pyridine-3,6-dicarboxylic 
acid 6-ethyl ester 3-methyl ester (182) 
To a solution of (4-methoxy-phenylimino)-acetic acid ethyl ester 179 (115 mg, 0.556 mmol) in 
CH2Cl2 (5.5 mL) at -78 oC was added ZnCl2 (76 mg, 0.556 mmol). The mixture was stirred for 
30 mins before the addition of Chan’s diene 170 (217 mg, 0.834). After 30 mins, benzaldehyde 
(282 μL, 2.78 mmol) was added and the reaction was stirred overnight at rt. The reaction was 
quenched with sat. aq. NaHCO3 (5 mL), and the layers were separated. The aqueous layer was 
extracted with CH2Cl2 (2 x 5 mL). The organics were combined, washed with water (10 mL) 
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and brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo. The residue was purified 
by column chromatography (10-20% EtOAc/petroleum ether (40-60)) to give the title 
compound as a mixture of diastereomers (107 mg, 0.261 mmol, 47% yield, 2.5:1 dr) as a 
yellow oil. Data presented is for the major diastereomer. 1H NMR (400 MHz, CDCl3): δ 12.20 
(1H, s, OH), 7.21-7.10 (5H, m, ArH), 6.83-6.77 (2H, m, H-9), 6.72-6.66 (2H, m, H-10), 5.52 (1H, 
s, H-2), 4.37 (1H, dd, J = 6.0, 5.5 Hz, H-6), 4.06 (2H, q, J = 7.3 Hz, H-7), 3.70 (3H, s, H-11), 3.64 
(3H, s, H-12), 3.02 (1H, dd, J = 17.6, 5.5 Hz, H-5), 2.92 (1H, dd, J = 17.6, 6.0 Hz, H-5), 1.10 (3H, 
t, J = 7.3 Hz, H-8) ppm; 13C NMR (101 MHz, CDCl3): δ 172.0 (C=O), 171.0 (C=O), 168.7 (C), 154.8 
(C), 141.5 (C), 140.0 (C), 128.4 (CH), 128.3 (CH), 127.8 (CH), 122.5 (CH), 114.0 (CH), 101.4 (C), 
61.1 (CH2), 59.7 (CH), 57.3 (CH), 55.4 (CH3), 51.6 (CH3), 32.6 (CH2), 14.1 (CH3) ppm; HRMS (ESI) 
412.1760 (M + H+. C23H26NO6 requires 412.1755), 434.1579 (M + Na+. C23H26NNaO6 requires 
434.1574); IR (ATR): νmax 2953, 1731 (C=O), 1662, 1623, 1510, 1443, 1242, 1225, 1181, 1036 
cm-1. 
 
 
tert-Butyl 3-trimethylsilanyloxy-but-2-enoate (184) 
Trimethylsilyl chloride (5.0 mL, 39.4 mmol) was added over 20 mins via syringe pump to a 
solution of tert-butyl acetoacetate (5.93 mL, 35.8 mmol) and triethylamine (5.98 mL, 43.0 
mmol) in hexane (70 mL) at rt. The reaction mixture was stirred overnight at rt. The mixture 
was diluted with hexane (70 mL) and passed through Celite, washing with hexane (2 x 50 mL), 
and concentrated in vacuo to afford the title compound (8.06 g, 35.0 mmol, 98% yield) as a 
colourless oil that was used in the next step without further purification. 1H NMR (400 MHz, 
CDCl3): δ 5.05 (s) and 5.00 (1H total, s, CH), 2.21 (s) and 1.85 (3H total, s, CH3), 1.46 (s) and 
1.45 (9H total, s, (CH3)3), 0.26 (s) and 0.25 (9H total, s, TMS) ppm. 1H NMR were in agreement 
with literature.168 
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1-tert-Butoxy-1,3-bis-trimethylsilanyloxy-buta-1,3-diene (tert-butyl Chan’s diene) (185) 
n-BuLi (2.37 M in hexanes, 11.0 mL, 26.2 mmol) was added to a solution of diisopropylamine 
(3.70 mL, 26.2 mmol) in THF (42 mL) at -78 oC. The mixture was stirred for 15 mins at -78 oC 
and 10 mins at rt, before being re-cooled to -78 oC. A solution of 184 (5.48 g, 23.8 mmol) in 
THF (24 mL) was added and the mixture was stirred for 30 mins at -78 oC. Trimethylsilyl 
chloride (4.08 mL, 32.1 mmol) was carefully added and the reaction was stirred for 1h at 0 oC. 
The mixture was warmed to rt, and volatiles were removed in vacuo. The residue was 
dissolved in hexane (100 mL) and passed through Celite, washing with hexane (2 x 50 mL). 
Organics were combined and concentrated in vacuo, and purified by kughelrohr distillation 
(0.7 mbar, 96 oC) to afford the title compound (6.72 g, 22.3 mmol, 94% yield) as a yellow oil. 
1H NMR (400 MHz, CDCl3): δ 4.54 (1H, s, CH), 4.25 (1H, d, J = 1.5 Hz, CH2), 4.20 (1H, d, J = 1.5 
Hz, CH2), 1.46 (s) and 1.36 (9H total, s, (CH3)3), 0.24 (s), 0.21 (s), 0.20 (s) and 0.17 (18H total, 
s, TMS) ppm. 1H NMR were in agreement with literature.168 
 
 
2-(4-Methoxy-phenylamino)-4-oxo-hexanedioic acid 6-tert-butyl ester 1-ethyl ester (186) 
To a solution of diisopropylamine (2.04 mL, 14.5 mmol) in THF (30 mL) at -78 °C was added n-
BuLi (2.35M in hexanes, 6.2 mL, 14.5 mmol). The solution was stirred for 10 mins at -78 °C 
then a further 5 mins at room temperature. A solution of tert-butyl acetoacetate (1.12 mL, 
7.26 mmol) in THF (5 mL) was added at -78 °C, then stirred for a further 40 mins. A solution 
of imine (4-methoxy-phenylimino)-acetic acid ethyl ester 179 (500 mg, 2.42 mmol) was added 
at -50 °C and the reaction was stirred for 30 mins, then quenched with 10 M acetic acid in THF 
(3.63 mL, 36.3 mmol). The mixture was warmed to room temperature and concentrated in 
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vacuo. The residue was partitioned between EtOAc (40 mL) and water (30 mL). The aqueous 
layer was extracted with EtOAc (2 x 30 mL). Organics were combined, washed with water (60 
mL) and brine (60 mL), dried (MgSO4), filtered and concentrated in vacuo. The residue was 
purified by column chromatography (15% ethyl acetate/hexane) to give the title compound 
(108 mg, 0.290 mmol, 12% yield) as a yellow oil. 1H NMR (400 MHz, CDCl3): δ 6.78-6.73 (2H, 
m, H-9), 6.66-6.61 (2H, m, H-10), 4.35 (1H, dd, J = 5.5, 5.5 Hz, H-5), 4.18 (1H, q, J = 7.0 Hz, H-
7), 4.18 (1H, q, J = 7.0 Hz, H-7), 3.73 (3H, s, H-11), 3.40 (1H, d, J = 15.5 Hz, H-2), 3.36 (1H, d, J 
= 15.5 Hz, H-2), 3.10 (1H, dd, J = 17.5, 5.5 Hz, H-4), 3.05 (1H, dd, J = 17.5, 5.5 Hz, H-4), 1.44 
(9H, s, (CH3)3), 1.22 (3H, t, J = 7.0 Hz, H-8) ppm;   13C NMR (101 MHz, CDCl3): δ 200.8 (C=O), 
172.9 (C=O), 166.1 (C=O), 153.2 (C), 140.5 (C), 115.9 (CH), 115.0 (CH), 82.4 (C), 61.7 (CH2), 55.8 
(CH3), 54.3 (CH), 51.1 (CH2), 45.1 (CH2), 28.0 (CH2), 14.2 (CH2) ppm; HRMS (ESI) 366.1914 (M + 
H+. C19H28NO6 requires 366.1911); IR (ATR): νmax 3374, 2978, 2934, 1730 (C=O), 1716 (C=O), 
1637, 1513, 1368, 1240, 1150 cm-1. 
 
General Procedure G - Synthesis of N-Boc-imines 
A suspension of benzenesulfonyl carbamic ester (8.15 mmol), K2CO3 (48.9 mmol) and Na2SO4 
(57.1 mmol) in THF (82 mL) was stirred under reflux for 3h. The mixture was cooled to rt, 
filtered through a sintered funnel and concentrated in vacuo. The imine was used without 
further purification.  
 
 
tert-Butyl (4-fluorobenzylidene)-carbamate (189e) 
Following general procedure G with sulfone 122e (1.12 g, 3.07 mmol), K2CO3 (2.54 g, 18.4 
mmol) and Na2SO4 (3.05 g, 21.5 mmol) gave the title compound (635 mg, 2.86 mmol, 93% 
yield) as a white solid. Mp 66.0-68.5 °C; 1H NMR (400 MHz, CDCl3): δ 8.85 (1H, s, H-1), 7.96-
7.90 (2H, m, H-2), 7.18-7.11 (2H, m, H-3), 1.58 (9H, s, (CH3)3) ppm; 13C NMR (101 MHz, CDCl3): 
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δ 168.5 (CH), 166.2 (d, JF = 257 Hz, CF), 162.5 (C=O), 132.7 (d, JF = 9.5 Hz, CH), 130.5 (d, JF = 
2.8 Hz, C), 116.4 (d, JF = 22.2 Hz CH), 82.5 (C), 28.0 (CH3) ppm; 19F NMR (376 MHz, CDCl3): δ -
103.9 ppm; HRMS (ESI) 224.1086 (M + H+. C12H15FNO2 requires 224.1081), 278.1166 (M + Na+. 
C13H18FNNaO3 requires 278.1163 for the methanol adduct); IR (ATR): νmax 3332, 2978, 1700 
(C=O), 1606, 1507, 1367, 1225, 1155 cm-1. 
 
 
tert-Butyl (4-methoxy-benzylidene)-carbamate (189f) 
Following general procedure G with sulfone 122f (1.07 g, 2.84 mmol), K2CO3 (2.35 g, 17.0 
mmol) and Na2SO4 (2.83 g, 19.9 mmol) gave the title compound (601 mg, 2.56 mmol, 90% 
yield) as a white solid. Mp 85.5-88.5 °C; 1H NMR (400 MHz, CDCl3): δ 8.87 (1H, s, H-1), 7.91-
7.85 (2H, m, H-2), 6.98-6.91 (2H, m, H-3), 3.86 (3H, s, H-4), 1.57 (9H, s, (CH3)3) ppm; 13C NMR 
(101 MHz, CDCl3): δ 170.0 (CH), 164.3 (C), 163.0 (C=O), 132.7 (CH), 127.0 (C), 114.4 (CH), 82.0 
(C), 55.6 (CH3), 28.0 (CH3) ppm; HRMS (ESI) 236.1290 (M + H+. C13H18NO3 requires 236.1281), 
290.1370 (M + Na+. C14H21NNaO4 requires 290.1363 for the methanol adduct); IR (ATR): νmax 
3374, 2977, 2935, 1705 (C=O), 1599, 1573, 1512, 1367, 1248, 1219, 1139 cm-1. 
 
 
tert-Butyl (pyridin-3-ylmethylene)-carbamate (189g) 
Following general procedure G with sulfone 122g (1.01 g, 2.90 mmol), K2CO3 (2.40 g, 17.4 
mmol) and Na2SO4 (2.88 g, 20.3 mmol) gave the title compound (642 mg, 3.11 mmol, 107% 
yield) as a yellow oil. 1H NMR (400 MHz, CDCl3): δ 9.01 (1H, d, J = 1.5 Hz, H-5), 8.89 (1H, s, H-
1), 8.77 (1H, dd, J = 4.8, 1.5 Hz, H-4), 8.28 (1H, ddd, J = 8.2, 1.5, 1.5 Hz, H-2), 7.42 (1H, dd, J = 
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8.2, 4.8 Hz, H-3), 1.59 (9H, s, (CH3)3) ppm; 13C NMR (101 MHz, CDCl3): δ 166.9 (CH), 162.1 
(C=O), 154.0 (CH), 136.0 (CH), 130.0 (CH), 83.0 (C), 28.0 (CH3) ppm; HRMS (ESI) 207.1133 (M 
+ H+. C11H15N2O2 requires 207.1128); IR (ATR): νmax 3199, 2977, 2932, 1708, 1511, 1367, 1269, 
1247, 1155 cm-1. 
 
 
tert-Butyl (4-methyl-thiazol-5-ylmethylene)-carbamate (189h) 
Following general procedure G with sulfone 122h (3.00 g, 8.15 mmol), K2CO3 (6.75 g, 48.9 
mmol) and Na2SO4 (8.11 g, 57.1 mmol) gave the title compound (1.81 g, 8.07 mmol, 99% yield) 
as an orange oil. 1H NMR (400 MHz, CDCl3): δ 9.17 (1H, d, J = 0.5 Hz, H-2), 8.88 (1H, s, H-1), 
2.68 (3H, s, H-3), 1.55 (9H, s, (CH3)3) ppm; 13C NMR (101 MHz, CDCl3): δ 162.3 (C=O), 161.8 (C), 
161.7 (CH), 158.2 (CH), 129.7 (C), 82.7 (C), 27.8 (CH3), 16.3 (CH3) ppm; HRMS (ESI) 281.0917 
(M + Na+. C11H18N2NaO3S requires 281.0930 for the methanol adduct); IR (ATR): νmax 2982, 
2931, 1705 (C=O), 1600, 1512, 1366, 1243, 1150 cm-1. 
 
 
tert-Butyl (1-methyl-1H-pyrazol-4-ylmethylene)-carbamate (189i) 
Following general procedure G with sulfone 122i (1.06 g, 3.02 mmol), K2CO3 (2.50 g, 18.1 
mmol) and Na2SO4 (3.00 g, 21.1 mmol) gave the title compound (602 mg, 2.87 mmol, 95% 
yield) as a colourless oil. 1H NMR (400 MHz, CDCl3): δ 8.92 (1H, s, H-1), 7.98 (1H, s, H-2), 7.94 
(1H, s, H-3), 3.94 (3H, s, H-4), 1.55 (9H, s, (CH3)3) ppm; 13C NMR (101 MHz, CDCl3): δ 163.3 
(CH), 162.8 (C=O), 141.8 (CH), 133.6 (CH), 119.9 (C), 81.9 (C), 39.6 (CH3), 28.0 (CH3) ppm; HRMS 
(ESI) 210.1239 (M + H+. C10H16N3O2 requires 210.1237), 264.1318 (M + Na+. C11H19N3NaO3 
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requires 264.1318 for the methanol adduct); IR (ATR): νmax 2980, 1706 (C=O), 1613, 1392, 
1367, 1246, 1149 cm-1. 
 
 
tert-Butyl (4-cyano-benzylidene)-carbamate (189j) 
Following general procedure G with sulfone 122j (1.15 g, 3.13 mmol), K2CO3 (2.59 g, 18.8 
mmol) and Na2SO4 (3.11 g, 21.9 mmol) gave the title compound (723 mg, 3.13 mmol, 100% 
yield) as a white amorphous solid. 1H NMR (400 MHz, CDCl3): δ 8.82 (1H, s, H-1), 8.03-7.97 
(2H, m, H-3), 7.79-7.74 (2H, m, H-2), 1.58 (9H, s, (CH3)3) ppm; 13C NMR (101 MHz, CDCl3): δ 
167.0 (CH), 162.0 (C=O), 137.9 (C), 132.7 (CH), 130.3 (CH), 118.1 (C), 116.5 (C), 83.3 (C), 28.0 
(CH3) ppm; HRMS (ESI) 231.1124 (M + H+. C13H15N2O2 requires 231.1128); IR (ATR): νmax 3357, 
2979, 2230 (CN), 1709 (C=O), 1630, 1502, 1368, 1252, 1150 cm-1. 
 
 
tert-Butyl (4-trifluoromethyl-benzylidene)-carbamate (189k) 
Following general procedure G with sulfone 122k (1.09 g, 2.63 mmol), K2CO3 (2.18 g, 15.8 
mmol) and Na2SO4 (2.61 g, 18.4 mmol) gave the title compound (710 mg, 2.60 mmol, 99% 
yield) as a white amorphous white solid. 1H NMR (400 MHz, CDCl3): δ 8.87 (1H, s, H-1), 8.02 
(2H, d, J = 8.2 Hz, H-2), 7.73 (2H, d, J = 8.2 Hz, H-3), 1.59 (9H, s, (CH3)3) ppm; 13C NMR (101 MHz, 
CDCl3): δ 167.8 (CH), 162.2 (C=O), 137.2 (C), 134.7 (q, JF = 32.8 Hz, C), 130.4 (CH), 126.0 (q, JF 
= 3.7 Hz, CH), 123.7 (q, JF = 274 Hz, CF3), 83.1 (C), 28.0 (CH3) ppm; 19F NMR (376 MHz, CDCl3): 
δ -63.0 ppm; HRMS (ESI) 328.1131 (M + Na+. C14H18F3NNaO3 requires 328.1131 for the 
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methanol adduct); IR (ATR): νmax 3354, 2980, 1701 (C=O), 1496, 1366, 1322, 1164, 1126, 1064 
cm-1. 
 
 
Methyl 2-[tert-butoxycarbonylamino-(4-fluorophenyl)-methyl]-3-oxo-butyrate (191) 
To a solution of Chan’s diene (87 mg, 0.336 mmol) in CH2Cl2 (1 mL) at -20 oC was added 
Cu(OTf)2 (8.1 mg, 0.0224 mmol). A solution of imine 189e (50 mg, 0.224 mmol) in CH2Cl2 (2 
mL) was added and the reaction was stirred at -20 oC overnight. The reaction was quenched 
with the addition of sat. aq. NaHCO3 (3 mL), and the mixture was warmed to rt with vigorous 
stirring. When the aqueous layer turned blue, the layers were separated. The aqueous layer 
was extracted with CH2Cl2 (2 x 3 mL). The organics were combined, washed with brine (5 mL), 
dried (MgSO4), filtered and concentrated in vacuo to give the title compound (47 mg, 0.139 
mmol, 62% yield) as a colourless oil after column chromatography (10-15% EtOAc/petroleum 
ether (40-60)). A 1:1 ratio of rotamers was observed. 1H NMR (400 MHz, CDCl3): δ 7.31-7.21 
(2H, m, H-3), 7.06-6.95 (2H, m, H-4), 6.15 (0.5H, br. s, NH), 5.80 (0.5H, br. s, NH), 5.50 (0.5H, 
br. s, H-2), 5.39 (0.5H, br. s, H-2), 4.7-3.88 (1H, m, H-1), 3.68 (1.5H, s, OCH3), 3.63 (1.5H, s, 
OCH3), 2.31 (1.5H, s, CH3), 2.16 (1.5H, s, CH3), 1.41 (4.5H, s, (CH3)3), 1.39 (4.5H, s, (CH3)3) ppm; 
13C NMR (101 MHz, CDCl3): δ 201.1 (C=O), 169.2 (C=O), 167.8 (C=O), 162.2 (d, JF = 248 Hz, C), 
155.3 (C), 155.1 (C), 135.7 (C), 135.5 (C), 128.3 (d, JF = 8.0 Hz, CH), 128.0 (d, JF = 8.2 Hz, CH), 
115.8 (d, JF = 5.1 Hz, CH), 115.6 (d, JF = 4.9 Hz, CH), 80.3 (C), 80.2 (C), 64.4 (CH), 63.4 (CH), 52.9 
(CH3), 52.6 (CH3), 30.6 (CH3), 29.0 (CH3), 28.4 (CH3) ppm; 19F NMR (376 MHz, CDCl3): δ -114.6, 
-114.7 ppm; HRMS (ESI) 362.1374 (M + Na+. C17H22FNNaO5 requires 362.1374); IR (ATR): νmax 
3358, 2979, 1712 (C=O), 1510, 1366, 1287, 1250, 1226, 1159 cm-1. 
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General Procedure H - One-Pot cyclisation 
To a solution of imine (1.14 mmol) in CH2Cl2 (11.4 mL) at -78 oC was added TiCl4 (4.56 mmol). 
Chan’s diene (2.28 mmol) was added and the mixture was stirred for 30 mins at -78 oC. To the 
mixture was added MeOH (18.2 mmol), and the mixture was stirred for 4h at rt. Ketone (5.70 
mmol) and NaHCO3 (45.6 mmol) were sequentially added, and the reaction was stirred 
overnight at rt. The reaction was quenched with 1.59M citric acid in MeOH (11.4 mmol), and 
the mixture was cooled to 0 oC. Water (8 mL) was carefully added, followed by dilution with 
CH2Cl2 (10 mL). The mixture was stirred vigorously for 30 mins at rt. The layers were separated 
and the aqueous layer was extracted with CH2Cl2 (2 x 10 mL). Organics were combined, 
washed with sat. aq. NaHCO3 (20 mL) and brine (20 mL), dried (MgSO4), filtered and 
concentrated in vacuo. The crude residue was purified by column chromatography.   
 
 
Methyl 6-(4-fluoro-phenyl)-4-oxo-1-aza-spiro[5.5]undecane-3-carboxylate (135c) 
Following general procedure H with imine 189e (175 mg, 0.785 mmol), TiCl4 (344 μL, 3.14 
mmol), Chan’s diene (408 mg, 1.57 mmol), MeOH (509 μL, 12.6 mmol), cyclohexanone (406 
µL, 3.93 mmol) and NaHCO3 (2.63 g, 31.4 mmol). Purification by column chromatography 
(50% EtOAc/hexane then 100% EtOAc) gave the title compound as a mixture of diastereomers 
(153 mg, 0.479 mmol, 61% yield, 5:1 dr) as a yellow oil. Data was consistent with the reported 
data for 135c on page 142. 
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Methyl 6-(4-cyano-phenyl)-4-oxo-1-aza-spiro[3.5]nonane-3-carboxylate (137b) 
Following general procedure H with imine 189j (87 mg, 0.377 mmol), TiCl4 (238 μL, 2.17 
mmol), Chan’s diene (283 mg, 1.09 mmol), MeOH (351 μL, 8.69 mmol), cyclobutanone (199  
μL, 2.72 mmol) and NaHCO3 (1.82 g, 21.7 mmol). Purification by column chromatography 
(25% EtOAc/hexane) gave the title compound as a mixture of diastereomers (41 mg, 0.139 
mmol, 37% yield, 2.5:1 dr) as a yellow oil. Data was consistent with the reported data for 137b 
on page 144. 
 
 
Methyl 6-(4-fluorophenyl)-4-oxo-9-oxa-1-aza-spiro[5.5]undecane-3-carboxylate (138b) 
Following general procedure H with imine 189e (86 mg, 0.386 mmol), TiCl4 (169 μL, 1.54 
mmol), Chan’s diene (200 mg, 0.772 mmol), MeOH (250 μL, 6.18 mmol), tetrahydro-4H-pyran-
4-one (193 mg, 1.93 mmol) and NaHCO3 (1.29 g, 15.4 mmol). Purification by column 
chromatography (20% EtOAc/hexane) gave the title compound as a mixture of diastereomers 
(86 mg, 0.266 mmol, 69% yield, 2:1 dr) as a yellow oil. Data was consistent with the reported 
data for 138b on page 145. 
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Methyl 6-(4-methoxyphenyl)-4-oxo-9-oxa-1-azaspiro[5.5]undecane-3-carboxylate (138c) 
Following general procedure H with imine 189f (138 mg, 0.587 mmol), TiCl4 (258 μL, 2.35 
mmol), Chan’s diene (304 mg, 1.17 mmol), MeOH (379 μL, 9.39 mmol), tetrahydro-4H-pyran-
4-one (294 mg, 2.94 mmol) and NaHCO3 (1.97 g, 23.5 mmol). Purification by column 
chromatography (30% EtOAc/hexane) gave the title compound as a mixture of diastereomers 
(121 mg, 0.363 mmol, 62% yield, 1.5:1 dr) as a red oil. Data was consistent with the reported 
data for 138c on page 146. 
 
 
Methyl 6-(4-methyl-thiazol-5-yl)-4-oxo-9-oxa-1-aza-spiro[5.5]undecane-3-carboxylate 
(138e) 
Following general procedure H with imine 189h (145 mg, 0.642 mmol), TiCl4 (282 μL, 2.57 
mmol), Chan’s diene (333 mg, 1.28 mmol), MeOH (416 μL, 10.3 mmol), tetrahydro-4H-pyran-
4-one (321 mg, 3.21 mmol) and NaHCO3 (2.16 g, 25.7 mmol). Purification by column 
chromatography (50% EtOAc/hexane then 100% EtOAc) gave the title compound as a mixture 
of diastereomers (102 mg, 0.315 mmol, 49% yield, 2.5:1 dr) as an orange solid. Data was 
consistent with the reported data for 138e on page 147. 
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Methyl 6-(1-methyl-1H-pyrazol-4-yl)-4-oxo-9-oxa-1-azaspiro[5.5]undecane-3-carboxylate 
(138f) 
Following general procedure H with imine 189i (138 mg, 0.660 mmol), TiCl4 (289 μL, 2.64 
mmol), Chan’s diene (343 mg, 1.32 mmol), MeOH (428 μL, 10.6 mmol), tetrahydro-4H-pyran-
4-one (330 mg, 3.30 mmol) and NaHCO3 (2.22 g, 26.4 mmol). Purification by column 
chromatography (100% EtOAc) gave the title compound as a mixture of diastereomers (14 
mg, 0.0462 mmol, 7% yield) as a red oil. Data was consistent with the reported data for 138f 
on page 148. 
 
 
Methyl 6-(4-methyl-thiazol-5-yl)-4-oxo-9-thia-1-aza-spiro[5.5]undecane-3-carboxylate 
(195) 
Following general procedure H with imine 189h (149 mg, 0.659 mmol), TiCl4 (289 μL, 2.64 
mmol), Chan’s diene (343 mg, 1.32 mmol), MeOH (424 μL, 10.5 mmol), tetrahydro-4H-
thiopyran-4-one (383 mg, 3.30 mmol) and NaHCO3 (2.22 g, 26.4 mmol). Purification by column 
chromatography (40% EtOAc/hexane) gave the title compound as a mixture of diastereomers 
(123 mg, 0.362 mmol, 55% yield, 3:1 dr) as a red oil. Data presented is for the major 
diastereomer. 1H NMR (400 MHz, CDCl3): δ 8.67 (1H, s, H-7), 4.43-4.32 (1H, m, H-6), 3.72 (3H, 
s, OCH3), 3.31 (1H, br. s, H-3), 3.16-3.06 (1H, m, H-10), 3.02 (1H, dd, J = 13.7, 11.5 Hz, H-5), 
3.05-2.94 (1H, m, H-10), 2.62 (1H, ddd, J = 13.7, 3.5, 1.0 Hz, H-5), 2.48 (3H, s, H-8), 2.42-2.33 
(2H, m, H-10), 2.12-1.75 (4H, m, H-9 and NH), 1.71 (1H, ddd, J = 14.5, 11.7, 3.2 Hz, H-9) ppm; 
13C NMR (101 MHz, CDCl3): δ 202.6 (C=O), 168.7 (C=O), 150.3 (C), 149.8 (C), 133.1 (C), 67.2 
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(CH), 59.1 (C), 52.6 (CH3), 48.4 (CH), 46.9 (CH2), 37.2 (CH2), 34.3 (CH2), 23.3 (CH2), 22.7 (CH2), 
15.7 (CH3) ppm; HRMS (ESI) 341.0990 (M + H+. C15H21N2O3S2 requires 341.0988); IR (ATR): νmax 
3314, 2952, 2922, 1705 (C=O), 1434, 1415, 1315, 1266, 1196, 1163 cm-1. 
 
 
6-(4-Methyl-thiazol-5-yl)-4-oxo-1,9-diaza-spiro[5.5]undecane-3,9-dicarboxylic acid 9-
benzyl ester 3-methyl ester (196) 
Following general procedure H with imine 189h (119 mg, 0.527 mmol), TiCl4 (231 μL, 2.11 
mmol), Chan’s diene (260 mg, 1.05 mmol), MeOH (341 μL, 8.43 mmol), 1-Z-4-piperidone (615 
mg, 2.64 mmol) and NaHCO3 (1.77 g, 21.1 mmol). Purification by column chromatography 
(40% EtOAc/hexane then 80% EtOAc/hexane) gave the title compound as a mixture of 
diastereomers (107 mg, 0.473 mmol, 45% yield, 2.5:1 dr) as an orange oil. Data presented is 
for the major diastereomer. 1H NMR (400 MHz, CDCl3): δ 8.67 (1H, s, H-7), 7.39-7.27 (5H, m, 
ArH), 5.11 (2H, s, H-11), 4.46-4.33 (1H, m, H-6), 3.95-3.76 (2H, m, H-10), 3.73 (3H, s, OCH3), 
3.43-3.24 (2H, m, H-10), 3.29 (1H, br. s, H-3), 3.05 (1H, dd, J = 13.5, 11.2 Hz, H-5), 2.70-2.60 
(1H, m, H-5), 2.46 (3H, s, H-8), 2.04 (1H, br. s, NH), 1.93-1.37 (4H, m, H-9) ppm; 13C NMR 
(101 MHz, CDCl3): δ 202.3 (C=O), 168.7 (C=O), 155.2 (C=O), 150.3 (CH), 149.9 (C), 136.7 (C), 
132.9 (C), 128.6 (CH), 128.2 (CH), 128.1 (CH), 67.3 (CH2), 66.7 (CH), 58.5 (C), 52.7 (CH3), 48.9 
(CH), 47.0 (CH2), 39.5 (CH2), 39.1(CH2), 35.6 (CH2), 32.4 (CH2), 15.7 (CH3) ppm; HRMS (ESI) 
458.1747 (M + H+. C23H28N3O5S requires 458.1744); IR (ATR): νmax 2951, 1698 (C=O), 1432, 
1247, 1165 cm-1. 
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Methyl 4-oxo-6-(4-trifluoromethyl-phenyl)-1-aza-spiro[5.5]undecane-3-carboxylate (197) 
Following general procedure H with imine 189k (314 mg, 1.15 mmol), TiCl4 (504 μL, 4.60 
mmol), Chan’s diene (598 mg, 2.30 mmol), MeOH (743 μL, 18.4 mmol), cyclohexanone (595 
μL, 5.75 mmol) and NaHCO3 (3.86 g, 46.0 mmol). Purification by column chromatography 
(10% EtOAc/hexane) gave an inseparable mixture of product and cyclohexanone. The mixture 
was dissolved in EtOAc (20 mL) and washed with water (10 x 10 mL), dried (MgSO4), filtered 
and concentrated to give the title compound as a mixture of diastereomers (117 mg, 0.322 
mmol, 28% yield, 1.5:1 dr) as a yellow oil. Data presented is for the major diastereomer. 1H 
NMR (400 MHz, CDCl3): δ 7.67-7.55 (4H, m, H-7 and H-8), 4.18 (1H, dd, J = 11.2, 3.8 Hz, H-6), 
3.73 (3H, s, OCH3), 3.42 (1H, br. s, H-3), 3.06 (1H, dd, J = 13.5, 11.2 Hz, H-5), 2.57 (1H, ddd, J = 
13.5, 3.8, 1.0 Hz, H-5), 1.78-1.29 (10H, m, cyclohexyl) ppm; 13C NMR (101 MHz, CDCl3): δ 204.6 
(C=O), 169.5 (C=O), 146.4 (C), 130.0 (q, JF = 32.4 Hz, C), 127.1 (CH), 125.9 (q, JF = 3.5 Hz, CH), 
124.1 (q, JF = 273 Hz, C), 66.6 (CH), 60.3 (C), 54.9 (CH), 52.3 (CH3), 45.8 (CH2), 36.6 (CH2), 33.3 
(CH2), 25.6 (CH2), 21.5 (CH2), 21.0 (CH2) ppm; 19F NMR (376 MHz, CDCl3): δ -62.4 ppm; HRMS 
(ESI) 370.1606 (M + H+. C19H23F3NO3 requires 370.1625); IR (ATR): νmax 2933, 2857, 1706 (C=O), 
1324, 1164, 1123, 1068 cm-1. 
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6-(4-Cyano-phenyl)-4-oxo-1,9-diaza-spiro[5.5]undecane-3,9-dicarboxylic acid 9-benzyl 
ester 3-methyl ester (198) 
Following general procedure H with imine 189j (131 mg, 0.570 mmol), TiCl4 (250 μL, 2.28 
mmol), Chan’s diene (296 mg, 1.14 mmol), MeOH (368 μL, 9.12 mmol), 1-Z-4-piperidone (664 
mg, 2.85 mmol) and NaHCO3 (1.92 g, 22.8 mmol). Purification by column chromatography 
(30% EtOAc/hexane) gave the title compound as a mixture of diastereomers (62 mg, 0.137 
mmol, 24% yield, 4:1 dr) as a yellow oil. Data presented is for the major diastereomer. 1H NMR 
(400 MHz, CDCl3): δ 7.71-7.64 (2H, m, H-8), 7.59-7.52 (2H, m, H-7), 7.39-7.28 (5H, m, ArH), 
5.10 (2H, s, H-11), 4.19-4.08 (1H, m, H-6), 3.92-3.75 (2H, m, H-10), 3.73 (3H, s, OCH3), 3.46-
3.34 (1H, m, H-10), 3.32 (1H, d, J = 1.0 Hz, H-3), 3.32-3.18 (1H, m, H-10), 3.03 (1H, dd, J = 13.7, 
11.5 Hz, H-5), 2.61 (1H, dd, J = 13.7, 3.5 Hz, H-5), 1.89-1.37 (4H, m, H-9) ppm; 13C NMR 
(101 MHz, CDCl3): δ 203.0 (C=O), 169.0 (C=O), 155.2 (C=O), 146.8 (C), 136.7 (C), 132.8 (CH), 
128.6 (CH), 128.2 (CH), 128.0 (CH), 127.5 (CH), 118.6 (CN), 112.0 (C), 67.3 (CH2), 66.7 (CH), 
58.9 (C), 55.0 (CH), 52.6 (CH3), 45.2 (CH2), 39.5 (CH2), 39.0 (CH2), 35.6 (CH2), 32.3 (CH2) ppm; 
HRMS (ESI) 462.2025 (M + H+. C26H28N3O5 requires 462.2023), 484.1841 (M + Na+. 
C26H27N3NaO5 requires 484.1843); IR (ATR): νmax 2952, 2227 (CN), 1694 (C=O), 1431, 1231, 
1164, 1120 cm-1. 
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Methyl 2,2-dimethyl-6-(4-methyl-thiazol-5-yl)-4-oxo-piperidine-3-carboxylate (199) 
Following general procedure H with imine 189h (321 mg, 1.42 mmol), TiCl4 (623 μL, 5.68 
mmol), Chan’s diene (738 mg, 2.84 mmol), MeOH (917 μL, 22.7 mmol), acetone (630 μL, 8.52 
mmol) and NaHCO3 (4.77 g, 56.8 mmol). Purification by column chromatography (75% 
EtOAc/hexane) gave the title compound as a mixture of diastereomers (96 mg, 0.341 mmol, 
24% yield, 1:1.5 dr) as a red solid. Data presented is for the major diastereomer. Mp 101.5-
106 oC; 1H NMR (400 MHz, CDCl3): δ 8.64 (1H, s, H-7), 4.62 (1H, dd, J = 11.0, 3.5 Hz, H-6), 3.74 
(3H, s, OCH3), 3.61 (1H, s, H-3), 2.59 (1H, dd, J = 13.5, 3.5 Hz, H-5), 2.43-2.40 (1H, m, H-5), 2.41 
(3H, s, H-8), 1.44 (3H, s, CH3), 1.32 (3H, s, CH3) ppm; 13C NMR (101 MHz, CDCl3): δ 202.3 (C=O), 
168.4 (C=O), 151.2 (CH), 148.7 (C), 134.1 (C), 66.9 (CH), 56.8 (C), 52.0 (CH3), 49.5 (CH2), 48.9 
(CH), 30.0 (CH3), 22.7 (CH3), 15.5 (CH3) ppm; HRMS (ESI) 283.1112 (M + H+. C13H19N2O3S 
requires 283.1111); IR (ATR): νmax 2953, 1747 (C=O), 1713 (C=O), 1435, 1341, 1276, 1192, 1121 
cm-1. 
 
 
Octa-1,7-diene-4,5-diol (212) 
A suspension of glyoxal (40 wt. % in water) (3 mL, 26.2 mmol), allyl bromide (5.66 mL, 65.4 
mmol), and tin powder (7.76 g, 65.4 mmol) in water (13 mL) and THF (13 mL) was sonicated 
in a rt water bath for 4.5h. The mixture was quenched with 25% aqueous KOH (30 mL) at rt. 
The mixture was diluted with diethyl ether (50 mL) and filtered through Celite, washing with 
diethyl ether (2 x 50 mL). The layers were separated and the organic layer was dried (MgSO4), 
filtered and concentrated in vacuo. The crude residue was purified by column 
chromatography (0-70% EtOAc/cyclohexane) to give the title compound (2.63 g, 18.6 mmol, 
71% yield) as a colourless oil. 1H NMR (400 MHz, CDCl3): δ 5.92-5.80 (2H, m, H-2), 5.21-5.11 
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(4H, m, H-1), 3.71-3.51 (2H, m, H-4), 2.42-2.32 (2H, m, O-H), 2.32-2.13 (4H, m, H-3) ppm; 13C-
NMR (101 MHz, CDCl3): δ 134.7 (CH), 134.4 (CH), 118.3 (CH2), 118.1 (CH2), 72.8 (CH), 72.7 (CH), 
38.2 (CH2), 36.4 (CH2) ppm; HRMS (ESI) 165.0876 (M + Na+. C8H14NaO2 requires 165.0886); IR 
(ATR): νmax 3310, 3077, 2978, 2941, 2901, 1642, 1497, 1434, 1214, 1050, 988, 913, 867 cm-1. 
 
 
But-3-enal (210b) 
Sodium periodate (2.56 g, 12.0 mmol) was added to a biphase of octa-1,7-diene-4,5-diol 212 
(1.70 g, 12.0 mmol) in CH2Cl2 (6 mL) and water (6 mL) at 0 °C. The mixture was stirred for 3h 
at 0 °C. Layers were separated and the aqueous was extracted with CH2Cl2 (2 x 1 mL). Organics 
were combined and passed through a phase separator to afford the title compound (1.38 g, 
19.7 mmol, 82% yield) as a colourless 12.1 wt. % solution in CH2Cl2. 1H NMR (400 MHz, CDCl3): 
δ 9.71 (1H, t, J = 2.0 Hz, H-4), 5.94 (1H, ddt, J = 17.0, 10.5, 7.0 Hz, H-2), 5.34-5.21 (2H, m, H-1), 
3.23-3.18 (2H, m, H-3) ppm; 13C-NMR (101 MHz, CDCl3): δ 199.6 (C=O), 128.1 (CH), 120.2 
(CH2), 48.2 (CH2) ppm; HRMS (ESI) 93.0314 (M + Na+. C4H6NaO requires 93.0311). Data was 
consistent with literature.208 
 
 
tert-Butyl (1-phenylsulfonyl)but-3-en-1-yl)carbamate (214) 
Water (19.5 mL), sodium benzenesulfinate (3.20 g, 19.5 mmol) and formic acid (3.74 mL, 98.0 
mmol) were sequentially added to a solution of but-3-enal 210b (12.1 wt. % in CH2Cl2) (11.3 
g, 19.5 mmol) and tert-butyl carbamate (2.29 g, 19.5 mmol) in CH2Cl2 (12 mL) (19.5 mL total 
CH2Cl2). The biphasic mixture was stirred for 2 days at rt. Layers were separated and the 
aqueous was extracted with CH2Cl2 (2 x 20 mL). Organics were combined, passed through a 
phase separator and concentrated in vacuo. The white solid was stirred in 10% 
Et2O/cyclohexane for 20 mins then filtered to give the title compound (3.90 g, 12.5 mmol, 
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64% yield) as a white solid. Mp 95.5-98 oC; 1H NMR (400 MHz, CDCl3): δ 7.96-7.91 (2H, m, 
ArH), 7.68-7.52 (3H, m, ArH), 5.92-5.76 (1H, m, H-2), 5.28-5.20 (2H, m, H-1), 5.06 (1H, br. d,  J 
= 10.0 Hz, NH), 4.96 (1H, td, J = 10.0, 4.0 Hz, H-4), 3.02-2.92 (1H, m, H-3), 2.70-2.58 (1H, m, H-
3), 1.23 (9H, s, (CH3)3) ppm; 13C-NMR (101 MHz, CDCl3): δ 153.7 (C=O), 136.9 (C), 133.9 (CH), 
131.1 (CH), 129.3 (CH), 129.1 (CH), 119.8 (CH2), 80.8 (C), 69.9 (CH), 31.2 (CH2), 28.0 (CH3) ppm; 
HRMS (ESI) 334.1082 (M + Na+. C15H21NNaO4S requires 334.1083); IR (ATR): νmax 3326, 2985, 
1686 (C=O), 1523, 1324, 1305, 1161, 1140, 1084 cm-1. 
 
 
tert-Butyl(buta-1,3-dien-1-yl)carbamate (219) 
Isolated as a consequence of the reaction between tert-butyl (1-phenylsulfonyl)but-3-en-1-
yl)carbamate 214 (1 eq) and NaH (3 eq) as an inseparable 4:1 E:Z mixture. (E)-tert-Butyl (buta-
1,3-dien-1-yl)carbamate: 1H NMR (400 MHz, CDCl3): δ 6.71 (1H, dd, J = 11.0, 10.5 Hz, H-4), 
6.26 (1H, ddd, J = 17.0, 11.0, 10.5 Hz, H-2), 5.64 (1H, dd, J = 11.0, 10.5 Hz, H-3), 5.00 (1H, d, J 
= 17.0 Hz, H-1), 4.87 (1H, d, J = 10.5 Hz, H-1), 1.47 (9H, s, (CH3)3) ppm; 13C-NMR (101 MHz, 
CDCl3): δ 152.5 (C=O), 134.7 (CH), 127.4 (CH), 112.7 (CH2), 111.0 (CH), 80.9 (C), 28.2 (CH3) 
ppm; (Z)-tert-Butyl (buta-1,3-dien-1-yl)carbamate: 1H NMR (400 MHz, CDCl3): δ 6.51-6.33 (2H, 
m, H-4 and H-2), 5.43-5.23 (1H, m, H-3), 5.21-5.14 (1H, m, H-3), 5.05-5.02 (1H, m, H-1), 1.49 
(9H, s, (CH3)3) ppm; 13C-NMR (101 MHz, CDCl3): δ 152.4 (C=O), 129.0 (CH), 123.1 (CH), 115.5 
(CH2), 107.1 (CH), 28.2 (CH3) ppm; IR (ATR): νmax 2971, 1694 (C=O), 1505, 1367, 1251, 1160, 
950 cm-1. 1H NMR was consistent with literature.209 
 
 
6-(Phenylsulfonyl)-1-tosyl-1,4,5,6-tetrahydropyridine (224) 
Glutaraldehyde (50% in water) (1.13 mL, 6.00 mmol) was added to a stirred solution of 4-
methylbenzenesulfonamide (1.03 g, 6.00 mmol) and sodium benzenesulfinate (0.985 g, 6.00 
191 
 
mmol) in water (10 mL) and formic acid (10 mL) at 40 °C. The mixture was stirred overnight 
at 40 °C. The white precipitate was filtered warm and washed with water (20 mL) and 
cyclohexane (20 mL). The white solid was stirred vigorously in a biphase of CH2Cl2 (20 mL) and 
sat. Aq. NaHCO3 (20 mL) for 1h at rt. Layers were separated and the aqueous was extracted 
with water (2 x 20 mL). Organics were combined, passed through a phase separator and 
concentrated in vacuo to give the title compound (1.45 g, 3.84 mmol, 64% yield) as a white 
solid. Mp 133-133.5 oC; 1H NMR (400 MHz, CDCl3): δ 8.03-7.98 (2H, m, ArH), 7.76-7.71 (1H, m, 
ArH), 7.67-7.61 (2H, m, ArH), 7.54 (2H, d, J = 8.5 Hz, ArH), 7.30 (2H, d, J = 8.5 Hz, ArH), 6.60-
6.54 (1H, m, H-2), 5.34-5.28 (1H, m, H-3), 5.04 (1H, br. d, J = 5.0 Hz, H-6), 2.70-2.62 (1H, m, H-
5), 2.62-2.50 (1H, m, H-4), 1.96-1.86 (1H, m, H-4), 1.25-1.13 (1H, m, H-5) ppm; 13C-NMR 
(101 MHz, CDCl3): δ 144.4 (C), 136.6 (C), 134.4 (C), 134.3 (CH), 129.9 (CH), 129.8 (CH), 129.0 
(CH), 127.1 (CH), 112.5 (CH), 71.5 (CH), 21.6 (CH3), 18.4 (CH2), 17.9 (CH2) ppm; HRMS (ESI) 
400.0649 (M + Na+. C18H19NNaO4S2) requires 400.0648); IR (ATR): νmax 3059, 2922, 1659, 1595, 
1450, 1364, 1322, 1308, 1172, 1144, 1084 cm-1. 
 
 
4-((Triisopropylsilyloxy)butan-1-ol (236) 
1,4-Butanediol (3.53 mL, 40.0 mmol) was added over 20 mins via syringe pump to a slurry of 
NaH (60% dispersion in mineral oil, 1.76 g, 44.0 mmol) in THF (57 mL) at 0 oC and the mixture 
stirred for 30 mins. Triisopropylsilyl chloride (8.56 mL, 40.0 mmol) was added over 20 mins 
via syringe pump at 0 oC, and the reaction was stirred overnight at rt. The reaction was 
quenched with sat. aq. NH4Cl (20 mL) and diluted with diethyl ether (100 mL). The layers were 
separated and the aqueous was extracted with diethyl ether (2 x 50 mL). The organics were 
combined, dried (MgSO4), filtered and concentrated in vacuo. The crude residue was purified 
by column chromatography (20% EtOAc/hexane) to give the title compound (9.08 g, 36.8 
mmol, 92% yield) as a colourless oil. 1H NMR (400 MHz, CDCl3): δ 3.74 (2H, t, J = 5.5 Hz, H-4), 
3.68-3.61 (2H, m, H-1), 1.73-1.60 (4H, m, H-2 and H-3), 1.09-1.01 (21H, m, OTIPS) ppm; 13C 
NMR (101 MHz, CDCl3): δ 63.7 (CH2), 62.9 (CH2), 30.5 (CH2), 30.2 (CH2), 18.1 (CH3), 12.0 (CH) 
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ppm; HRMS (ESI) 269.1871 (M + Na+. C13H30O2Si requires 269.1907); IR (ATR): νmax 3334, 2941, 
2891, 2865, 1463, 1247, 1103, 1061 cm-1. 
 
 
4-((Triisopropylsilyl)oxy)butanal (237) 
To a solution of oxalyl chloride (2.06 mL, 24.3 mmol) in CH2Cl2 (225 mL) at -78 oC was added 
DMSO (1.8 mL, 25.4 mmol). The mixture was stirred for 1h before the addition of alcohol 236 
(5.00 g, 20.3 mmol) at -78 oC, and the reaction mixture was stirred for a further 1h. 
Triethylamine (14.2 mL, 102 mmol) was added and the mixture was stirred for 30 mins at rt. 
2M HCl (15 mL) was added and the layers were separated. The aqueous layer was extracted 
with CH2Cl2 (2 x 20 mL). The organics were combined, washed with 2M HCl (50 mL) and brine 
(100 mL), dried (MgSO4), filtered and concentrated in vacuo. The crude residue was purified 
by column chromatography (5% EtOAc/hexane) to give the title compound (4.22 g, 16.2 
mmol, 85% yield) as a colourless oil. 1H NMR (400 MHz, CDCl3): δ 9.79 (1H, t, J = 1.5 Hz, H-1), 
3.72 (2H, t, J = 6.0 Hz, H-4), 2.53 (2H, td, J = 7.0, 1.5 Hz, H-2), 1.87 (2H, tt, J = 7.0, 6.0 Hz, H-3) 
ppm; 13C NMR (101 MHz, CDCl3): δ 202.9 (C=O), 62.5 (CH2), 40.9 (CH2), 25.8 (CH2), 18.1 (CH3), 
12.0 (CH) ppm; HRMS (ESI) 267.1652 (M + Na+. C13H28NaO2Si requires 267.1751); IR (ATR): νmax 
2942, 2892, 2865, 1727 (C=O), 1463, 1247, 1102, 1069, 1013 cm-1. 
 
 
(1-Benzenesulfonyl-4-triisopropylsilanyloxy-butyl)-carbamic acid tert-butyl ester (238) 
Following general procedure A with aldehyde 237 (3.09 g, 12.7 mmol), tert-butyl carbamate 
(991 mg, 8.47 mmol) and benzenesulfinic acid sodium salt (2.77 g, 16.9 mmol) to give the title 
compound (2.62 g, 5.59 mmol, 66% yield) as a white solid. Mp 80-82.5 °C; 1H NMR (400 MHz, 
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CDCl3): δ 7.91 (2H, d, J = 7.8 Hz, H-1), 7.65-7.58 (1H, m, H-3), 7.56-7.49 (2H, m, H-2), 5.10 (1H, 
d, J = 10.5 Hz, NH), 4.86 (1H, dt, J = 10.5, 3.2 Hz, H-4), 3.72 (2H, t, J = 6.0 Hz, H-7), 2.43-2.29 
(1H, m, H-5), 1.93-1.80 (1H, m, H-5), 1.79-1.62 (2H, m, H-6), 1.21 (9H, s, (CH3)3), 1.07-1.01 
(21H, m, OTIPS) ppm; 13C NMR (101 MHz, CDCl3): δ 154.0 (C=O), 137.1 (C), 133.9 (CH), 129.4 
(CH), 129.1 (CH), 80.8 (C), 70.9 (CH), 62.3 (CH2), 28.7 (CH2), 28.1 (CH3), 23.2 (CH2), 18.1 (CH3), 
12.0 (CH) ppm; HRMS (ESI) 508.2538 (M + Na+. C24H43NNaO5SSi requires 508.2523); IR (ATR): 
νmax 3337, 2942, 2891, 2865, 1720 (C=O), 1516, 1447, 1367, 1308, 1245, 1166, 1141, 1083 cm-
1. 
 
 
Methyl 5-tert-butoxycarbonylamino-3-hydroxy-8-triisopropylsilanyloxy-oct-2-enoate (239) 
Following general procedure B with sulfone 238 (2.00 g, 4.12 mmol), NaH (60% dispersion in 
mineral oil, 0.496 g, 12.4 mmol), methyl acetoacetate (1.34 mL, 12.4 mmol), diisopropylamine 
(3.48 mL, 24.7 mmol) and n-BuLi (2.24 M in hexanes, 11.0 mL, 24.7 mmol). The residue was 
purified by column chromatography (20% EtOAc/hexane) to give the title compound (1.07 g, 
2.35 mmol, 57% yield) as a colourless oil. 1H NMR (400 MHz, CDCl3): δ 12.01 (1H, s, OH), 5.02 
(1H, s, H-2), 4.78 (1H, br. d, J = 8.7 Hz, NH), 3.93-3.78 (1H, m, H-5), 3.73-3.63 (2H, m, H-8), 3.71 
(3H, s, OCH3), 2.39 (2H, br. d, J = 5.5 Hz, H-4), 1.69-1.50 (4H, m, H-6 and H-7), 1.42 (9H, s, 
(CH3)3), 1.09-0.99 (21H, m, OTIPS) ppm; 13C NMR (101 MHz, CDCl3): δ 175.6 (C), 172.9 (C=O), 
155.5 (C=O), 91.1 (CH), 79.3 (C), 63.0 (CH2), 51.3 (CH3), 48.8 (CH), 40.4 (CH2), 30.8 (CH2), 29.5 
(CH2), 28.5 (CH3), 18.1 (CH3), 18.1 (CH) ppm; HRMS (ESI) 482.2910 (M + Na+. C23H45NNaO6Si 
requires 482.2908); IR (ATR): νmax 3374, 2942, 2865, 1747 (C=O), 1711 (C=O), 1505, 1450, 
1365, 1243, 1168, 1102 cm-1. 
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Methyl 6-(3-hydroxy-propyl)-4-oxo-1-aza-spiro[3.5]nonane-3-carboxylate (241) 
Following general procedure C with the hydrochloride salt of 239 (238 mg, 0.603 mmol), 
cyclobutanone (225 μL, 3.02 mmol) and NaHCO3 (254 mg, 3.02 mmol). The residue was 
purified by column chromatography (100% ethyl acetate) to give the title compound as a 
mixture of diastereomers (21 mg, 0.0797 mmol, 8% yield, 6:1 dr) as a colourless oil. Data 
presented is for the major diastereomer. 1H NMR (400 MHz, CDCl3): δ 3.73-3.66 (1H, m, H-9), 
3.71 (3H, s, OCH3), 3.62-3.53 (1H, m, H-9), 3.58 (1H, d, J = 1.2 Hz, H-3), 2.87-2.77 (1H, m, H-6), 
2.40 (1H, dd, J = 13.7, 11.5 Hz, H-5), 2.31 (1H, ddd, J = 13.7, 3.7, 1.2 Hz, H-5), 2.18-2.06 (1H, 
m, H-10), 2.04-1.59 (8H, m, H-7, H-8, H-10 and H-11), 1.56-1.44 (1H, m, H-7) ppm; 13C NMR 
(101 MHz, CDCl3): δ 203.2 (C=O), 169.1 (C=O), 65.6 (CH), 62.9 (CH2), 62.6 (C), 53.2 (CH3), 52.6 
(CH), 46.9 (CH2), 36.1 (CH2), 32.1 (CH2), 31.5 (CH2), 30.9, (CH2), 14.6 (CH2) ppm; HRMS (ESI) 
256.1547 (M + H+. C13H22NO4 requires 256.1543); IR (ATR): νmax 3299, 2937, 1705 (C=O), 1434, 
1334, 1289, 1267, 1196, 1169, 1059 cm-1. 
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9. Abbreviations 
 
μW  microwaves 
Ac  acetyl 
AIBN  azobisisobutyronitrile 
Ala  alanine 
aq  aqueous 
ax  axial 
BINOL  1,1’-bi-2-naphthol 
Bn  benzyl 
Boc  tert-butyloxycarbonyl 
Bz  benzoyl 
Bu  butyl 
Cbz  carboxybenzyl 
CCR5  C-C chemokine receptor type 5 
CDI  carbonyldiimidazole 
d  doublet 
DABCO 1,4-diazabicyclo[2.2.2]octane 
DABAL.Me3 bis(trimethylaluminium)-1,4-diazabicyclo[2.2.2]octane adduct 
DAST  diethylaminosulfur trifluoride 
DBU  1,8-diazabicyclo[5.4.0]undec-7-ene 
DCE  1,2-dichloroethane 
DIBAL-H diisobutylaluminium hydride 
DIPEA  diisopropylethylamine 
DMAP  4-dimethylaminopyridine 
DMF  N,N-dimethylformamide 
DMPU  N,N’-dimethylpropyleneurea 
DMSO  dimethylsulfoxide 
dr  diastereomeric ratio 
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DTBMP 2,6-di-tert-butyl-4-methylpyridine 
ee  enantiomeric excess 
eq  equatorial 
Eq  equivalents 
ESI  Electrospray ionisation 
Et  ethyl 
FBDD  Fragment-based drug discovery 
Fmoc  fluorenylmethyloxycarbonyl 
Fsp3  Fraction of sp3 
HIV  Human immunodeficiency virus 
HRMS  High-resolution mass spectometry 
HSQC  Heteronuclear single quantum coherence 
HPLC  High-performance liquid chromatography 
HTS  High-throughput screening 
J  coupling constant (Hz) 
LCMS  Liquid chromatography mass spectrometry 
LDA  lithium diisopropylamide 
LiDBB  lithium 4,4’-di-tert-butylbiphenylide 
LLAMA  Lead-likeness and molecular analysis 
m  multiplet 
mCPBA m-chloroperoxybenzoic acid 
MDAP  Mass-directed autopurification 
Me  methyl 
Mp  melting point 
Ms  mesyl 
n-Bu  n-butyl 
NAD+  nicotinamide adenine dinucleotide 
NFSI  N-fluorobenzenesulfonimide 
NMR  Nuclear magnetic resonance 
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PBF  Plane of best fit 
pg  page   
Ph  phenyl 
PMB  paramethoxybenzyl 
PMI  Principal moments of inertia 
PMP  paramethoxyphenyl 
pr  propyl 
p-TSA  p-toluenesulfonic acid 
q  quartet 
rt  room temperature 
s  singlet 
sat  saturated   
SnAP  tin-amine protocol 
t  triplet 
TBAB  tetrabutylammonium bromide 
TBAF  tetrabutylammonium fluoride 
TBD  1,5,7-triazabicyclo[4.4.0]dec-5-ene 
TBS  tert-butyldimethylsilyl 
Tf  triflate 
TFA  trifluoroacetic acid 
THF  tetrahydrofuran 
TIPS  triisopropylsilyl 
TLC  Thin layer chromatography 
TMS  trimethylsilyl 
Ts  tosyl 
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